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 Rare peripheral blood cells are defined as white blood cells (WBC) at a 
population frequency of less than 1 in 1,000. Because blood is a relatively non-invasive 
and accessible sample, it has the potential to be exploited as a surrogate tissue for 
biomarker development. This PhD project therefore focused on the development and 
validation of pharmacodynamic biomarkers in rare WBCs using flow cytometry 
techniques. These biomarkers were developed and utilised for use in three clinical 
studies, the LY3143921 phase I trial, the SIOP Ependymoma II trial and the 
PROSPECT-NE observational study. 
 An assay focusing on phosphorylated MCM2 (pMCM2) and ki-67 staining of 
peripheral blood cells was developed for an early phase clinical trial of LY3143921, a 
novel CDC7 inhibitor. These proteins were tested in vitro, ex vivo and in vivo. The 
results indicated a significant association between the number of ki-67 positive cells as 
a percentage of pMCM2 positive WBCs and drug exposure. Furthermore, an 
appropriate method was successfully developed to preserve pMCM2 and ki-67 signal 
in samples being transported from national clinical centres, to facilitate its 
incorporation in the clinical trial. 
 An assay for the detection of acetylated histone H4 (acH4) was developed for 
patients receiving valproic acid, a HDAC inhibitor, as a part of the SIOP Ependymoma II 
trial. The applicability of the assay was tested in vitro, ex vivo and in patient samples. 
AcH4 signal was associated with drug exposure in vitro and ex vivo but was not 
associated with dose or concentration of valproic acid WBCs in patient samples. This 
finding was potentially related to the relatively low plasma drug concentrations 
observed at the dose levels studied. Additional patients with higher drug exposures 
need to be recruited to future studies to further investigate this issue. 
 The protein of interest for the PROSPECT-NE observational study was ki-67, 
which was detected using the same assay as developed for the LY3143921 trial. This 
study focussed on the prognostic utility of ki-67, rather than its potential predictive or 
mechanistic properties. The results suggested significant differences in overall survival 
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between patients with high and low ki-67 positive WBCs. There was no association 
observed between ki-67 positive WBCs and plasma ki-67 in this study. 
 In conclusion, pMCM2 positivity in ki-67 positive cells was identified as a 
potentially useful pharmacodynamic biomarker, with applicability to an ongoing 
clinical trial. For acH4 positive cells, their utility as a pharmacodynamic biomarker 
remains questionable and requires further investigation. Lastly, a high proportion of 
ki-67 positive WBCs was found to be associated with decreased overall survival in 
people with cancer recruited to a Phase I clinical trial. These findings highlight the 
potential utility of peripheral rare WBCs as pharmacodynamic and prognostic 
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Chapter 1. Introduction 
1.1 Cancer 
1.1.1 Aetiology of cancer 
 The term ‘cancer’ was derived from a Greek word ‘karkinos’ which was used by 
Hippocrates of Kos around 400 BC (Faguet, 2015). It was used to describe the 
appearance of invasive solid tumours with projections penetrating into adjacent tissue 
macroscopically resembling a crab. It was not until the 19th century, however, that it 
became commonly accepted that tumours were a disease with cellular aetiology, and 
only in the 20th century that cancer was recognised as a disease of dysregulated hyper-
proliferation of cells. More recently scientists have come to consider cancer as a 
disease of genetic abnormalities. For instance, mutations of RAS and the RAS-family 
genes have been found to be associated with lung cancer, colon cancer, pancreatic 
cancer and acute myeloid leukaemia (Feinberg and Vogelstein, 1983; Radich et al., 
1990; Sugio et al., 1994; Nishigaki et al., 2005). Similarly, mutations and deletions of 
BRCA1 and BRCA2 genes are related to breast and ovarian cancers (Narod et al., 1993; 
Schmutzler et al., 1997; Tseng et al., 1997) and amplifications of EGFR (HER1) genes 
can lead to glioblastoma, head and neck cancer, and osteosarcoma (Grandis and 
Tweardy, 1993; Hayashi et al., 1997; Akatsuka et al., 2002). 
 These alterations of genes can be inherited, leading to an increased risk of 
cancer developing in a lifetime, or somatic, appearing due to endogenous or 
environmental triggers. Many studies have demonstrated associations between 
environmental factors and cancers. In 1775, an association between scrotal cancer and 
chimney-sweeping was first observed by Percivall Pott (Brown and Thornton, 1957). 
Later, a meta-analysis of multiple cohort studies showed that exposure to asbestos 
increased the risk of developing lung cancer and that the increased risk was still 
present in non-smokers (Ollier et al., 2014; Paris et al., 2017). Tobacco is another well-
known cause of cancer, especially lung cancer (Doll and Hill, 1950). Similarly, the 
presence of aflatoxins produced by mould in some grains such as corn, peanut and rice 
is associated with liver cancer (Liu et al., 2012). In addition, infections with certain 
types of virus such as HPV 16 and 18 are known to be associated with risk of cervical 
cancer (Cogliano et al., 2005). 
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1.1.2 Cancer treatment and therapeutics 
Since cancer was first identified, numerous treatment strategies, including 
surgery, medication, radiation and more recently stem cell transplantation, have been 
developed (DeVita et al., 2018). Focusing on pharmacologic treatment, there are many 
different types of drugs used to treat cancer patients. These can be divided into two 
major groups which are small drugs and biologics. Small molecule compounds can be 
further categorised into cytotoxic and targeted drugs, while monoclonal antibodies 
(MABs) have until recently resembled small molecule drugs in the pathways they 
target. MABs can now be further categorised into anti-proliferative and immune 
checkpoint inhibitors (Reichert, 2001). 
1.1.2.1 Traditional cytotoxic drugs 
Cytotoxic drugs are drugs that are toxic to cells and mostly this toxicity results 
in cell death. However, as the drugs are toxic to the vast majority of cells, both 
cancerous and normal tissues are affected. This means that cytotoxic drugs have many 
serious side effects related directly to their mechanism of action, such as leukopenia, 
cardiotoxicity, hepatotoxicity and gastrointestinal toxicity. According to Thirumaran R 
et al, there are five major types of traditional cytotoxic drugs divided by mechanism of 
action (Thirumaran et al., 2007). 
 
Alkylating agents 
 The mechanism of alkylating agents is covalent binding to DNA. The alkylating 
agents contain electron-rich atoms, which form covalent bonds with DNA and create 
inter- and intra-strand cross-links. When DNA is bound with the drug, cells will detect 
the damage and start the apoptotic process, consequently causing cell death (Trams et 
al., 1961). 
 The first drug in this group and the first cytotoxic drug developed was nitrogen 
mustard. This was followed ten years later by cyclophosphamide, which is essentially a 
prodrug of nitrogen mustard (Friedman and Seligman, 1954). These early drugs were 
derived from mustard gas, a chemical warfare agent used during World War 1. It was 
observed that in addition to being a strong vesicant, the mustards also had cytotoxic 
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activity that depleted bone marrow and lymph nodes, consequently reducing the 
numbers of WBC (Gilman, 1946). This agent was therefore suggested as a new 
treatment for lymphoma during World War 2 (DeVita and Chu, 2008). Another group 
of drugs with a very similar mechanism of action to these alkylating agents are the 




 Most antimetabolites have similar structures to endogenous substances 
required for cell division. Therefore, cells will allow antimetabolite agents to substitute 
these compounds, resulting in DNA synthesis interference (Avendaño and Menéndez, 
2008). Tumour cells with high growth rate such as gastrointestinal tumours or cancer 
in bone marrow are most affected by these drugs (Spooner et al., 1982; Schuetz and 
Diasio, 1985). 
 Antimetabolites can be further divided into 3 subclasses. The first group, the 
folate antagonists, includes methotrexate, a drug first synthesized in 1948 which led to 
successful remissions in the treatment of leukaemia (Farber et al., 1948). The second 
group, the purine antagonists, was first developed in 1951 (Hitchings and Elion, 1954). 
This group includes 6-mercaptopurine and azathioprine. The last group are the 
pyrimidine antagonists, which includes 5-fluorouracil (5-FU), gemcitabine, capecitabine 
and cytarabine (Ara-C). The first drug in this group, 5-FU, was first synthesized in 1957 




 The mechanism of action of most anti-tumour antibiotics is blocking 
topoisomerase II activity and intercalating into the flat space between the bases of 
DNA double helix (Sartiano et al., 1979). Most antibiotics in this class contain an 
anthracycline structure and they were first isolated from the bacteria, Streptomyces. 
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Examples of drugs in this class include doxorubicin, epirubicin, daunorubicin, 
actinomycin-D and mitoxantrone (Thirumaran et al., 2007). The first drug in this group 
is actinomycin-D which was developed during World War 2 period and mostly used in 
paediatric tumours between 1950 and 1960 (Pinkel, 1959). 
 
Topoisomerase inhibitors 
 The topoisomerase inhibitor group of anticancer drugs consists of some anti-
tumour antibiotics such as doxorubicin and mitoxantrone and the plant alkaloids 
(Pommier, 2006). For example, etoposide is an alkaloid drug extracted from the 
Podophyllum plant. The project that led to the discovery of etoposide started in the 
1950s but it wasn’t until 1965 that this drug successfully went into cancer clinical trials 
(Imbert, 1998). Irinotecan and topotecan are isolated from the Camptotheca plant 
species. These two drugs were synthesized based on the discovery of camptothecin in 
1966 and were approved by the US FDA in the mid 1990s (Wall et al., 1966). 
The mechanism of action of the topoisomerase inhibitors is binding to 
topoisomerase I and/or II enzymes, resulting in prevention of DNA ligation after 
cleavage and torsional relief. These irreversible covalent cross-links between the 
topoisomerase and DNA prevent its replication and thereby cause cell death (Binaschi 
et al., 1995). 
 
Mitotic inhibitors 
 Anti-microtubule agents, which were discovered in the 1950s and entered 
clinical use in the 1960s, work by interrupting the organisation and dynamics of the 
mitotic spindle within the cell. Consequently, mitosis is prevented and the cell cycle 
stops (Cheng and Crasta, 2017). Most agents used in this class were originally 
extracted from two major plants: the periwinkle plant (Catharanthus roseus G. Don) 
and the Pacific yew (Taxus brevifolia Nutt) (Eric, 1997). 
 Vinca alkaloids are a group of anti-cancer drug extracted from the periwinkle 
plant (Moudi et al., 2013). Vinblastine, vincristine and vinorelbine are examples of 
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vinca alkaloids. Their mechanism of action is inhibition of tubulin polymerization and 
prevention of mitotic spindle formation. The other group of antimicrotubules is the 
taxane derivatives, which were initially extracted from the bark of the Pacific Yew tree 
(Ojima et al., 2016). In contrast to the vinca alkaloids, the taxanes, including paclitaxel, 
docetaxel and cabazitaxel, shift microtubules dynamics towards stabilisation and the 
formation of aberrant intracellular structures, resulting in cell death (Abal et al., 2003). 
 
1.1.2.2 Targeted therapies 
 With the discovery of multiple oncogenes and proto-oncogenes, the 
development of anti-cancer drugs has more recently focused on the synthesis of drugs 
that directly target the cancer genes and proliferative pathways rather than 
conventional cytotoxic drugs (Sawyers, 2004). Recently there are more than 30 
targeted anti-cancer drugs approved by US FDA and more than 20 targets in 
development processes (National Cancer Institute, 2019). 
 The RAS-RAF-MEK pathway is one of the most important targets for cancer 
treatment because upregulation of MAPK cascades were found to be associated with 
carcinogenesis (McCain, 2013). Examples of drugs approved in this class are dabrafenib 
(target BRAF), vemurafenib (target BRAF) and trametinib (target MEK). Another critical 
pathway in cancer is the PI3K-AKT-mTOR pathway (Porta et al., 2014). Anti-cancer 
drugs targeting this pathway which are approved for clinical use include everolimus 
and temsirolimus (Ciuffreda et al., 2010). 
 Based on the hallmarks of cancer, there are several targets for cancer 
therapeutics being developed and/or FDA approved (Hanahan and Weinberg, 2011). 
For example, PARP inhibitors such as olaparib target genome instability and mutation 
(Tangutoori et al., 2015). VEGF signalling inhibitors such as bevacizumab inhibit 
angiogenesis (Ellis and Hicklin, 2008). EGFR inhibitors such as cetuximab, erlotinib and 
panitumumab target sustaining cell proliferative signalling (Ono and Kuwano, 2006). 
Flavopiridol, a cyclin-dependent kinase inhibitor, works by evading growth suppressors 
of cells (Sedlacek, 2001). The HGF/c-Met pathway is another target to stop cancer 
invasion and metastasis; rilotumumab, onartuzumab and tivantinib are examples of 
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drugs inhibiting HGF and/or c-Met (Smyth et al., 2014). In addition, the development 
of immune checkpoint inhibitors, e.g. CTLA-4 inhibitors, PD-1 inhibitors and PD-L1 
inhibitors, is ongoing (Darvin et al., 2018). 
 
1.2 Cancer biomarkers 
1.2.1 Definition of a biomarker 
 The term ‘biomarker’ or ‘biological marker’ has been defined by several 
organisations since 1988. As defined by the National Institutes of Health Biomarkers 
Definitions Working Group, a biomarker is “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention” (Biomarkers 
Definitions Working Group, 2001). An alternative definition established by WHO in 
2001 defines a biomarker as “any substance, structure or process that can be 
measured in the body or its products and influence or predict the incidence of 
outcome or disease” (WHO, 2001). 
According to these definitions, biomarkers can be any biological or molecular 
entity including specific cells, proteins, molecules, genes, gene products or hormones, 
which can be used to measure a biological process (Huss, 2015). Furthermore, some 
people may include pulse rate, blood pressure, and routine laboratory tests in their 
definitions of a biomarker if they use these variables to measure biological processes 
(Strimbu and Tavel, 2010). 
1.2.2 Biomarker classification 
 There are several categorisation systems of biomarkers currently in use, with 
biomarkers classified by their intended purposes into six major groups: screening, 







 Several substances have been developed or are being developed as markers for 
the early detection of cancer (Duffy, 2015). For example, vanillymandelic acid (VMA) 
and homovanillic acid (HVA) have been used in screening for neuroblastoma in 
newborn infants (Hanai et al., 1987). Alpha fetoprotein (AFP) is effectively used in 
screening of hepatocellular cancer, especially in patients infected with hepatitis B virus 
(HBV) or hepatitis C virus (HCV) (Tsuchiya et al., 2015). CA125 is currently used for 




 Diagnostic biomarkers are used to indicate the existence of pathological 
changes in tissues or organs, or indicate occurrence of abnormal cells or tissue 
function (Davis et al., 2013). For example, using aspartate aminotransferase to platelet 
ratio index (APRI) to indicate liver fibrosis is an example of this type of biomarker (Jin 
et al., 2012). However, although many biomarkers are currently used for helping 
diagnosis and/or sub-classification of tumour stage, none are currently recommended 
in clinical practice guidelines to be used alone for cancer diagnosis. 
 
Monitoring biomarkers 
 Monitoring biomarkers are characteristics that can be serially measured to 
assess the status of a disease (Califf, 2018). This type of biomarker commonly overlaps 
with other categories of biomarkers. Examples include CA15-3, which is used in the 
therapeutic monitoring of breast cancer and PSA, which can be used to monitor 
prostate cancer. Similarly, thyroglobulin can be used in the monitoring of thyroid 






 This biomarker class is able to predict the natural course of the disease/effect 
and inform the long-term outcome. For instance, CA125 half-life has been shown to 
correlate with survival rate in patients with cancer of the ovary; women with ≤20 days 
of CA125 half-life had worse overall survival compared to who had a half-life >20 days 
(Colakovic et al., 2000). Oestrogen receptor (ER) and Progesterone receptor (PR) status 
can be used to predict the prognosis of breast cancer patients (Yip and Rhodes, 2014). 
 
Predictive biomarkers 
 Unlike the prognostic biomarkers that predict the natural outcome of the 
disease, predictive biomarkers predict the outcome of treatment (Mordente et al., 
2015). In other words, predictive biomarkers can indicate the probability of a specific 
response to treatment. KRAS mutation is an example of a predictive biomarker 
because it can distinguish patients with metastatic colorectal cancer who do not 
benefit from EGFR inhibiting therapy (Lièvre et al., 2006). In addition, HER2 receptor in 
patients with breast cancer is used to identify patients likely to respond to treatment 




 Mechanistic biomarkers link directly to the modulation of a specific target or 
signalling pathway (Davis et al., 2013). For example, adipsin is used as a biomarker for 
disruption of NOTCH-1 signalling and induction of goblet cell proliferation in the small 
intestine (Searfoss et al., 2003). As this type of biomarker can measure mechanism of 
action of the drug, it can also be used as a pharmacodynamic biomarker. 
1.2.3 Importance of biomarkers in cancer research 
 As biomarkers can be used for many purposes, their utilities in cancer are 
numerous, including screening, diagnosis, prognosis, prediction of therapeutic 
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response, tumour staging and monitoring efficacy of cancer therapy (Henry and Hayes, 
2012). Nevertheless, not all biomarkers are currently used clinically as many proposed 
diagnostic biomarkers provide insufficient sensitivity and/or specificity. Additionally, 
apart from HCG and AFP, the accuracy of biomarkers for tumour staging remains poor 
(Kulasingam and Diamandis, 2008). 
 Many biomarkers with high accuracy and precision are approved by the US FDA 
for screening and monitoring of cancer therapy (Sauter, 2017). Examples include digital 
rectal examination (DRE) which is widely used as a screening biomarker for prostate 
cancer and CEA which is a serum protein effectively used to monitor colorectal cancer 
(Torosian and Daly, 1991; Jones et al., 2018). 
 Focusing on the area of cancer drug discovery and development, biomarkers 
can have several essential roles, ranging from confirmation of the pharmacological 
mechanism of a drug to the prediction of clinical outcome (Floyd and McShane, 2004). 
Biomarkers also play important roles in early stage drug development, including 
therapeutic target identification and validation, candidate drug screening and 
optimisation, proof-of-concept, and drug combination mechanistic understanding. 
Furthermore, biomarkers can be used in the prediction of patient response, resistance 
and toxicity of a drug (Kelloff and Sigman, 2012). 
 
1.3 Techniques for biomarker development 
 Various techniques have been used for biomarker discovery and development. 
The development process can be divided into 4 main stages: the discovery of potential 
biomarkers, biomarker assay development, technical qualification of assays and the 
clinical validation of new biomarkers (Cummings et al., 2008). 
 Approaches to biomarker discovery can be considered in terms of the tissue 
being analysed. These can be described in terms of ‘-omics’ (Davis et al., 2013; Kewal, 
2017). Firstly, genomics involve techniques such as DNA sequencing, microarrays, gel 
electrophoresis and PCR to measure nucleic acid sequences. Proteomics on the other 
hand are technologies designed to examine protein expression and characterisation. 
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They have huge potential in biomarker development, especially at the level of 
diagnostic and predictive biomarkers. Well-known proteomic techniques such as ELISA, 
mass spectrometry and Western blot are now widely used. 
 Metabolomics refers to the study of all metabolites found in biological samples. 
For example, techniques such as high-resolution NMR spectroscopy are effective to 
quantify in vivo metabolites and generate metabolic profiles. Other techniques 
including mass spectrometry, vibrational spectroscopy and other imaging techniques 
can also be used (Zhang et al., 2012a). Lastly, analytes in cells and tissues can be 
measured by ‘histocytomic’ approaches (Davis et al., 2013). Analysis of cell structure 
and function can be performed by techniques such as microscopy and flow cytometry. 
In addition, immunohistochemistry can be applied for phenotypic characterisation of 
tissues. 
 Deciding the most suitable approach for assessing any given biomarker 
depends on many parameters. For example, which tissues express the biomarker or 
have an active metabolic pathway to be measured. Once tissues have been identified, 
the most suitable technology for analysis of the marker in that tissue must be decided. 
In addition, the feasibility and safety of sample collection, cost of the approach, 
stability of the samples collected and delivery time to the laboratory are factors that 
need to be concerned in biomarker selection. The projects described in this thesis 
focus on rare cell populations in peripheral blood samples. The investigation of these 
populations was initially developed in parallel with establishing CTC detection assays 
using imaging flow cytometry. 
1.3.1 Principles of flow cytometry 
 Flow cytometry is one of the most commonly used techniques in biomarker 
discovery and development. It was developed and has been used for over 50 years 
(Muirhead et al., 1985). This technique is based on the principles of 
immunofluorescence and cell/particle-analysing technologies. The anatomy of a flow 
cytometer can be described under 3 main headings, namely fluidics, optical and 
electronic systems, as shown in Figure 1.1 (BD Biosciences, 2000). Particles are 
suspended and introduced into the fluidics system focused into single objects. The 
optics system consists of lasers to excite fluorochromes and filters to direct emitted 
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light to the electronics of the system, typically photomultiplier tubes (PMT). The digital 
signals generated by the PMT’s are then processed for computer analysis (BD 
Biosciences, 2000). 
 
Figure 1.1. The anatomy of a conventional flow cytometer. 
Particles are injected into the core where they pass through the path of laser 
beams. Scattered and emitted light are detected by either silicon photodiodes 
or PMTs for analysis. Taken from BD Biosciences. Introduction to Flow 
Cytometry: A Learning Guide Manual. 2000. 
 
Flow cytometry techniques are heavily dependent on immunofluorescence and 
the appropriate selection of fluorochromes is critical. Fluorochromes are selected 
based on excitation potential with the wavelengths of lasers in the machine. Knowing 
the excitation and emission properties of fluorescent compounds is essential for the 
selection of combination of fluorochromes which optimally work together. Table 1.1 










DAPI 350 470 405 
Hoechst 350 461 405 
FITC 490 525 488 
Alexa Fluor 488 490 525 488 
PE 565 578 488, 561 
Cy3 554 568 561 
Alexa Fluor 546 556 573 561 
APC-Cy7 650 785 658 
Alexa Fluor 647 650 665 658 
 
Table 1.1. Examples of fluorochromes for immunophenotyping with excitation and 
emission peaks at different wavelengths. 
Adapted from Overton WR. Guide to Flow Cytometry. Dako; 2006. p. 17-22. 
1.3.2 Imaging flow cytometry and its application in biomarker development 
 Imaging flow cytometry is a technology that combines conventional flow 
cytometry with microscopy. While conventional flow cytometers capture and convert 
emitted photons to electrical signals on a photomultiplier tube, imaging flow 
cytometers are able to capture high resolution magnified images on a charge coupled 
device (CCD) camera. The CCD cameras in the ImageStream can collect emitted 
florescence light that is magnified by a microscopic objective lens and spectrally 
resolve it into six discrete bandwidths by an array of dichroic filters as shown in Figure 
1.2 (Amnis Corporation; Han et al., 2016). 
 Based on these functions of imaging flow cytometry, high content data can be 
provided for biomarker development. The unique information given by imaging flow 
cytometers includes localisation of proteins or particles in cells. For instance, by visual 






Figure 1.2. The anatomy of an imaging flow cytometer (ImageStream). 
Particles injected through the tube, excited fluorochromes and emitted light at 
90° is magnified, spectrally resolved and detected. Taken from Amnis 
Corporation. The ImageStreamX Mark II Imaging Flow Cytometer 
 
 Although imaging flow cytometry provides useful information for research, it 
also has its drawbacks. A major limitation is that as the machine has to capture so 
many cell images, the speed of acquisition decreases significantly. Whereas 
conventional flow cytometers can acquire up to 10,000 events/second, imaging flow 
cytometers can process less than half this number (Barteneva et al., 2012). For 
example the ImageStream system has a maximum acquisition rate of 4,000 
cells/second at 20× magnification and only 1,200 cells/sec at 60× magnification (Amnis 
Corporation). Another challenge is the significant size of the data generated by imaging 
flow cytometers because each collected particle contains an image file. For a file with 
100,000 cells acquired, the size will be approximately 1.5-2.5 GB for example. This may 
slow down the analysis of data and quickly cause shortage of storage space when 




1.4 Surrogate tissues used in pharmacodynamic biomarker development 
 In the area of biomarker development, selection of suitable surrogate tissues is 
another critical point to be considered, as different tissues provide the researcher with 
different information. In general an ideal tissue should be non-invasive, relevant to the 
drug and facilitate measurement of the biomarker of interest. Biopsy samples 
comprising the target are widely considered to be an ideal tissue, but they are invasive 
and not always safe to obtain (Floyd and McShane, 2004). Therefore, utilisation of 
blood derivatives such as white blood cells as a surrogate tissue, is another option to 
be considered. 
1.4.1 Peripheral blood components 
 Human blood contains numerous components which can be divided into two 
major groups: a solid part referred to as formed or cellular elements and a liquid part 
called plasma (Silverthorn, 2013). Plasma consists of water (90% of volume) and more 
than 100 different solutes including plasma proteins such as albumin (60% of proteins) 
and globulin (36% of proteins), non-protein nitrogenous substances, organic nutrients, 
electrolytes respiratory gases and hormones (Marieb and Keller, 2017). 
 Formed elements in blood consist of erythrocytes, leukocytes, and platelets. 
Erythrocytes or red blood cells are cells without nuclei or organelles. Their shapes are 
like biconcave or flattened discs with depressed centres. When looking through a 
microscope, they appear lighter in colour at the thin centres than at the edges. Red 
blood cells play an important role in transporting oxygen from the lungs to tissues and 
carrying carbon dioxide from the tissues back to lungs. They can function for 
approximately 100-120 days and then are destroyed in the spleens (Crosby, 1959; 
Jelkmann, 1992). 
Platelets are cell fragments of large cells called megakaryocytes. Platelets are 
instrumental in the coagulation process together with other coagulation factors. 
Moreover, platelets contain some chemical granules which are important in clotting 
process such as serotonin, calcium ion, enzymes and platelet-derived growth factor 
(Marcus, 1969; Harrison, 2005). 
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Leukocytes or white blood cells are the last formed elements with only 4,800-
10,800 cells per microliter of blood (4.8-10.8 × 109/L). However, they can be exploited 
in biomarker development because WBCs contain more particles including a variety of 
proteins, granules and nuclei. Further details of white blood cells are described below 
(Feher, 2012; Ashton, 2013). 
1.4.2 Characteristics of white blood cells 
 White blood cells are the only type of blood cell which can be called complete 
cells as they have nuclei and other organelles. White blood cells can be classified in 
two different ways (Figure 1.3) (Marieb and Keller, 2017): by expression of granules 
and by their original stem cells. For the granule classification, there are two types of 
white blood cells that can be defined as either granulocytes (with granules) or 
agranulocytes (without granules). Neutrophils, eosinophils and basophils are 
granulocytes, while lymphocytes and monocytes are agranulocytes. However, when 
divided by their original stem cell, neutrophils, eosinophils, basophils and monocytes 
are in the myeloid group, since they are all derived from myeloid stem cells. On the 
other hand, lymphocytes are classified as lymphoid because of their lymphoid origin. 
 The functionality of imaging flow cytometry allows granularity to be measured 
and expressed as side scatter. Since granules contain proteins and enzymes, they are 
opaque and can refract laser beams, resulting in side scatter. The granularity of white 
blood cells therefore can be used to differentiate types of white blood cells. Basically 
granulocytes, i.e. neutrophils, basophils and eosinophils, present with a high side 
scatter due to their dense granules. On the contrary, lymphocytes with small 
cytoplasm and no granules exhibit very low side scatter. Monocytes, are typically 
intermediate in size and density between granulocytes and lymphocytes. 
 Without additional phenotyping the ImageStream system allows resolution of 
lymphocytes and granulocytes. Furthermore, eosinophils are able to directly bind to 
fluorochromes such as FITC, resulting in false positives (Floyd et al., 1983). This study 





Figure 1.3. Formation of white blood cells from hemocytoblasts to mature cells. 
White blood cells can be classified either as myeloid and lymphoid cells or 
granular and agranular leukocytes. Taken from Marieb EN and Keller SM. 
Pearson Education; 2017. p. 363-81. 
 
 In addition to granular expression, myeloid and lymphoid cells exhibit 
additional characteristics including differences in life span and expression of 
genes/proteins. Although myeloid cells are the major population of cells comprising 
>75% of all white blood cells, they generally have a short lifespan, especially in the 
case of neutrophils (Ashton, 2013). A previously published study showed that 
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expression of surface markers such as CD45 increased 1.6 times in granulocytes, as 
compared to 0.9 times in lymphocytes, when left in EDTA tube for 24 hours 
(Immunicon Corporation). Thus, any assays of myeloid cells should have minimal 
complexity and rapid data collection; otherwise it may alter the results due to changes 
inside myeloid cells (Priel and Kuhns, 2019). 
 Myeloid and lymphoid cells also exhibit differences in gene and protein 
expression as shown in several studies (Hashimoto et al., 2003; Palmer et al., 2006), 
with results suggesting that myeloid cells express more genes than lymphoid cells. 
Moreover, the majority of genes expressed in each cell type have different functions, 
resulting in different responses to treatment between the two populations. Therefore, 
WBC type is a key parameter to be considered in pharmacodynamic biomarker 
development. 
 Since many characteristics of myeloid and lymphoid cells are variable between 
cell type, the current studies focused on differences in terms of the expression of 
biomarkers of interest. Protein expression in each WBC population was measured and 
compared to the other WBC types, in order to determine the most appropriate cell 
populations for particular biomarkers of interest. 
 
1.5 Clinical trials related to this study 
1.5.1 CDC7 inhibitor LY3143921 - Phase I clinical trial 
 A Cancer Research UK Phase I Trial of LY3143921 is a first in human trial of a 
new drug, namely LY3143921, in adult patients with advanced solid tumours. The main 
aim of this study is to find out the maximum tolerated dose of LY3143921 that can be 
safely administered to patients. Secondary objectives include assessments of 
pharmacokinetic and pharmacodynamic properties of the drug. 
 The clinical trial eligibility criteria includes patients being 18 years or older. 
Patients must have histological or cytological diagnosis of incurable, 
advanced/metastatic solid cancer, WHO performance status of 0 or 1, life expectancy 




 Patients are excluded from the trial if they received radiotherapy (except for 
control of symptoms where irradiated lesions will not be followed for response), 
endocrine therapy, immunotherapy or chemotherapy during the previous 4 weeks. 
Additionally, if they present grade 2 or greater toxicities due to previous treatments, 
have symptomatic brain metastases, have hypotension or uncontrolled hypertension, 
have co-existing active infection, have known to be serologically positive for hepatitis 
B, hepatitis C or HIV, have a history of allergy or auto-immune disease, or have other 
serious concurrent medical conditions, they are ineligible for the trial. 
 LY3143921 hydrate is administered orally to the recruited patients, either once 
or twice a day depending on the particular patient cohort. Patients have to stay in 
hospital for 1-3 nights to closely monitor any side effects. Blood samples are taken 9 
times over the first 24 hours post-treatment, and once on day 2 for side effect 
monitoring and PK/PD analyses. Blood samples – 7 blood tests over a period of 24 
hours – are collected again 4 weeks later. 
 As LY3143921 is a CDC7 kinase inhibitor, this PhD project aimed to develop an 
assay to measure the consequences of CDC7 inhibition. The appropriate candidates for 
CDC7 inhibitors include phosphorylated MCM2 and ki-67 as downstream proteins in 
the CDC7 pathway. 
1.5.2 SIOP Ependymoma II clinical trial 
 The SIOP Ependymoma trial is a large clinical trial run by the International 
Society of Paediatric Oncology to study the diagnosis and treatment of children, 
adolescents and young adults with ependymoma. This study consists of two main 
parts; the first part is focused on the results of post-operation MRI or CT scan and the 
second part is looking at treatment pathways. Patients recruited in the first-part trial 
would receive MRI or CT scan to observe the existence of tumour and the patients with 
recurrence might be recruited to the second part of the project. The acH4 analysis 
project which is the focus of this thesis, is part of the second part of the trial which is 
divided into 3 strata. Stratum 1 is a phase III randomised study for patients whose age 
≥12 months and <22 years at diagnosis and have had a complete resection with no 
measurable residual disease. The recruited patients will be randomised to receive 
conformal radiotherapy followed by either 16 weeks of chemotherapy or observation. 
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Stratum 2 is a randomised phase II study for patients with the same range of age as 
stratum 1 but have inoperable measurable residual disease. Patients will be 
randomised to receive two different treatment schedules of chemotherapy either with 
vincristine, etoposide and cyclophosphamide (VEC) or VEC plus high dose 
methotrexate. 
 Stratum 3 involves children <12 months of age or those not eligible to receive 
radiotherapy, and this is where the acH4 biomarker work is incorporated. Patients who 
are eligible for this stratum must have newly diagnosed intracranial ependymoma of 
WHO grade II-III confirmed by central pathological review and be ineligible to receive 
radiotherapy due to age at diagnosis. In addition, patients must have adequate bone 
marrow function, liver function and renal function. They must have received no 
previous chemotherapy (except steroids), no previous radiotherapy, no co-existent 
unrelated disease, e.g. renal and haematological diseases that would render the 
patient unable to receive chemotherapy, no medical contraindication to 
chemotherapy and no signs of infection. 
 The recruited patients are randomised to receive dose dense chemotherapy, 
alternating myelosuppressive and relatively non-myelosuppressive drugs at 2 weekly 
intervals, with or without valproic acid. For valproic acid, the initial dose of 30 
mg/kg/day is administered to patients in 2 divided doses (15 mg/kg/dose) for two 
weeks, with the potential for the dose to be increased weekly (up to 60 mg/kg/day in 2 
divided doses), depending on the drug concentrations observed. If therapeutic levels 
of 100-150 µg/mL are not achieved when giving 60 mg/kg/day, valproic acid can be 
administered in three divided doses (20 mg/kg/dose twice daily). If therapeutic levels 
are still not achieved, the dose can be slightly increased up to 70 mg/kg/day in 3 
divided doses (23.3 mg/kg/dose). 
 Blood samples for the pharmacodynamic study are obtained pre-treatment 
(prior to the first dose of valproate) and at 4-hour post valproate administration 
following the initial valproate dose. Once the individualised dose resulting in target 
trough valproate concentrations has been determined, pharmacodynamic samples are 
again taken at the same time points (4 hours post-treatment and prior to the next 
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dose). Additional blood samples can be taken at 6 monthly intervals until the end of 
treatment, whether or not patients achieve the therapeutic target. 
 Since valproic acid acts as an inhibitor of the HDAC enzyme, acetylation of 
histone H4 is a result of valproic acid activity and can be developed as a potential 
marker for measurement of HDAC inhibiting effect. This PhD project therefore aimed 
to develop an assay to detect acH4 as a pharmacodynamic biomarker of valproic acid. 
1.5.3 PROSPECT-NE observational study 
 PROSPECT-NE (Molecular PROfiling in Early Clinical Trials – North East) is an 
observational study that primarily aims to determine the range of molecular 
abnormalities presented in patients with cancer. This trial started in September 2017 
but the ki-67 analysis project was only included as part of the study in February 2018. 
The inclusion criteria are histological or cytological diagnosis of cancer, ECOG 
performance status of 0-2 and age >16 years old. Patients must not have known HIV, 
hepatitis B or hepatitis C positive and must have expected life expectancy >8 weeks. 
 The eligible patients are referred to the Sir Bobby Robson Unit at the Freeman 
Hospital for potential entry onto a Phase I trial. Whilst awaiting a trial, the recruited 
patients can donate blood every 4-6 weeks, up to a maximum of four times. These 
blood samples are then processed in the laboratory for ki-67 analysis. Patients will not 
receive any chemotherapy or cancer-relating treatment but they can receive palliative 
care such as corticosteroids. 
 In addition to blood samples, patients are also subject to other clinical 
assessments. For instance, performance status, RMH score, and health related quality 
of life measured with EQ-5D and EORTC QLQ-C30 questionnaires are documented at 
each visit. Also, patients are asked to perform grip strength test as a biomarker 
associated with frailty and poor prognosis. Additional blood tests such as CBC, 
albumin, LDH and C-reactive protein are performed only when necessary. 
 Ki-67 protein is a well-known proliferation marker and is recently an interest in 
the field of cancer prognosis (Scholzen and Gerdes, 2000). However, most prognostic 
studies focused on ki-67 expression in tumour tissue although WBC is considered a 
safer surrogate tissue. Therefore, this PhD project aimed to investigate the possibility 
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of utilising ki-67 as a potential prognostic biomarker in patients recruited to the 
PROSPECT-NE clinical trial. 
 
1.6. Aims and objectives 
 The primary objective of the work described in this thesis was to investigate the 
characterization of rare cell phenotypes in peripheral blood, in order to develop them 
as surrogate tissues for pharmacodynamic biomarker assays. The rare cell phenotypes 
utilised in this study were divided into three populations depending on the relevant 
clinical studies. For the LY3143921 clinical trial, CDC7, pMCM2 and ki-67 expression in 
lymphoid cells were studied. For the SIOP Ependymoma II trial, acH4 expression in 
myeloid cells was focused on. Lastly, ki-67 expression in lymphoid cells was 
investigated for the PROSPECT-NE clinical study. The main aims were as follows: 
1. To validate imaging flow cytometry assays for CDC7, pMCM2 and ki-67 
incorporating assay variability, reproducibility, sample collection and storage 
experiments. 
2. To measure pMCM2 and ki-67 positive lymphoid cells as a PD biomarker as part 
of a Phase I clinical trial of LY3143921, a novel CDC7 inhibitor. 
3. To validate imaging flow cytometry assays for acH4 regarding assay variability 
and reproducibility. 
4. To measure acH4 positive myeloid cells as a PD biomarker as part of a clinical 
trial in children with ependymoma receiving valproic acid. 
5. To characterise the phenotype of a ki-67 cell population in an observational 
study using imaging flow cytometry and to investigate the prognostic utility of 






Chapter 2. Materials and Methods 
2.1  Materials and reagents 
 The CDC7 inhibitor LY3143921 was obtained from Eli-Lilly and Company. 
Valproic acid sodium salt and DMSO were from Sigma Life Science. The primary 
antibody, clone EP4120, against pMCM2 Ser53 was from Abcam and secondary goat 
anti-rabbit antibody conjugated to phycoerythrin (PE) was from Life Technologies. 
CDC7 antibody (polyclonal) conjugated to fluorescein isothiocyanate (FITC) was 
obtained from Bioss Antibodies. The acH4 antibody (polyclonal) conjugated to PE was 
from Milli-Mark. The ki-67 antibody clone B56 conjugated to Alexa Fluor 647 and 
Lyse/Fix Buffer were obtained from BD Biosciences. DAPI (4',6-Diamidino-2-
Phenylindole, Dilactate) was from BioLegend. 
 RPMI-1640 medium with L-glutamine and sodium bicarbonate was from Sigma-
Aldrich. Bovine serum antigen (BSA) solution was obtained from Miltenyi Biotec. Foetal 
bovine serum (FBS) and tablets were from Gibco by Life Technologies. The ki-67 ELISA 
kit was from R&D Systems. The ultracentrifugal filters, Centrifree, were from Merck 
Millipore. 
 
2.2 Cell culture 
HL-60 (Human promyelocytic leukaemia) cells were cultured in RPMI-1640 
medium supplemented with 2 mM L-glutamine and 10% FBS. Cells were cultured in 75 
mm3 flasks with 1×106 cells in 20 mL of media. Flasks were incubated at 37°C in a 5% 
CO2 incubator. Sub-culturing was performed every 3-4 days by transferring 1×106 cells 
to a new flask with 20 mL of media. Cells were routinely tested for mycoplasma every 




2.3 Whole blood collection and white blood cell extraction 
2.3.1 Blood samples from healthy volunteers 
Whole blood from healthy volunteers was obtained from students and staff 
members at the Northern Institute for Cancer Research, Newcastle University. The 
protocol was approved by the ethics committee of Newcastle University (protocol 
number ET13-002). All blood samples were taken from volunteer donors by registered 
doctors and were transferred directly to specific blood tubes depending on the 
experimental protocol. 
To isolate white blood cells, red blood cells in whole blood samples were lysed 
by BD Lyse/Fix Buffer. This buffer was diluted in distilled water (1:5) and whole blood 
was added in the proportion of 20 mL of diluted buffer per 1 mL of whole blood. The 
solution was well mixed and incubated at 37°C for 10 minutes, followed by 
centrifugation at 500×g for 10 minutes. The supernatant was gently poured off and the 
cell pellet was resuspended in 1 mL of PBS and transferred to an Eppendorf tube. The 
sample tube was centrifuged at 500×g for 5 minutes and the supernatant removed. 
The cell pellet was again washed with 1 mL of PBS, centrifuged (500×g for 5 minutes) 
and the supernatant removed. Lastly, cells were resuspended in ice cold methanol for 
permeabilisation. The white blood cell suspension was stored at -20°C for at least 24 
hours. 
2.3.2 Blood samples from patients in the SIOP Ependymoma trial 
Whole blood samples were collected from children with ependymoma being 
treated with valproic acid as part of the SIOP Ependymoma II clinical trial. The study 
protocol was approved by the UK East Midlands Multicentre Research Ethics 
Committee and written informed consent was obtained from patients or parents as 
appropriate. Participating clinical sites were based in several cities around the UK 
including Nottingham, Leeds, Sheffield, Oxford and Cambridge. Whole blood was 
drawn from participants and added directly to the diluted BD Lyse/Fix Buffer, which 
was prepared using the protocol described above (section 2.3.1), to fix WBCs and lyse 
RBCs. The blood tubes were frozen on dry ice, and then delivered to the laboratory 
within 3 days. 
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When frozen blood samples arrived the laboratory, blood tubes were warmed 
in a water bath at 37°C for 30 minutes or until the whole sample was defrosted. 
Samples were then centrifuged at 500×g for 10 minutes and the supernatant removed, 
washed with 1 mL PBS solution and transferred to Eppendorf tubes. The washing step 
was repeated and cell pellets were resuspended in ice cold methanol. Samples were 
stored at -20°C until used. This process was performed within 24 hours of the samples 
arriving in the laboratory. 
2.3.3 Blood samples from patients in the PROSPECT-NE trial 
Whole blood was taken from cancer patients participating in the PROSPECT-NE 
clinical trial at the Freeman Hospital, Newcastle upon Tyne. Appropriate ethical 
approval and consent was obtained. Whole blood was added directly to CellSave 
tubes and delivered to the laboratory within 5 days of collection. White blood cells 
were isolated from patient samples using the protocol described in section 2.3.1. 
 
2.4 Free valproic acid extraction and valproic acid quantification 
 Plasma samples from patients studied on the SIOP Ependymoma trial were 
frozen and delivered to the laboratory at the same time as whole blood samples. To 
obtain free valproic acid, plasma samples were defrosted in a 37°C water bath for 30 
minutes, and then centrifuged at 2,000×g for 5 minutes. The supernatant was pipetted 
into the reservoir of an ultrafiltration filter. Samples were centrifuged at 1,500×g for 
20 minutes following the manufacturer’s instruction. The clear filtered solutions were 
sent to the Department of Blood Sciences laboratory at the Royal Victoria Infirmary, 
Newcastle upon Tyne, to measure concentrations of valproic acid. These were 
analysed alongside patient plasma samples, in order to measure free and total valproic 
acid levels, respectively. 
 Concentration of valproic acid in plasma, either as free or total drug, was 
quantified using a Roche/Hitachi Cobas C 701 analyser. The assay is based on a 
homogeneous enzyme immunoassay technique, i.e. the competition between drug in 
the sample and drug labelled with the enzyme G6PDH for antibody binding sites. The 
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measuring range of this machine is 2.8-150 µg/mL (19.4-1040 µM) and the 
repeatability (within-run precision) is 4.8%CV (Roche Diagnostics, 2012). 
 
2.5 CDC7, pMCM2 and ki-67 assay validation experiments 
2.5.1 In vitro concentration dependent experiments 
 HL-60 cells (1×106) were seeded in 2 mL RPMI-1640 medium supplemented 
with 10% FBS in 6-well plates. LY3143921 hydrate powder was dissolved in distilled 
water (dH2O) to make up 100 µg/mL of drug solution. The solution was pipetted to the 
prepared wells at final concentrations of 0.001, 0.01, 0.1, 1 and 10 µg/mL, with dH2O 
added to the last well as a negative control. The volume of all wells were adjusted with 
dH2O. The plate was then incubated at 37°C, 5% CO2 for 6 hours. 
Cell suspensions were harvested by transfer to Eppendorf tubes and 
centrifuged at 500×g for 5 minutes. The media was aspirated and cell pellets washed 
twice with 1 mL PBS. Cells were centrifuged at 500×g for 5 minutes and supernatants 
removed. Lastly cells were resuspended in -20°C methanol and stored in a -20°C 
freezer for at least 24 hours before analysis. 
2.5.2 Ex vivo concentration dependent experiments 
Whole blood samples from healthy volunteers were collected into EDTA tubes, 
and then divided into Falcon™ tubes (2 mL of blood/tube). LY3143921 powder was 
dissolved in dH2O to obtain a stock concentration of 10 mg/mL. The drug solution was 
diluted with dH2O to 1 mg/mL and added to each blood tube to obtain final 
concentrations of 0.001, 0.01, 0.1, 1, 10 and 100 µg/mL and the final volume adjusted 
with the solvent. Distilled water was added to the last tube as a negative control. All 
tubes were incubated in a shaking incubator at 200 rpm, 37°C for 6 hours. Blood 
samples were collected using the protocol mentioned in section 2.3.1. The experiment 
was performed three times with three independent blood donors. 
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2.5.3 Ex vivo time dependent experiments 
 Whole blood in EDTA tubes collected from healthy volunteers, was divided into 
two sets of Falcon™ tubes (2 mL of blood/tube). The first set was treated with 
10 µg/mL of LY3143921 in dH2O and the second set was treated with dH2O at the same 
volume. Both sets of blood tube were incubated in a shaking incubator at 200 rpm, 
37°C. One blood tube in each group was collected at time points of 0, 0.5, 1, 3 and 6 
hours. The collected blood samples were immediately processed for RBC lysis and WBC 
fixation using the protocol mentioned in section 2.3.1. The experiment was performed 
three times with blood collected from three independent donors. 
2.5.4 In vivo experiments 
 In vivo experiments were performed in 6-8 weeks old female CD1 mice which 
were between 25-30 g. Eighteen mice were divided into three equal groups of six mice 
per group. LY3143921 was re-suspended in a vehicle of 5% Ethanol and 95% (1%w/v) 
HPMC; the final concentrations of the drug were 1.5 mg/mL for 15 mg/kg group and 5 
mg/mL for 50 mg/kg group. The first and second groups of mice received 15 mg/kg and 
50 mg/kg of LY3143921 suspension by oral gavage, while vehicle was administered to 
the third group. Blood samples were collected from the tail veins of three mice per 
group before treatment as baseline control, and then collected at 6 hours. The other 
three mice in each group were bled at 3 and 24 hours post-treatment and all mice 
were sacrificed after the second blood collection. All blood samples were processed 
using the same protocols for human samples as mentioned in section 2.3.1. 
2.5.5 Whole blood storage stability tests 
2.5.5.1 Whole blood storage in different blood tubes 
 Different commercially available blood collection tubes including EDTA tubes, 
CellSave tubes, TransFix tubes and Streck tubes were tested for their ability to 
preserve CDC7, pMCM2 and ki-67 antigens. Whole blood from one donor was divided 
equally and added to each blood tube following the manufacturer’s instructions. EDTA 
tubes containing whole blood were stored at 2-8°C while the other tubes were stored 
at room temperature as recommended by manufacturers. Aliquots of blood (2mL) 
from each tube were collected to measure CDC7, pMCM2 and ki-67 expression at 0, 6, 
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24, 48 and 72 hours. RBC lysis and WBC fixation were as described in section 2.3.1. 
Experiments were performed three times with three independent blood donors. 
2.5.5.2 Whole blood storage at -80°C 
 One part Lyse/Fix Buffer was diluted in 4 parts distilled water to make up a 
stock solution. Twenty mL of the buffer was added to each of six Falcon tubes. Whole 
blood from a healthy volunteer was added to the prepared buffer in the proportion of 
1 mL of whole blood to 20 mL of buffer. The tubes were gently inverted eight times 
and immediately frozen at -80°C. Samples were further processed at time points of 0, 
1, 2, 3, 4 and 5 days. The collected blood tubes were thawed and WBCs isolated using 
the protocol for frozen blood as described in section 2.3.2. The experiment was 
performed three times with three independent blood donors. 
2.5.6 CDC7, pMCM2 and ki-67 antibody incubation assays 
 Aliquots of cells (1x106) in methanol were pipetted into an Eppendorf tube and 
centrifuged at 500×g for 5 minutes. Methanol was aspirated and the cell pellet was re-
suspended in 1 mL of a solution of 5% BSA in PBS. The cell suspension was centrifuged 
at 500×g for 5 minutes, the supernatant removed and the pellet re-suspended in 1 mL 
of 5% BSA in PBS. The cells were incubated in the solution for 1 hour at room 
temperature for protein blocking. 
 Following blocking the cells were centrifuged at 500×g for 5 minutes, the 
supernatant removed and the pellet re-suspended in 1 mL of 5% BSA in PBS with 1 µL 
of pMCM2 primary antibody. Cells were incubated with the antibody for 1 hour at 
room temperature and then washed with 1 mL of 5% BSA in PBS. The cells were then 
incubated in 1 mL of 5% BSA in PBS with 1 µL of secondary antibody conjugated with 
PE conjugated goat anti-rabbit secondary, 0.5 µL of CDC7 antibody conjugated with 
FITC and 5 µL of DAPI for 1 hour at room temperature. The antibody solution was then 
removed and cells washed with 1 mL of 5% BSA in PBS. 
 Lastly, the cells were centrifuged at 500×g for 5 minutes and 90% of the 
supernatant was aspirated before 1 µL of antibody against ki-67 conjugated with 
AlexaFluor 647 was added to the remaining cell suspension. The cells were incubated 
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with the antibody for 1 hour and washed with 1 mL of 5% BSA in PBS. The supernatant 
was removed and cells were analysed by an imaging flow cytometer. 
 For any samples where a CDC7 signal was not required, CDC7 antibody was not 
added to the sample at the second incubation step. This protocol was applied to all cell 
types including cell lines, mouse WBCs and human WBCs. 
 
2.6 Acetylated histone H4 assay validation 
2.6.1 In vitro concentration dependent experiments 
Aliquots of RPMI-1640 medium supplemented with 10% FBS (2mL) were 
pipetted into each well of a 6-well plate and then one million HL-60 cells were seeded 
in each well. Valproate sodium powder was dissolved in RPMI-1640 medium to make 
up a 50 mM stock solution. The solution was pipetted to the prepared wells to yield 
final concentrations of 0.5, 1, 2, 4 and 8 mM, with medium only added to the last well 
as a negative control. The volume in each well was adjusted with the medium. The 
plate was then incubated at 37°C, 5% CO2 for 6 hours. Cell samples were collected 
using the protocol for cell lines as described in section 2.5.1. The experiments were 
repeated three times. 
2.6.2 In vitro time dependent experiments 
HL-60 cells (1x106) were seeded in 2 mL RPMI-1640 medium supplemented 
with 10% FBS in 6-well plates. Valproate sodium powder was dissolved in RPMI-1640 
medium to make up a 50 mM stock solution. The solution was then pipetted into all 
prepared wells to provide a final concentration of 4 mM sodium valproate in each well. 
The cell suspension in the first well was collected immediately as a baseline control. 
The plate was then incubated at 37°C with 5% CO2 for up to 24 hours. The treated cells 
were harvested at 0.5, 1, 3, 6 and 24 hours post-treatment. Cell samples were 
collected using the protocol for cell lines as described in 2.5.1. The experiment was 
repeated three times. 
30 
 
2.6.3 Ex vivo concentration experiments 
Whole blood from a healthy volunteer was collected into EDTA tubes and 
divided into 6 Falcon™ tubes (2 mL of blood per tube). Valproate sodium powder was 
dissolved in RPMI-1640 medium to obtain a concentration of 50 mM. The drug solution 
was added to individual blood tubes to generate final concentrations of 0.5, 1, 2, 4 and 
8 mM and the final volume was adjusted with RPMI-1640 medium. The medium was 
added to the last tube as a negative control. All tubes were incubated in a shaking 
incubator at 200 rpm, 37°C for 6 hours. RBC lysis and WBC fixation were processed 
following the protocol described in section 2.3.1. 
2.6.4 acH4 antibody incubation assay 
Aliquots of cells (1x106) in cold methanol were pipetted into Eppendorf tubes. 
The cell suspensions were centrifuged at 500×g for 5 minutes at room temperature 
and the methanol was aspirated. Cell pellets were then re-suspended in 1 mL of 5% 
BSA in PBS and again centrifuged at 500×g for 5 minutes at room temperature. The 
supernatant was aspirated and cells were incubated with 1 mL of 5%BSA in PBS for 1 
hour at room temperature, centrifuged and the supernatant again removed. The 
antibody against acH4 (1 µL) was added to the cell suspensions and incubated 
overnight at 2-8 °C. 
Cells were washed with 1 mL of 5% BSA in PBS, centrifuged and the 
supernatant removed. DAPI (5 µL) was pipetted into the cell suspensions, which were 
incubated at room temperature for 1 hour. One mL of 5% BSA in PBS was added to 
each tube to wash the cells. The tubes were then centrifuged and the supernatants 
aspirated. Lastly acH4 expression was measured by an imaging flow cytometer as 
described below. 
 
2.7 Assay for ki-67 detection for the PROSPECT-NE trial 
 WBCs (1x106) in methanol, as prepared in section 2.3.3, were pipetted into 
Eppendorf tubes. Samples were centrifuged at 500×g for 5 minutes at room 
temperature and the methanol was aspirated. The cells were re-suspended in 1 mL 5% 
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BSA in PBS, centrifuged at the same speed and the supernatants aspirated. The cells 
were then incubated in 1 mL 5% BSA in PBS at room temperature for 1 hour for protein 
blocking. 
 WBCs were centrifuged again at 500xg for 5 minutes and the supernatants 
removed. Ki-67 antibody (1 µL) and DAPI (5 µL) were added to the samples, which 
were mixed well and incubated at room temperature for 1 hour. The cells were then 
washed with 1 mL of 5% BSA/PBS and centrifuged to remove the supernatants. 
Samples were run on the ImageStream imaging flow cytometer to measure ki-67 
expression. 
 
2.8 Imaging flow cytometer data collection 
Cell suspensions as prepared above were analysed on an ImageStream 
imaging flow cytometer with the parameters listed below as appropriate: 
 To measure CDC7, pMCM2 and ki-67 expression the 405 nm laser was set at 30 
mW, The 488 nm laser at 50 mW, the 642 nm laser at 100 mW and the 785 nm 
laser at 11.83 mW. 
 To measure ki-67 expression, the 405 nm laser was set at 30 mW, the 642 nm 
laser at 100 mW and the 785 nm laser at 11.83 mW. 
 To measure acH4 expression, the 405 nm laser was set at 30 mW, the 488 nm 
laser at 100 mW and the 785 nm laser at 11.83 mW. 
The gating used to collect cells of interest is illustrated in Figure 2.1. First, round 
single cells were gated from area and aspect ratio; particles with 50-200 µm2 in area 
and 0.6-1.0 in aspect ratio were gated as round single cells. This population was then 
screened by raw maximum intensity of DAPI to exclude non-cell particles. Any particles 
showing expression of DAPI were identified as cells and collected. For cell lines, 5,000 




   
Figure 2.1. Illustration of the imaging flow cytometry gating used to collect the cells 
of interest in this study. 
Round single cells (RSC) were gated from the scatter graph of aspect ratio against 
area, and then nucleated cells in the RSC population were identified by the 
histogram of raw maximum intensity of DAPI (Ch07). 
 
2.9 Data analysis by Ideas software 
2.9.1 Analysis of CDC7, pMCM2 and ki-67  
The data analysis process is illustrated in Figure 2.2. Collected cells from the 
imaging flow cytometer were analysed using Ideas software version 6.2. Cells were 
first gated as round single cells (RSC) by the area and aspect ratio to reduce non-cell 
particles and clusters of cells. Of the RSC population only cells in focus were selected 
for further analysis using a predefined feature in the Ideas software, gradient root 
mean squared, of bright field; cells with a value greater than 60 were included in the 
focused cell group. 
Focused cells were divided into two populations – myeloid and lymphoid cells – 
using intensity of side scatter and area of cells. The expression of CDC7, pMCM2 and 
ki-67 was assessed in each population based on the intensity of staining and similarity 
in localisation between protein and nuclear (DAPI) staining. Cells with high intensity 
and high similarity, with positive signal in the nucleus, were identified as positive. As 
the majority of CDC7 was cytoplasmic expression, the CDC7 expression was assessed 
by gating all CDC7 positive cells (nuclear and cytoplasmic positive cells). For pMCM2 
and ki-67 expression, only nuclear positive cells were counted. 
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The results were reported as percentages of CDC7 positive, nuclear pMCM2 
positive and nuclear ki-67 positive cells in myeloid, lymphoid and total WBC 
populations. The percentage of pMCM2 positive cells was also shown as a proportion 
of ki-67 positive cells. Moreover, the intensity of all three proteins was measured in 
each cell population by histograms (data not shown) and reported as mean and 




















Figure 2.2. The process of data analysis of CDC7, pMCM2 and ki-67. 
Round single cells (RSC) were first gated and the focused cells gated out of the 
RSC population. Cells were then divided into myeloid and lymphoid cells. CDC7, 
pMCM2 and ki-67 expression levels were determined in each cell type by 
looking at the similarity between protein and DAPI expression and intensity of 
protein. 
  







2.9.2 Analysis of acH4  
Collected cells from the imaging flow cytometer were analysed using Ideas 
software version 6.2. As shown in Figure 2.3, cells were first gated for round single 
cells, focused cells, and myeloid and lymphoid cells using the same gating as described 
in section 2.9.1. Myeloid and lymphoid cells were then gated for nuclear acH4 positive 
cells using a scatter graph between intensity of acH4 and similarity between acH4 and 
DAPI; cells with high similarity and high intensity of acH4 were identified as nuclear 
acH4 positive cells. 
Results were expressed as percentage of acH4 positive cells in myeloid, 
lymphoid and total WBC populations. Furthermore, mean and median intensities of 





















Figure 2.3. Summary of data analysis of acH4. 
Round single cells (RSC) were first gated and the focused cells gated out of the 
RSC population. Cells were then divided into myeloid and lymphoid cells. The 
level of acH4 expression in each cell type was determined by looking at the 
similarity between acH4 and DAPI expression and intensity of protein. 

















2.9.3 The analysis of ki-67  
 Cells collected by the imaging flow cytometer were analysed with Ideas 
software version 6.2. Round single cells, focused cells, and myeloid and lymphoid cells 
were gated using the same gating as described in section 2.9.1. In common with the 
pMCM2 analysis, similarity of ki-67 and DAPI expression alongside ki-67 intensity were 
applied to identify nuclear ki-67 positive cells as shown in Figure 2.4. The number of 
ki-67 positive cells was expressed as percentage of positive cells in the myeloid, 




















Figure 2.4. Analysis of ki-67 expression in patient samples from the PROSPECT-NE 
clinical trial. 
Round single cells (RSC) were first gated, and then focused cells were gated from 
the RSC population. Cells were then divided into myeloid and lymphoid cells 
using side scatter intensity. Each cell type was assessed for ki-67 expression by 
looking at the similarity between ki-67 and DAPI expression and intensity of the 
protein. 
 







2.10 ELISA assay for detection of circulating ki-67  
 When blood samples in CellSave tubes from patients studied on the 
PROSPECT-NE trial were delivered to the laboratory for ki-67 cell analysis, plasma was 
also collected. To obtain plasma, whole blood was centrifuged at 1000×g for 10 
minutes at 4°C. Plasma was then aliquoted to Eppendorf tubes and immediately frozen 
at -80°C prior to analysis. 
 ELISA plates were prepared following the manufacturer’s instructions. Briefly, 
diluted capture antibody (100 µL) was added to each well in a 96-well plate and 
incubated overnight to coat the wells. The capture antibody was aspirated and each 
well was washed with 400 µL of wash buffer 3 times. The plates were blocked by 
adding 300 µL reagent diluent to each well and incubating for 1 hour at room 
temperature. The plates were then washed 3 times with wash buffer. 
One aliquot of plasma sample was thawed in a 37°C water bath for 30 minutes, 
and then 100 µL of each plasma sample and ki-67 standard solutions, were pipetted to 
the prepared wells and incubated for 2 hours at room temperature. The plates were 
then washed twice. The diluted detection antibody (100 µL) was added to each well, 
incubated for 2 hours and the wells were then again washed twice. The diluted 
streptavidin-HRP solution (100 µL) was added to each well and incubated in the dark 
for 20 minutes and the washing step was repeated twice more. Substrate solution 
(100 µL) was added to each well and incubated in the dark for 20 minutes. The stop 
solution (50 µL of 2 N Sulphuric acid) was then added to each well and gently mixed. 
 Lastly, the absorbance of light at 450 nm (A450) was measured for each well 
using the Omega microplate spectrophotometer. A standard curve between A450 and 
ki-67 concentration was generated using the four parameter logistic curve-fit function 




2.11 Statistical analysis 
 All statistical analyses in this PhD project were performed using either 
GraphPad Prism 6 or IBM SPSS Statistics 24 programmes, depending on the tests being 
carried out. Comparison tests including one-way and two-way ANOVA and the Mann-
Whitney U-test, and correlation tests including Spearman’s correlation were 
performed using GraphPad Prism 6. Survival analysis and the cox proportional hazard 







Chapter 3. Development of an assay for pMCM2 and ki-67 as 
pharmacodynamic biomarkers for LY3143921, a CDC7 inhibitor 
3.1 Introduction 
 LY3143921 is a novel anti-cancer agent designed to inhibit the cell division cycle 
7 kinase (CDC7), an enzyme involved in the initiation of DNA replication cell cycle 
regulation and found to be over-expressed in cancer cell lines and tumour material. 
The efficacy of the drug has been tested in both cell lines (in vitro) and animals (in 
vivo), and a first-in-human trial to test its safety in man is now ongoing. Development 
and validation of a robust pharmacodynamic biomarker would be advantageous to 
demonstrate the mechanism of action of the drug in a clinical setting. Based on its 
proposed mechanism of action, CDC7, pMCM2 and ki-67 represent potentially useful 
proteins to focus on for the development of an appropriate biomarker assay for 
LY3143921. 
3.1.1 Physiologic roles of CDC7 in mammalian cells 
 CDC7 is a serine/threonine kinase protein which was first discovered in 
Saccharomyces cerevisiae yeast in 1974 (Hartwell et al., 1974). This protein, known as 
hsk1 in yeast, has been shown to have significant importance in yeast budding in many 
studies (Patterson et al., 1986; Bahman et al., 1988; Buck et al., 1991; Sherlock and 
Rosamond, 1993). In mammalian cells, numerous studies have suggested crucial 
functions of CDC7 related to cell division including mitosis, meiotic recombination, 
checkpoint regulation and DNA damage repair (Jiang and Hunter, 1997; Kumagai et al., 
1999). 
 Cells initiate DNA replication at a particular sequence in a genome called the 
replication origin (Bousset and Diffley, 1998). There are 2 main steps in DNA 
replication which are origin licensing and origin activation (Walter, 2000). During the 
origin licensing process, CDC7 phosphorylates subunits of the MCM2-7 complex 
including MCM2, MCM4 and MCM6 (Masai et al., 2000). CDC7 also phosphorylates 
other replication proteins including DNA polymerase alpha p180, CDC45, ORC4 subunit 
of the ORC1-6 complex, SV40 T antigen and CINP which is a CDK2 interacting protein 
(Weinreich and Stillman, 1999; Masai et al., 2000; Nougarede et al., 2000). 
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 The DBF4 subunit is another protein which has been reported to interact with 
CDC7 in S-phase checkpoint activation. These two proteins bind to form a protein 
complex which is called DBF4-dependent kinase (DDK). DDK was found to control 
initiation of DNA replication and shown to be essential for phosphorylation of the 
MCM2-7 complex (Figure 3.1) (Enserink, 2011). This pathway is further explained in 
section 3.1.2 of this thesis. 
 
 
Figure 3.1.  Regulation of DNA replication by the cell cycle. 
Taken from Enserink JM. InTech; 2011. p. 391-408. 
 
 CDC7 was also found to be involved in the meiotic process. Although the roles 
of CDC7 in pre-meiotic DNA replication remain unclear, its roles in meiotic 
recombination are clearer. In the same way that MCM2 phosphorylation plays a role in 
the mitotic pathway, CDC7 acts together with CDK protein to phosphorylate MER2 at 
Ser 29 (Masai et al., 2000). In addition to studies in yeast indicating the importance of 
CDC7 during meiosis, studies in CDC7-/- mice also reported disrupted spermatogenesis 
and infertility (Kim et al., 2003). 
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3.1.2  Regulation of MCM2 by CDC7 
 Phosphorylation of MCM proteins has been studied over a number of years. 
Several in vitro studies suggested that, of all seven MCM proteins, MCM2, MCM3, 
MCM4 and MCM6 subunits are substrates for the CDC7-DBF4 complex (Lei et al., 1997; 
Sheu and Stillman, 2006); the results have also been confirmed in vivo. Among the four 
MCM proteins mentioned, MCM2 was found to be the most essential substrate for 
CDC7 (Tsuji et al., 2006; Bruck and Kaplan, 2009). 
 The pathway of phosphorylation of MCM2 proteins has not yet been fully 
described. As illustrated in Figure 3.1, it is known that CDC7 works together with DBF4 
protein to form a DDK complex. This DDK phosphorylates MCM2 protein which is 
thought to increase its affinity for CDC45 and GINS (Tanaka and Araki, 2010). This 
results in formation of a complex between CDC45, GINS and MCM2-7, followed by 
induction of the unwinding of double-stranded DNA and initiation of DNA replication. 
 More recently published studies have suggested that only distinct residues of 
the MCM2 protein are phosphorylated by the DDK complex and that each 
phosphorylation site of MCM2 has a different affinity to interact with this CDC7 kinase 
complex (Montagnoli et al., 2006). This study found only minimal changes in levels of 
pMCM2 at Ser108 but a strong decrease in levels of Ser40/41 and Ser53 MCM2 
phosphorylation when CDC7 was depleted. 
3.1.3  Association of CDC7, MCM2 and cancer 
 Associations of cell proteins and cancer have been studied for many decades. 
Focusing on CDC7 and pMCM2, several preclinical and clinical studies have suggested 
correlations between these two proteins and several types of cancer. For instance, an 
in vitro study reported overexpression of CDC7 in multiple cancer types including CNS, 
colon, non-small cell lung and leukaemia cell lines as compared to normal tissue cell 
lines (Bonte et al., 2008). 
 These associations have also been shown in clinical studies. For example, a 
study indicated correlations between high CDC7 expression in diffuse large B-cell 
lymphoma (DLBCL) tissues measured by IHC and poor prognosis in DLBCL patients (Hou 
et al., 2012). Similarly in epithelial ovarian carcinoma, patients with higher CDC7 
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expression in tumour specimens determined by IHC had significant lower overall and 
disease-free survivals (Kulkarni et al., 2009). Another study also reported 
overexpression in CDC7 in malignant salivary gland tumours and this was associated 
with tumour grade (Jaafari-Ashkavandi et al., 2017). 
In contrast to the previous findings, a study in colorectal cancer cells found 
33.6% negative, 57.2% weak and 9.2% strong CDC7 expression in patient tumour cells 
measured by immunohistochemistry (Melling et al., 2015). They reported that 
reduction in CDC7 expression was associated with high tumour stage and tumour 
grade. Also, patients with stronger CDC7 expression in cancer cells exhibited longer 
survival times than those with weak or negative CDC7 expression. 
 Expression of MCM2 protein has also been studied in many types of cancer. A 
recent meta-analysis from 9 studies suggested that overexpression of MCM2 was 
associated with poor overall survival (Gou et al., 2018). In patients with lung squamous 
cell carcinoma, MCM2 was found to be correlated with malignant status and overall 
survival (Wu et al., 2018). Furthermore, MCM2 showed higher potential to predict 
recurrence rate in bladder cancer than CK20, ki-67 or histological grade (Burger et al., 
2007). 
 Although there are many publications indicating associations between MCM2 
and various parameters of cancers, none of them have addressed the potential 
application of phosphorylated MCM2 as a predictive or prognostic biomarker for 
cancer. Instead, pMCM2 has been commonly used as a pharmacodynamic biomarker, 
especially since CDC7 inhibiting agents have been developed. For instance, pMCM2 
was used as a pharmacodynamic biomarker in the development of XL-413 (Koltun et 
al., 2012) and TAK-931, another novel CDC7-selective inhibitor (Iwai et al., 2019). 
3.1.4 Function of ki-67 in man 
 The ki-67 protein was originally discovered in Kiel city in Germany in 1983 
(Gerdes et al., 1984). Since its discovery, however, the biological function of the 
protein remains unclear (Scholzen and Gerdes, 2000). Early studies suggested that 
inhibition of ki-67 could inhibit DNA synthesis and result in a decreased rate of cell 
division. These results highlighted the important roles of ki-67 in cell proliferation. 
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 On the other hand, several recent studies have generated different results. For 
example, mouse NIH-3T3 cells lacking ki-67 proliferated normally without apparent cell 
cycle delays. Moreover, it was found that depletion of ki-67 in HeLa and U2OS cell lines 
did not alter cell cycle distribution or ribosomal RNA synthesis (Sobecki et al., 2016). 
These findings are challenging the previous perspective of ki-67 as an important factor 
for cell proliferation. 
 Even though the importance of ki-67 in cell proliferation remains controversial, 
ki-67 has been proven to be a promising marker of cell proliferation. Early studies 
indicated negative expression of ki-67 in peripheral blood leukocytes during G0 phase 
but found ki-67 to be highly expressed in S, G2, and M phase cells (Gerdes et al., 1984). 
With these findings, ki-67 has been used as marker of cell proliferation for decades 
especially in cancer research. 
3.1.5 ki-67 as a biomarker for cancer 
 Based on its promising activity as a marker of cell proliferation, ki-67 has been 
studied in diseases of anomalous proliferation such as cancer for several years. Many 
papers have reported on various possible utilities for the ki-67 protein in the area of 
cancer, including its potential use as a diagnostic tool, a prognostic tool and a 
therapeutic target. Studies in ki-67 as a diagnostic marker, however, remain scarce and 
this area requires further development.  
 Unlike the diagnostic biomarker application, use of ki-67 as a prognostic tool 
has been widely studied in many types of cancer especially breast cancer. A study 
reported that recurrent breast cancer patients with higher ki-67 expression in tumour 
biopsies had significantly shorter disease free intervals and overall survival (Nishimura 
et al., 2014). These results conformed to those obtained in other studies, including 
studies of triple negative breast cancer patients and African breast cancer patients 
(Agboola et al., 2013; Mrklić et al., 2013; Pathmanathan et al., 2014). 
 The utility of ki-67 in other cancers has been much less studied and the results 
obtained have been ambiguous. A study in prostate cancer reported higher mean and 
median ki-67 in patients with recurrent prostate cancer (Wilkins et al., 2018). 
Additionally ki-67 was found to be associated with overall survival in cervical cancer 
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patients (Pan et al., 2015). In contrast, ki-67 did not provide apparent prognostic effect 
in non-small cell lung cancer, bladder cancer or gastric cancer (Yang et al., 2006; 
Czyzewska et al., 2009; Warli et al., 2018). 
 An alternative application of ki-67 in the field of cancer is as a therapeutic 
target for therapy. Examples of drug in this group include antisense 
oligodeoxynucleotides (ASOs), peptide nucleic acids (PNAs) and adenovirus. These 
agents are generated to have a sequence that specifically targets ki-67 nucleotide 
sequence. Several studies have been published involving many anti-cancer agents with 
different mechanisms related to ki-67, with the most promising agents being ASOs. 
ASOs are a class of RNA interference (RNAi) agents which interfere with ki-67 
production and result in specific inhibition of cell proliferation (Yang et al., 2018). 
Phosphorothioate antisense oligodeoxyribonucleotide, an example of an ASO, 
provided efficacy in inhibition of cancer cell proliferation and tumour growth in vitro 
and in vivo (Kausch et al., 2003). Nevertheless, the clinical application of ASOs has 
been limited due to their non-specific binding, low affinity and susceptibility to 
nuclease degradation. PNAs were the second class of RNAi agents synthesized and 
showed stronger effects in terms of inhibition of proliferation and induction of 
apoptosis in renal carcinoma cells in vitro as compared to ASOs (Zheng et al., 2005). In 
addition, there are other mechanisms of cancer therapy such as conditionally 
replicative adenovirus which inhibit ki-67 promoter gene and result in inhibition of 
cancer cell migration and invasion (Yang et al., 2018). 
3.1.6 CDC7 inhibitors as anticancer drug 
  Inhibition of CDC7 kinase competes for ATP and prevents it from being able to 
phosphorylate substrates such as MCM2, resulting in potent cell death in cancer cells 
but minimal inhibitory effects on cell viability in normal cells (Kim et al., 2008; Sawa 
and Masai, 2009; Montagnoli et al., 2010). Following this pathway, the first ATP-
competitive CDC7 inhibitor, (S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoro-ethyl)-1,5,6,7-
tetrahydropyrrolo[3,2-c]pyridin-4-one, was developed in 2008, and several classes of 
CDC7 inhibitor have since been developed (Menichincheri et al., 2009). The functional 
structures of CDC7 inhibiting compounds developed include pyrrolopyridinone, 
indazoles, pyrido-thienopyrimidines, 1H-pyrrolo[2,3-b]pyridines, 5-heteroaryl-3-
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carboxamido-2-aryl pyrroles and benzofuropyrimidinone (Montagnoli et al., 2008; 
Shafer et al., 2008; Ermoli et al., 2009; Zhao et al., 2009; Menichincheri et al., 2010). 
 Among them, PHA-767491 was the first agent that showed highly potent 
inhibition of CDC7 activity both in vitro and in vivo (Montagnoli et al., 2008). Further to 
this success, several CDC7 inhibiting agents have been developed and entered clinical 
trials. For example, the orally administered CDC7 inhibitor, NMS-1116354, was studied 
in a phase I clinical trial setting between 2009 and 2012 (U.S. National Library of 
Medicine, 2009c). BMS-863233, also known as XL-413, was studied in two clinical trials 
(phase I/II) in 2009/2010 (U.S. National Library of Medicine, 2009a; U.S. National 
Library of Medicine, 2009b). Since then, many CDC7 inhibitors including TAK-931, 
SRA141 and LY3143921 have also been developed (U.S. National Library of Medicine, 
2017; Hansen et al., 2018; Toshio et al., 2018). 
 LY3143921 is a novel CDC7 inhibitor developed by Eli-Lilly and Company. Figure 
3.2 illustrates the chemical structure of this agent. The efficacy and toxicity of 
LY3143921 have been tested in both cell lines, including SW620, A2780, HL-60 and 
AX521 cells, and animal studies involving mouse, rats, dogs and monkeys. In vivo 
studies demonstrated that administration of 10 mg/kg of the drug to mice resulted in a 
Cmax of 1810±350 ng/mL and a Tmax of 3±1.15 hours. In comparison, beagle dogs 
receiving 6 mg/kg and monkeys receiving 3 mg/kg of the drug showed a higher Cmax 
(4160±1650 and 4450±491 ng/mL, respectively). For pharmacodynamic studies, CDC7 
expression in mouse xenograft tumour tissues was potently inhibited by LY3143921 
and resulted in a huge decrease in pMCM2 (>70% as measured by IHC) for up to 12 
hours after the last dose. Moreover, several studies in xenograft tumour models also 
reported stable disease and tumour regression in many types of cancer including lung, 





Figure 3.2.  Molecular structure of LY3143921 
 
 The first phase I clinical trial of LY3143921 started in May 2017. The inclusion 
criteria were patients with many types of advanced cancer including bladder, 
colorectal, breast, head and neck and kidney, who had failure from regular treatment 
(refractory cancer). This trial consisted of two parts; the first part was an optimisation 
of dose and frequency of LY3143921 and the latter part involved treatment of patients 
with the drug regimen determined in stage I. Tumour biopsies were taken before 
treatment and again during the first cycle of treatment. Blood samples were taken 
regularly and closely monitored to observe any adverse effects of the drug (Cancer 
Research UK, 2017). 
3.1.7 Pharmacodynamic biomarkers for CDC7 inhibitors 
 Pharmacodynamic biomarkers are increasingly included in clinical trials in 
oncology, especially in terms of proof-of-mechanism. In this respect, they could be 
utilised in patient monitoring if correlations are shown between the biomarkers and 
clinical response. Focusing on CDC7 inhibitors, previously published clinical trials have 
suggested various different pharmacodynamic biomarkers of relevance. Based on the 
pathway of CDC7 mentioned above, several downstream proteins could be used as 
biomarkers including MCM2-7 complex, DBF4 protein or CDC7 itself (Enserink, 2011). 
 Among them, pMCM2 is considered a promising candidate for development as 
a CDC7 inhibitor biomarker. However, different phosphorylation sites of MCM2 were 
found to respond differently to CDC7 inhibitors. Montagnoli et al performed HeLa cell 
transfection with interference RNA targeting CDC7 for up to 72 hours. The 
phosphorylation of MCM2 proteins at different subunits was measured using SDS-
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PAGE Western Blotting. The results suggested that phosphorylation of MCM2 subunits 
at Ser40 and Ser53 were completely dependent on CDC7 activity and had the potential 
to act as pharmacodynamic biomarkers (Montagnoli et al., 2006). 
 Not only direct CDC7 downstream proteins could be used as biomarkers for 
CDC7 inhibitors, other indirectly involved proteins could also be utilised. A study of 
XL413 indicated a decrease in pCHK1 (Ser317) when A431 epidermoid carcinoma cells 
were treated with a combination of XL413 and etoposide as compared to etoposide 
alone. (Robertson, 2008). Another study of PHA-767491 showed decreases in several 
proteins including MCL-1, BCL-A1 and NOXA when CLL cell lines were treated with ≥5 
µM of the drug (Natoni et al., 2011). These findings have suggested some potential 
pharmacodynamic biomarkers for further development of CDC7 inhibitors. 
The association between CDC7 and ki-67 proteins has been sparsely studied and 
there are no publications confirming correlations between CDC7 inhibitors and 
changes in ki-67. As the mechanism of action of CDC7 inhibition involves inhibition of 
cell proliferation, ki-67 should be considered as a potential indirect biomarker for CDC7 
inhibitors. This study therefore included ki-67 as an indirect biomarker of cell inhibition 
induced by LY3143921.  
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3.2 Chapter specific aims 
 The studies outlined in this chapter primarily aimed to develop and validate an 
imaging flow cytometry assay for detection of potential pharmacodynamic biomarkers 
for LY3143921 including CDC7, pMCM2 and ki-67 proteins. The objectives of 
development included the following: 
• Optimisation of antibodies used in the assay including CDC7, pMCM2 and ki-67 
antibodies. 
• Investigation of changes in proteins of interest in HL-60 cell lines with 
increasing LY3143921 concentration and duration of treatment. 
• Investigation of changes in proteins of interest in human WBCs when treated 
with increasing concentrations of LY3143921. 
• Investigation of changes in proteins of interest in mouse WBCs when animals 
treated with different doses of LY3143921. 
• Optimisation of preservation methods for proteins of interest using different 
storage conditions including commercial preservative blood tubes and fixed 





3.3.1 Antibody validation 
3.3.1.1 CDC7 antibody validation 
 The most suitable volume of antibody against CDC7 protein to be used in the 
assay was first optimised. HL-60 cells were fixed with ice cold methanol and incubated 
with different volumes of CDC7 antibody (0.5, 1, 2 and 4 µL) together with 5 µL of DAPI 
for 1 hour. The cells were analysed for CDC7 expression levels using an imaging flow 
cytometer. Specificity of CDC7 antibody was determined by comparison of CDC7 
expressions in HL-60 cells with/without 1,25-dihydroxyvitamin D3 treatment in pilot 
experiments (data not shown), based upon the study by Brackman et al (Brackman et 
al., 1995). 
  
Figure 3.3 shows the intensity of CDC7 expression in histograms alongside examples of 
cells at the peak of the graph and scatter plots showing the population of cells with 
high CDC7 expression in the nucleus, namely nuclear CDC7 positive cells. As compared 
to incubations with no antibody, cells with 0.5 and 1 µL of antibody provided 
observable signals. The results suggested that the CDC7 antibody had the required 
sensitivity to detect signals of CDC7 protein at all antibody dilutions as compared to 
the control. As shown in Figure 3.4, a background mean intensity of 28,000 was 
observed, while 0.5 µL of antibody exhibited a mean intensity of 76,000 which 
increased to 141,000 with 4 µL of antibody. 
 Although the obtained CDC7 intensity signal was not likely to be saturated at a 
concentration of 4 µL, the percentages of nuclear CDC7 positive cells at all 
concentrations were found to be similar (Figure 3.5). With 0.5 µL of antibody, 97% 
nuclear CDC7 positive cells were detected as compared to 0.72% from the control. 
Higher volumes of antibody did not generate higher number of positive cells; the 
percentages of CDC7 positive cells at 1, 2 and 4 µL of antibody were 98.1%, 99.6% and 
96%, respectively. The results therefore suggested that 0.5 µL was sufficient to be used 
in the assay and that increasing the antibody volume did not show conclusive benefits 





















Figure 3.3.  Histograms of the intensity of CDC7, examples of cells at the peaks of 
histograms, and scatter plots between intensity of CDC7 and similarity of CDC7 and 
DAPI. 
Samples were collected from HL-60 cell lines incubated with different volumes 
of CDC7 antibody for 1 hour. 
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Figure 3.4. Mean intensity of CDC7 expression in HL-60 cells incubated with different 
volumes of CDC7 antibody (0-4 µL) for 1 hour. 
The results shown are from a single experiment. Mean intensity refers to 
average expression of protein in all cells collected from one sample. 
 

























Figure 3.5. Percentage of nuclear CDC7 positive in HL-60 cells incubated with 
different volumes of CDC7 antibody (0-4 µL) for 1 hour. 




3.3.1.2 pMCM2 antibody validation 
 The antibody against MCM2 phosphorylation at serine 53 was tested to find 
the optimal volume for the assay. Different volumes of pMCM2 primary antibody (0, 1, 
2.5, 5 and 10 µL) were incubated with HL-60 cell lines for 1 hour. PE secondary 
antibody (1 µL) and DAPI (5 µL) were then added to all tubes, incubated for 1 hour and 
the PE signal measured by imaging flow cytometry. 
 Figure 3.6 shows histograms of pMCM2 intensity and scatter graphs between 
similarity of pMCM2 and DAPI and intensity of pMCM2 with examples of cells from 
each antibody volume. As compared to the control (no pMCM2 primary antibody), all 
dilutions of pMCM2 primary antibody generated detectable signals. In addition, the 
histograms revealed bimodal curves for antibody volumes of 1, 2.5 and 5 µL but not for 
10 µL. Focusing on the mean intensity of pMCM2 expression (Figure 3.7), the values 
ranged between 23,000 and 27,000 for all concentrations of pMCM2 primary antibody 
with very low pMCM2 signal (1,200 mean intensity) for samples without pMCM2 
antibody. 
 In agreement with the pMCM2 intensity data, the percentages of nuclear 
pMCM2 positive cells for all volumes of pMCM2 antibody were observed to be stable 
(Figure 3.8). The percentages of pMCM2 positive cells were 59.8%, 57.4%, 62.0% and 
64.5% for 1, 2.5, 5 and 10 µL of antibody, respectively. There were no pMCM2 positive 
cells detected in the samples without pMCM2 antibody. These results therefore 
suggested that 1 µL of pMCM2 primary antibody with 1 µL of PE secondary antibody 
was suitable for the assay because it generated as strong a signal and number of 





















Figure 3.6. Histograms of the intensity of pMCM2, examples of cells at the peaks of 
histograms, and scatter plots between similarity of pMCM2 and DAPI. 
Samples were collected from HL-60 cell lines which were incubated with 
different volumes of pMCM2 primary antibody for 1 hour. The volume of PE 
secondary antibody was fixed at 1 µL. 
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Figure 3.7. Mean intensity of pMCM2 expression in HL-60 cells with different 
volumes of pMCM2 primary antibody for 1 hour. 
PE secondary antibody was 1 µL for all concentrations of primary antibody. The 
results shown are from a single experiment. Mean intensity refers to average 
expression of protein in all cells collected from one sample. 
 


























Figure 3.8. Percentage of nuclear pMCM2 positive in HL-60 cells incubated with 
different volumes of pMCM2 antibody for 1 hour. 
PE secondary antibody was 1 µL for all concentrations of primary antibody. The 





3.3.1.3 ki-67 antibody validation 
 In order to optimise the volume of FITC-conjugated antibody against ki-67, 
HL-60 cell lines were incubated with ki-67 antibody at volumes of 1, 2, 3 and 4 µL 
together with 5 µL of DAPI for 1 hour. Cells were washed with 1 mL of 5% BSA in PBS 
and ki-67 expression quantified by imaging flow cytometry. 
 The results shown in Figure 3.9 indicate non-normal distribution curves of ki-67 
intensity, so the median was considered instead of mean for ki-67 expression. The 
representative images of cells for each volume of antibody clearly show detectable 
signals of ki-67 when incubated with 1 µL of antibody or higher as compared to control 
cells (no antibody). Figure 3.10 suggests an increase in median intensity of ki-67 
expression with increasing amount of ki-67 antibody. Median ki-67 signals of 170,000, 
230,000, 277,000 and 313,000 were observed with ki-67 antibody volumes of 1, 2, 3 
and 4 µL, respectively; without the antibody added, cells expressed a signal intensity of 
14,500. 
 Figure 3.11 shows high percentages of nuclear ki-67 positive cells with up to 
90% positive cells. The numbers of positive cells were similar for all antibody dilutions; 
there were 85.7%, 88.5%, 87.9% and 90.1% positive cells at volumes of 1, 2, 3 and 4 µL. 
The control without antibody showed no ki-67 positive cells. Based on the obtained 
results, 1 µL of ki-67 antibody was efficient for the developed assay and therefore was 





















Figure 3.9. Histograms of the intensity of ki-67, examples of cells at the peaks of 
histograms, and scatter plots between similarity of ki-67 and DAPI. 
Samples were collected from HL-60 cell lines that were incubated with different 
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Figure 3.10. Median intensity of ki-67 expression in HL-60 cell lines with different 
volumes of ki-67 antibody (0-4 µL) for 1 hour. 
The results shown are from a single experiment. Median intensity refers to the 
median expression of protein in all cells collected from one sample. 
 
























Figure 3.11. Percentage of ki-67 positive cells in HL-60 cell lines incubated with 
different volumes of ki-67 antibody (0-4 µL) for 1 hour. 




3.3.2 Inter- and intra-staining variation of the developed assay 
 The precision of the developed assay was tested before embarking on 
additional experiments with white blood cells. White blood cells obtained from a 
healthy donor were divided into seven tubes and incubated with pMCM2 and ki-67 
antibody at different conditions. Five samples were incubated with the same master 
mix of antibodies and analysed on the same day, with a single sample measured three 
times to investigate the accuracy and precision of the imaging flow cytometer. 
Additional samples were stained 1 week and 2 weeks after the first experiment 
following the same protocol. 
 The number of cells with high expression of pMCM2 and ki-67 (pMCM2 positive 
and ki-67 positive cells) were counted and expressed as a proportion of all white blood 
cells. The first sample which was measured 3 times generated comparable percentages 
of pMCM2 and ki-67 positive cells ( 
Table 3.1) with percentage of coefficient of variation (%CV) less than 10% (8% for 
pMCM2 and 6.9% for ki-67). The %CVs of five samples incubated in parallel with the 
same master mix were 12% for pMCM2 and 5.7% for ki-67 as shown in Table 3.2. The 
%CVs of the sixth and seventh samples which were incubated with different master 
mix of antibodies were higher (14.4% for pMCM2 and 12.3% for ki-67, Table 3.3). All 









1/1 0.25 1.13 21.6 
1/2 0.27 1.28 20.3 
1/3 0.23 1.15 19.8 
Flow cytometer 
precision 
Mean 0.25 1.19 20.57 
%CV 8.00 6.86 4.52 
 
Table 3.1. Precision of the imaging flow cytometer in measurement of pMCM2 and 











Average of sample 1 0.25 1.19 20.57 
2 0.25 1.09 21.4 
3 0.28 1.19 22.6 
4 0.26 1.09 23.5 
5 0.33 1.14 28.1 
Intra-staining variation Mean 0.27 1.14 23.23 
%CV 12.27 4.32 12.66 
Table 3.2. Intra-staining variation in pMCM2 and ki-67 in 5 samples from the same 
donor. 









Average of sample 1-5 0.27 1.14 23.23 
6 0.27 1.05 25.4 
7 0.21 0.89 23.5 
Inter-staining variation Mean 0.24 0.98 24.11 
%CV 15.16 12.40 4.52 
Table 3.3. Inter-staining variation in pMCM2 and ki-67 in 7 samples from the same 
donor. 
 Sample 6 and 7 were stained in experiments performed on different days using 
the same assay as sample 1-5 with different master mixes of antibodies. 
 
3.3.3 LY3143921 concentration dependent in vitro experiments 
 The developed and validated assay was first tested in HL-60 cell lines in an in 
vitro setting. HL-60 cells were treated with LY3143921 at concentrations ranging from 
0.001-10 µg/mL for 6 hours. Cells were incubated with CDC7, pMCM2 and ki-67 
antibodies according to the protocol mentioned in Chapter 2 and the results are shown 
in Figure 3.12 Figure 3.13. Based on the histograms and scatter graphs as compared 
between 0 and 10 µg/mL, LY3143921 was clearly associated with a decrease in the 
expression of pMCM2 but not CDC7 or ki-67. Moreover, this changed the pattern of 
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pMCM2 expression from a single peak to two peaks which distinguish positive and 
negative cell populations. 
 Looking at the number of protein positive cells, the percentage of CDC7 
positive cells was not affected by the drug, with an average of approximately 90% 
CDC7 positive cells obtained at all concentrations of LY3143921 (Figure 3.13A). 
However, significant decreases in nuclear pMCM2 expression were observed following 
treatment with increasing concentrations of LY3143921 (one-way ANOVA, p-value 
<0.0001) (Figure 3.13B). Mean percentages of pMCM2 positive cells were 69.2%, 
64.6%, 61.4%, 48.3%, 36.2% and 18.2% at concentrations of 0, 0.001, 0.01, 0.1, 1 and 
10 µg/mL, respectively. Figure 3.13C shows mean percentages of ki-67 positive cells 
ranging from 21% to 29.1%; the sample treated with 0.01 µg/mL of the drug had the 
lowest number ki-67 positive cells (21%) and the control had the highest number 
(29.1%). These values measured, although were statistically significant different, 















Figure 3.12. Histograms of mean intensity, scatter plots of mean intensity and similarity between protein and DAPI, and examples of cells with 
protein positivity. 
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Figure 3.13. Percentages of CDC7 positive (A), pMCM2 positive (B) and ki-67 positive 
(C) cells in HL-60 cell lines treated with different concentrations of LY3143921 for 6 
hours. 







3.3.4 LY3143921 concentration dependent ex vivo experiments 
 Whole blood samples from three healthy donors were collected, incubated 
with a range of concentrations of LY3143921 (0.001-100 µg/mL) for 6 hours and then 
processed and analysed according to the imaging flow cytometry assay procedure 
described in Chapter 2. Representative images of white blood cells with high levels of 
expression of CDC7, pMCM2, ki-67 and all three of these proteins are shown in Figure 
3.14. As DAPI identified the localisation of the nucleus of the cell, localisation of the 
proteins being investigated could be estimated using similarity in shape between DAPI 
and that protein. The CDC7 antibody detected signal outside the nucleus (cytoplasmic 
expression), while pMCM2 and ki-67 were expressed in the nucleus. 
 Protein expression could be investigated using several parameters such as 
mean intensity and number of protein positive (highly expressed) cells. Looking at the 
intensity of proteins,  
Figure 3.15 shows histograms of CDC7, pMCM2 and ki-67 intensity in myeloid and 
lymphoid cells following an increase in LY3143921 concentrations. The expression of 
CDC7 in myeloid cells was clearly higher than lymphoid cells. This difference, however, 
was not found in pMCM2 and ki-67 expression. Moreover, compared to the control 
cells treated with no drug, neither population showed clear changes in protein 








Figure 3.14. Examples of white blood cells with high expression levels of proteins including CDC7 (A), pMCM2 (B), ki-67 (C) and triple 
protein expression (D). 
DAPI locates the nucleus of the cell. 
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Figure 3.15. Histograms of intensity of CDC7, pMCM2 and ki-67 following different 
concentrations (0-100 µg/mL) of LY3143921 treatment for 6 hours. 
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 Focusing on numbers of positive cells, the percentages of CDC7 positive 
myeloid cells, lymphoid cells and total WBCs are shown in Figure 3.16A, percentages of 
nuclear pMCM2 positive cells are shown in Figure 3.16B, and percentages of nuclear 
ki-67 positive cells are shown in Figure 3.16C. In agreement with the signal intensity 
results, percentages of CDC7 positive cells were shown to be markedly different 
between myeloid and lymphoid cell populations, with >90% of myeloid cells being 
CDC7 positive, as compared to <5% of lymphoid cells. However, the level of CDC7 
expression in either cell type was not significantly changed when treated with 
LY3143921. 
 In contrast to the results generated in cell lines, the decrease in percentage of 
pMCM2 positive WBCs with increasing concentrations of LY3143921 was not 
significant, although a trend towards a decrease was observed. In the myeloid cell 
population, percentages of pMCM2 positive cells were 0.15% with no drug treatment 
and 0.17% at 100 µg/mL of LY3143921. In contrast, percentages of pMCM2 positive 
lymphoid cells were 0.29% in untreated cells and 0.13% at 100 µg/mL of LY3143921. 
These results suggest that the trend towards a decrease in pMCM2 positivity was more 
visible in lymphoid than myeloid cells. 
 For ki-67 positivity, in agreement with the in vitro cell line results, there was no 
change in either the myeloid or lymphoid populations following incubation of cells 
with LY3143921. Percentages of ki-67 positive cells at 0, 1 and 100 µg/mL LY3143921 
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Figure 3.16. Percentages of myeloid, lymphoid and white blood cells with positivity 
for CDC7 (A), pMCM2 (B) and ki-67 (C) following incubation with LY3143921. 
WBCs were collected from whole blood samples treated with different 
concentrations of LY3143921 (0-100 µg/mL) for 6 hours. A, B and C indicate 
percentages of CDC7, pMCM2 and ki-67 positivity in myeloid, lymphoid and 
total WBCs, respectively. Mean and SD shown from 3 independent healthy 
donors. 
 
 Although there were no significant changes in percentages of protein positive 
cells in WBCs treated with LY3143921, a drug response was observed in a specific 
population of cells. Focusing on the population of WBCs that were ki-67 positive, a 
trend towards a reduction in pMCM2 positive cells in this population was clearly 
observed (Figure 3.17). Mean percentages of pMCM2 positive cells in myeloid cells 
with ki-67 positivity decreased from 69.1% in untreated cells to 25.5% at a 
concentration of LY3143921 of 100 µg/mL. Similarly, mean percentages of pMCM2 
positive cells in lymphoid cells with ki-67 positivity decreased from 58.5% in untreated 
cells to 21.5% at a LY3143921 concentration of 100 µg/mL. In both cases a trend for a 
concentration-dependent effect was observed although this did not reach statistical 
significance by one-way ANOVA. 
 Based on the results obtained with CDC7 protein in both cell lines and whole 




for this study. Furthermore, the majority of CDC7 positive cells in this study exhibited 
cytoplasmic expression, which is highly controversial because CDC7 expression is 
thought to be mainly found only in the nucleus. Only studies in melanoma cells and 
neuron have reported predominantly cytoplasmic CDC7 expression (Liachko et al., 
2013; Gad et al., 2019). However, it is unclear whether the antibody used for CDC7 
detection also cross-reacted with some other proteins in the cytoplasm. Therefore, 
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Figure 3.17. Percentages of pMCM2 positive cells in myeloid, lymphoid and white 
blood cells with ki-67 positivity. 
WBCs were collected from whole blood samples treated with different 
concentrations of LY3143921 (0-100 µg/mL) for 6 hours. Mean and SD shown 
from 3 independent healthy donors. 
 
 The experiments carried out using blood samples collected from healthy 
donors were next performed using whole blood samples obtained from three cancer 
patients. The comparable ex vivo results are shown in Figure 3.18, with no changes 
again observed in pMCM2 and ki-67 in the total WBC population following incubation 
with LY3143921, but a significant decrease in percentage of pMCM2 positive cells in 
the ki-67 positive cell population. Percentages of nuclear pMCM2 positive myeloid cells 
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ranged from 0.12 - 0.32% and percentages of nuclear pMCM2 positive lymphoid cells 
ranged from 0.63 - 0.88% across the range of LY3143921 concentrations investigated 
(Figure 3.18A). Percentages of nuclear ki-67 positive cells ranged from 0.17 - 0.29% of 
myeloid cells and 1.1 - 1.6% of lymphoid cells (Figure 3.18B). Taking the ki-67 positive 
myeloid cell population, percentages of pMCM2 positive cells decreased from 51.8% in 
untreated cells to 19.8% in cells treated with LY3143921 at a concentration of 
100 µg/mL. Similarly, despite non-statistically significant, a reduction in percentage of 
pMCM2 positive cells from 55.7% to 36.9% was observed in ki-67 positive lymphoid 
cells following treatment with 100 µg/mL LY3143921 (Figure 3.18C). Concentration-
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Figure 3.18. Percentages of myeloid, lymphoid and white blood cells with positivity 
for pMCM2 (A), ki-67 (B) and pMCM2 in a ki-67 positive cell population (C). 
Whole blood samples obtained from cancer patients were treated with 
different concentrations of LY3143921 (0-100 µg/mL) for 6 hours. Mean and SD 






3.3.5 LY3143921 time dependent ex vivo experiments 
 To confirm that decreases in pMCM2 in ki-67 positive cells resulted from the 
drug, as opposed to spontaneous degradation of proteins under the experimental 
conditions, time-dependent ex vivo experiments with negative controls were 
performed as described in Chapter 2. For pMCM2 expression, percentages of pMCM2 
positive myeloid cells decreased from 0.15 to 0.06% when treated with LY3143921 for 
6 hours. However, these percentages also decreased in the untreated control group 
from 0.15 to 0.08%. The same trend was observed in the lymphoid cell population, 
with decreases in pMCM2 positivity from 0.47 to 0.12% in the drug treated group and 
0.47 to 0.14% in the control group (Figure 3.19A). 
 A different pattern of results were observed in percentages of nuclear ki-67 
positive cells over time, with less marked reductions over a 6-hour incubation period. 
The percentages of ki-67 positive myeloid cells increased from 0.17% to 0.22% in the 
treated group but decreased from 0.17% to 0.07% in the untreated group. Reduced 
percentages of ki-67 positive cells from 0.60% to 0.46% and from 0.60% to 0.17% were 
observed in treated and untreated lymphoid cells over this time period, respectively 
(Figure 3.19B). 
 Percentages of pMCM2 positive cells in the ki-67 positive population were 
found to significantly decrease with increasing LY3143921 incubation times for up to 6 
hours. Myeloid cells treated with the drug exhibited a decrease in pMCM2 positive 
cells as a proportion of ki-67 positive cells, from 66.7% to 25.4%, while the untreated 
cells showed no change (from 66.7% to 66.9%). Similarly, percentages of pMCM2 
positive lymphoid cells in the ki-67 positive population decreased from 71.2% to 25.7% 
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Figure 3.19. Percentages of pMCM2 positive myeloid and lymphoid cells (A), ki-67 
positive myeloid and lymphoid cells (B) and pMCM2 positive myeloid and lymphoid 
cells in the ki-67 positive cell population (C). 
Results were obtained from whole blood samples treated with 10 µg/mL 
LY3143921 for up to 6 hours as compared to non-treated whole blood as a 
control. Mean and SD shown from 3 independent healthy donors. 
 
3.3.6 LY3143921 in vivo experiments 
 The application of the developed assay in an in vivo mouse model was next 
investigated. Eighteen mice were divided to 3 groups of six and each group was 
administered a different oral dose of LY3143921 (0, 15 or 50 mg/kg). Blood samples 
were collected from the animals at 0, 3, 6 and 24 hours post-treatment. The same 
protocol as used for the previously described experiments with human blood was 
applied to the mouse blood. 
 As shown in Figure 3.20A, a significant decrease in percentage of pMCM2 
positive WBCs was observed over a period of 24 hours in the 50 mg/kg treatment 
group as compared to the control untreated group (two-way ANOVA, p-value 0.0146). 
The mean percentage of pMCM2 positive cells decreased from 1.80% to 0.58% when 
treated with 50 mg/kg of LY3143921 for 24 hours while there was no observable 
change in the untreated control group. When treated with 15 mg/kg of the drug, the 
percentage of pMCM2 positive cells decreased from 1.47% to 0.76% but this decrease 




 In contrast, no significant change in percentage of ki-67 positive cells was 
observed in any of the treatment or control groups (Figure 3.20B). Mean percentages 
of ki-67 positive cells ranged from 0.77 – 0.97%, 0.40 – 0.62% and 0.66 – 0.81% in the 
untreated group, 15 mg/kg and 50 mg/kg treated with the drug for 24 hours, 
respectively. These changes in percentage of ki-67 positive cells were not statistically 
significant (two-way ANOVA, p-value >0.5). 
  Focusing on the ki-67 positive population, significant decreases in percentages 
of pMCM2 positive cells were observed following treatment with LY3143921 (Figure 
3.20C). Mean percentages of pMCM2 positive cells in the ki-67 positive population 
when treated with 15 mg/kg of the drug for 24 hours decreased from 70.0% to 38.6% 
and when treated with 50 mg/kg of the drug for 24 hours decreased from 56.6% to 
13.9%. P-values of both differences determined by two-way ANOVA were <0.0001. 
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Figure 3.20. Percentages of nuclear pMCM2 positive cells in all WBCs (A), nuclear 
ki-67 positive cells in all WBCs (B) and of nuclear pMCM2 positive cells in ki-67 
positive WBCs (C) observed in an in vivo mouse model. 
White blood cells were separated from mice treated with single doses of 
LY3143921 (15 or 50 mg/kg) and whole blood samples were collected at 0, 3, 6 
and 24 hours following administration. Mean and SD shown from 3 sets of 






3.3.7  Stability tests of pMCM2 and ki-67 in preserved whole blood 
 In a clinical setting whole blood samples may be taken at different clinical sites 
and would need to be delivered to the laboratory for analysis. As the shipment of 
samples may take several days to arrive in the laboratory, a method to reliably 
preserve pMCM2 and ki-67 protein in clinical samples needed to be developed. 
Proteins can be preserved using various different methods, with many brands of blood 
preservative tubes available with the potential to maintain pMCM2 and ki-67 integrity. 
In addition, freezing fixed WBCs at -80°C may be an effective approach for 
preservation of pMCM2 and ki-67. These methods were therefore tested in the current 
study. 
 
3.3.7.1 Stability of pMCM2 and ki-67 in different commercial blood tubes 
 Four commercial preservative tubes were tested including EDTA tubes, 
CellSave tubes, TransFix tubes and Streck tubes. Whole blood was collected from 
healthy donors, added to each type of tube and stored for up to 3 days. EDTA tubes 
were stored at 2-8°C while other tubes were stored at room temperature according to 
the manufacturer’s instructions. Blood samples were collected from all tube types at 0, 
6, 24, 48 and 72 hours after the addition of blood. Samples were processed following 
the protocol described in Chapter 2. 
 Mean percentages of CDC7 positive WBCs remained stable throughout the 72 
hour incubation period for all tubes except Streck tubes (Figure 3.21A). Average levels 
of CDC7 measured in CellSave, EDTA and TransFix tubes were 67%, 76% and 69%, 
respectively and did not show any change with time. For the Streck tubes, the 
percentage of CDC7 positive cells was observed to decrease from 65% to 43% when 
stored for 72 hours. 
 The characteristics of pMCM2 positive WBCs in the various tube types was 
markedly different from CDC7 (Figure 3.21B). Mean percentages of pMCM2 positive 
cells from 3 independent experiments increased from 0.27% to 0.63% when stored in 
CellSave tube for 24 hours and then decreased to 0.37% at 3 days. Further 
investigation revealed that this increase mainly resulted from an increase in pMCM2 
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positivity in myeloid cells; percentages of pMCM2 positive cells in the myeloid cell 
population increased from 0.09% to 0.61% while in lymphoid cells increased from 
0.55% to 0.73% (data not shown on the graph). This pattern of change was not seen in 
other tubes. Expression of pMCM2 decreased from 0.28% to 0.14% when stored in 
EDTA tubes and from 0.23% to 0.12% when stored in Streck tubes. The expression of 
pMCM2 was undetectable in TransFix tubes at all time points of storage, so this tube 
was not suitable for pMCM2 measurement. 
 The expression of ki-67 is shown in Figure 3.21C. After storage in CellSave tube 
for 24 hours, the percentage of ki-67 positive cells increased from 0.23% to 0.46% and 
then slightly decreased to 0.41% at 3 days. This fluctuation was predominately due to 
variation of ki-67 positivity in myeloid cells which increased from 0.05% to 0.17% at 1 
day and then decreased to 0.09% at day 3 (data not shown on the graph). For EDTA 
and Streck tube, percentages of ki-67 positive WBCs remained stable throughout 72 
hour of storage. No ki-67 expression was detected in WBC stored in TransFix tubes at 
any of the time points investigated. 
 The percentage of pMCM2 positive cells measured in the ki-67 positive 
population was observed to decrease with time in CellSave, EDTA and Streck tubes 
(Figure 3.21D). Although the percentage of pMCM2 positive cells was found to be 
increased at 24-48 hours after storage in CellSave tubes, it still decreased when 
considered as proportion of ki-67 positive cells. Mean percentages of pMCM2 in ki-67 
positive cells decreased from 79.4% to 27.6% in CellSave tubes, from 24.9% to 4.9% in 
EDTA tubes and from 28.4% to 16.9% in Streck tubes. 
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Figure 3.21. Percentages of CDC7 positive cells in all WBCs (A), nuclear pMCM2 
positive cells in all WBCs (B), nuclear ki-67 positive cells in all WBCs (C) and 
percentage of nuclear pMCM2 positive cells in ki-67 positive WBCs (D). 
WBCs were separated from whole blood samples stored in different types of 






3.3.7.2 Stability of pMCM2 and ki-67 when fixed with Lyse/Fix buffer and stored 
at -80°C 
 An alternative method to preserve pMCM2 and ki-67 involved freezing the 
fixed samples at -80°C. To investigate this approach, whole blood was collected from 
healthy donors and added to freshly prepared Lyse/Fix buffer solution (6 tubes per 
donor). The first tube was further processed following the protocol immediately, while 
the other tubes were frozen at -80°C. A tube of sample was analysed at time points of 
1, 2, 3, 4 and 5 days after freezing. Blood tubes were thawed in a 37°C water bath for 
30 minutes and then processed using the protocol described in Chapter 2. 
 The results obtained from this set of experiments showed that sample stability 
was maintained for measuring percentages of positive cells for both pMCM2 (Figure 
3.22A) and ki-67 (Figure 3.22B) for up to 5 days. Mean percentages of pMCM2 positive 
myeloid, lymphoid and total white blood cells were 0.26%, 0.95% and 0.46% at time 
zero and 0.26%, 0.61% and 0.36% at the 5-day time point, respectively. 
 Similarly, average percentages of ki-67 positive cells at time zero and when 
frozen for 5 days were 0.46% and 0.45% for myeloid cells, 1.45% and 1.14% for 
lymphoid cells, and 0.74% and 0.63% for total WBCs, respectively. The percentages of 
pMCM2 positive cells in a ki-67 positive WBC population ranged between 45-60% for 
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Figure 3.22. Percentages of nuclear pMCM2 positive cells in all WBCs (A), nuclear ki-
67 positive cells in all WBCs (B) and nuclear pMCM2 positive cells in ki-67 positive 
WBCs (C). 
White blood cells were separated from whole blood samples, fixed in Lyse/Fix 







 An assay for detection of potential pharmacodynamic biomarkers of a CDC7 
inhibitor including CDC7, pMCM2 and ki-67 proteins has been developed and validated 
in cell lines (in vitro), white blood cells (ex vivo) and in a mouse model (in vivo). In 
addition, the most appropriate method of collection and storage of clinical samples 
was investigated to find the optimal method for ensuring the integrity of the data 
following delivery to the laboratory for analysis. 
 LY3143921 is a novel anti-cancer agent developed with the proposed 
mechanism of CDC7 inhibition. However, there is currently no pharmacodynamic 
biomarker for this agent developed for use in clinical trials. As CDC7 phosphorylates 
the MCM2 protein, inhibition of CDC7 by the drug should result in a reduction of 
pMCM2 expression. In addition, as the CDC7 pathway is essential for cell proliferation 
and division, ki-67, a well-known proliferation marker, was also investigated as a 
potential biomarker for LY3143921. 
 The results of antibody optimisation indicated good potency of all antibodies 
used in this study including antibody against CDC7, pMCM2 and ki-67. However when 
HL-60 cell lines were treated with LY3143921, no differences were observed in CDC7 
expression or ki-67 expression at concentrations of LY3143921 up to 10 µg/mL. 
According to pre-clinical data from the company, drug peak concentrations in rats and 
dogs ranged between 0.2-8 µg/mL with the highest tolerated dose up to 20 mg/kg. 
These concentrations were similar to the concentrations used in this study but 
decreases in ki-67 were not observed as expected. 
 These findings are in contrast to previous studies of similar drugs such as 
PHA-767491 and XL413 (Montagnoli et al., 2008; Sasi et al., 2014). Montagnoli, et al. 
reported a decrease in CDC7 expression in HeLa cells treated with 5 µM of PHA-767491 
for 24 hours measured by Western blot (Montagnoli et al., 2008). Sasi, et al. presented 
reductions in CDC7 kinase activity in bacteria cells treated with different 
concentrations of PHA-767491 and XL413 with IC50 values of 18.6 nM and 22.7 nM, 
respectively (Sasi et al., 2014). The difference might result from cytoplasmic CDC7 
expression observed in this chapter which was potentially caused by differences in 
antibodies, methods and different cell lines used. Given our results involved CDC7 
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cytoplasmic staining, more comparable data may have been generated with an assay 
that had improved specificity and quantified nuclear CDC7 expression. 
 In contrast to CDC7 and ki-67, the percentage of pMCM2 positive HL-60 cells 
was significantly decreased over the concentration range of LY3143921 investigated. 
This conformed to the proposed mechanism of action of LY3143921 as a CDC7 kinase 
inhibitor. The drug inhibits functions of CDC7 and therefore affect its downstream 
proteins instead of directly depleting CDC7. 
 Ex vivo experiments with whole blood showed comparable results as generated 
in vitro, with no changes in percentages of CDC7 or ki-67 positive cells but a trend 
towards a decrease in pMCM2 positive cells following treatment with LY3143921. 
Following analysis of these data, there were no further investigations carried out into 
the measurement of CDC7 protein as a potential biomarker for LY3143921 activity. 
Although no changes were observed in the percentage of ki-67 positive cells following 
treatment with LY3143921, a potentially important relationship was observed when 
focusing on the percentage of pMCM2 positive cells measured within the ki-67 positive 
cell population. Indeed, the significant decrease in pMCM2 observed in this cell 
population following treatment with LY3143921 was found to be more robust than the 
decrease in pMCM2 in the whole WBC population. However, according to the results, 
the concentration of LY3143921 in patient samples should be higher than 10 µg/mL in 
order to observe comparable pMCM2 decreases. 
 These findings were confirmed with the results obtained from in vivo mouse 
experiments. According to the LY3143921 pharmacokinetic profile in mouse, the dose 
of 20.8 – 10.4mg/kg was identified as midrange dose, while over 30 mg/kg was high 
dose (data from the company – personal communication). Therefore the doses used in 
this chapter were reasonable to classify mice into high-dose and moderate-dose 
groups. In addition, the pharmacokinetic profile indicated that tmax of the 10 mg/kg 
drug was 3±1.15 hours which was comparable with the percentage of pMCM2 positive 
cells shown in Figure 3.20A. As given the dose of 10 mg/kg resulted in a detectable 
decrease in pMCM2, the doses of 15 mg/kg and 50 mg/kg used in this study were 
expected to generate higher significant decreases. Although using pMCM2 alone 
provided the required level of sensitivity to detect the effect of LY3143921 in mouse 
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WBCs, measuring the percentage of pMCM2 in a ki-67 positive population provided a 
greater power of detection. 
 To the best of our knowledge, studies investigating associations between 
pMCM2 and ki-67 are very limited. There was only one published study which 
previously mentioned a significant correlation between CDC7, pMCM2 and ki-67 
(Krawczyk et al., 2009). This study was investigating the prognostic effects of several 
proliferative markers including CDC7, pMCM2 and ki-67 in invasive breast cancer and 
the results suggested significant correlations among these three proteins. Nonetheless, 
this study did not propose a rationale for the correlations observed, so could not 
provide any insights to explain our findings. A possible explanation is that cells with a 
higher proliferation rate (high ki-67 expression) may respond to the drug better than 
normal cells. Another possible reason is that as LY3143921 causes cell cycle arrest, the 
ki-67 level was stable while pMCM2 levels decreased. These hypotheses, however, 
need to be further investigated. 
 The results generated in the current chapter suggest a potential benefit in using 
two proteins of interest in combination to provide a robust biomarker. While pMCM2 
itself was sensitive enough to detect the effect of LY3143921, its use in combination 
with ki-67 allowed us to focus on a specific population of proliferating cells. Although 
pMCM2 expression decreased with increasing concentrations of LY3143921, the 
overall effects on cancer cells and clinical effects in patients need to be further 
evaluated in the clinic. 
 With regard to storage of clinical samples, our results suggested that none of 
the commercial blood tubes tested including CellSave, TransFix and Streck tubes 
were suitable for preservation of the three proteins of interest (CDC7, pMCM2 and 
ki-67) as well as EDTA tubes stored at 2-8 °C. However, it was found that freezing fixed 
samples in Lyse/Fix buffer at -80°C was able to preserve pMCM2 and ki-67 proteins for 
up to 5 days. This preservation method can therefore be applied to clinical samples in a 
clinical trial setting. 
In conclusion, a promising assay for detection of pMCM2 and ki-67 as a 
combined pharmacodynamic biomarker of LY3143921 has been developed and 
validated. This assay has the potential to be applied to the analysis of patient samples 
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following treatment with LY3143921 in a clinical trial setting. Furthermore, the 
applicability of this assay for use with other CDC7 inhibitors such as PHA-767491 could 






Chapter 4. Development and pre-clinical application of an assay for 
detection of histone H4 acetylation as a pharmacodynamic 
biomarker for valproic acid 
4.1 Introduction 
4.1.1 Histones, histone acetylation and histone acetylation enzymes 
 Histones are a group of proteins isolated through acid-extractions and named 
by Albrecht Kossel in 1884 (Kossel, 1884). Studies of histone structure have revealed 
two parts of chromatin structure: a core histone octamer and a tetramer portion. Each 
octamer consists of two nucleosomal histones which are H3 and H4 while each 
tetramer is composed of H2A and H2B dimers (Kornberg, 1974). 
 The acetylation of histones was discovered nearly a century after their initial 
isolation (Allfrey et al., 1964). The addition of an acetyl moiety to the ε-amino group of 
a lysine residue which was later defined as Nε-acetylation was revealed (Gershey et al., 
1968). This pathway involves two essential groups of enzymes: histone 
acetyltransferases (HATs) and histone deacetylases (HDACs). Discovery of HAT 
enzymes in the mid-1990s led to a surge of interest in histone acetylation. HATs are 
classified into three major groups including the GNAT-family, MYST-family and 
CBP/p300 family. Gu, et al identified their association with tumour suppressor p53, 
identifying histones as proteins of interest in cancer research (Gu and Roeder, 1997). 
 While studies investigating the impact of HATs on cancers are ongoing, HDACs 
are currently considered to represent a more relevant drug target in relation to their 
association with cancers (Cress and Seto, 2000; Mahlknecht and Hoelzer, 2000). This 
contributed to the discovery of the first naturally extracted HDAC inhibitor, 
Trichostatin A (Yoshida et al., 1987). Since then, a number of HDAC inhibitors have 
been discovered and developed which will be discussed later. 
4.1.2 Classification of histone deacetylases 
  Histone deacetylase (HDAC) enzymes have been extensively studied alongside 
the development of HDAC inhibitors. These enzymes are classified into 4 major classes 
as described in Table 4.1 (West and Johnstone, 2014). Class I includes HDAC1, HDAC2, 
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HDAC3 and HDAC8. Class II includes HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and 
HDAC10. HDAC4, HDAC5, HDAC7 and HDAC9 are in subclass IIa while HDAC6 and 
HDAC10 are in subclass IIb. Class III is called the SIRTUIN class because these enzymes 
contain a SIRTUIN catalytic domain instead of a HDAC catalytic domain. This class 
consists of SIRT1 to SIRT7, which can be subdivided to 4 minor classes. Lastly, class IV 
includes only HDAC11. 
 Several studies have suggested a correlation between specific HDACs and 
certain cancer types as highlighted in Table 4.1 (West and Johnstone, 2014; Patra et 
al., 2019). For instance, all HDACs in class I have been shown to be deregulated in 
many cancers, with HDAC1 overexpressed in gastric, lung and breast carcinomas (Choi 
et al., 2001; Zhang et al., 2005; Minamiya et al., 2011). Overexpression of HDAC1, 
HDAC2 and HDAC3 has also been found in renal cell, colorectal and gastric cancer as 
well as in classical Hodgkin’s lymphoma (Fritzsche et al., 2008; Weichert et al., 2008; 
Adams et al., 2010). Class IIa HDACs have also been linked to several types of cancer. A 
study reported that HDAC4 expression was upregulated in renal, bladder and 
colorectal cancer (Ozdağ et al., 2006). HDAC5 and HDAC9 were overexpressed and 
have been linked to poor survival in high-risk medulloblastoma patients (Milde et al., 
2010). HDAC6 in class IIb was found to be overexpressed in oral squamous cell 












HDAC HDAC protein 
associations 
Expression in cancer Examples of functional 
involvement 
Class I (homologous to RDP3 yeast protein, nuclear location, ubiquitous tissue 
expression) 




KD induced growth arrest, 
decreased viability, increased 
apoptosis and induced 
genomic instability in colon, 
breast, and osteosarcoma 
cancer cell lines 





KD induced growth arrest, 
decreased viability, and 
increased apoptosis in colon 
and breast cancer cell lines, 
and induced apoptosis and 
decreased lung cancer in vivo 
HDAC3 HDAC4, HDAC5, 
HDAC7 




Decreased in liver 
KD decreased viability and 
increased apoptosis in colon 
cancer cell lines 
HDAC8  Elevated in 
neuroblastoma 
KD reduced proliferation of 
lung, colon, and cervical 
cancer cells 
Class IIa (homologous to Hda1 yeast protein, shuttle between nucleus and 
cytoplasm, tissue-restricted expression 
HDAC4 HDAC3-NCor  KD increased VEGF 
expression and reduced 
growth in chondrosarcoma 
cell lines 
KD induced apoptosis and 
decreased cell viability of 
colon and glioblastoma 
tumours in vivo 
HDAC5 HDAC3-NCor  Elevated in 
medulloblastoma; 
decreased in lung 
KD decreased cell growth and 
viability in medulloblastoma  
HDAC7 HDAC3-NCor  Elevated in ALL; 
decreased in lung 
KD induced growth arrest in 
colon and breast cancer cells 
HDAC9  Elevated in ALL, 
medullablastoma 
KD inhibited homologous 
recombination, increased 
sensitivity to DNA damage and 
decreased medulloblastoma 





HDAC HDAC protein 
associations 
Expression in cancer Examples of functional 
involvement 
Class IIb (homologous to yeast protein Hda1, mostly cytoplasmic location, tissue-
restricted expression) 
HDAC6 HDAC11 Elevated in breast, 
cutaneous T-cell 
lymphoma; 
decreased in lung  
KD decreased VEGF expression 
and decreased cell viability 
HDAC10   KD inhibited homologous 
recombination, increased 
sensitivity to DNA damage and 
decreased VEGF expression 
Class IV (unknown yeast protein homology, cytoplasmic location, tissue-restricted 
expression) 
HDAC11 HDAC6 Elevated in breast, 
renal, liver 
KD induced apoptosis in colon, 
prostate, breast and ovarian 
cancer cell lines 
KD = knockdown (gene silencing by siRNA). ALL = acute lymphoblastic leukaemia 
 
Table 4.1. The association of HDAC in cancer. 
Adapted from West AC, et al. J Clin Invest. 2014;124(1):30-39. and Patra S, et al. 
Cell Mol Life Sci. 2019;76(17):3263-3282. 
 
 Although proteins in the SIRTUIN class do not contain HDAC catalytic domains 
and are occasionally not classified as HDACs, these proteins were found to have 
important roles in cancer. For example, upregulation of SIRT1 has been reported in 
AML, prostate cancer and non-melanoma. In contrast, downregulation of SIRT1 has 
been reported in colon cancer (Barneda-Zahonero and Parra, 2012), while levels of 
SIRT3 and SIRT7 expression were increased in breast cancer (Ashraf et al., 2006). Some 
studies have reported downregulation of SIRT2 in gliomas and gastric carcinoma and 
have suggested that this protein might acts as a tumour suppressor (Hiratsuka et al., 
2003; Inoue et al., 2007). Additionally dysregulation of SIRT3 was reported in many 
types of breast cancer (Ashraf et al., 2006). 
 Studies of class IV HDAC and cancer are limited. Overexpression of HDAC11 has 
been found in several carcinoma cell lines including colon, prostate, breast and ovarian 
cells (Deubzer et al., 2013). However, the translation and clinical relevance of these 
findings are currently lacking and the expression of this protein in tumour tissue 
requires further investigation. 
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4.1.3 Histone deacetylase inhibitors as anticancer drugs 
 Since the association between HDAC and cancer was discovered, many 
anticancer drugs based on this mechanism of action have been discovered, developed 
and clinically tested. HDAC inhibitors can be classified based on their chemical 
structures or their targets. In terms of their chemical structures, HDAC inhibitors are 
classified into three major groups: short chain fatty acids, hydroxamic acids and 
miscellaneous agents (Manal et al., 2016). Examples of chemical structure of HDAC 
inhibitors are illustrated in Figure 4.1. 
 
Figure 4.1. Chemical structures of selective HDAC inhibitors. The cap, linker and the 
Zn2+ binding group are represented in blue, green and red, respectively. 




 The derivatives of short chain fatty acids include valproic acid and butyric acid. 
Valproic acid has been studied in cancer for several decades and been shown to have 
potency against both solid tumours and leukaemia in preclinical studies (Göttlicher et 
al., 2001; Shabbeer et al., 2007). Phenyl butyrate also achieved effective results in 
preclinical trials (Warrell et al., 1998; Iannitti and Palmieri, 2011). These findings 
contributed to the development of several butyrate-based anticancer prodrugs 
including tributyrin, AN-1, AN-7, 3,4,6-OBu3GlcNAc, PMX 550B and PMX 550D (Manal 
et al., 2016). 
 The other backbone structure of HDAC inhibitors is hydroxamic acid, which was 
first reported to exhibit HDAC inhibitory effects in 2001, subsequently a number of 
hydroxamate-based anticancer drugs have been developed (Lavoie et al., 2001). 
Vorinostat or suberoylanilide hydroxamic acid (SAHA) was the first US FDA approved 
hydroxamic acid based HDAC inhibitor for the treatment of cutaneous T-cell lymphoma 
(Mann et al., 2007). Other approved drugs in this class include abexinostat, reminostat, 
panobinostat, mocetinostat, pracinostat and givinostat. 
 Focusing on the target sites of HDAC inhibitors, it is known that different drugs 
target different types of HDAC (Table 4.2) (Eckschlager et al., 2017). Most 
hydroxamate-based agents inhibit almost all HDACs except SIRTUIN (pan HDAC 
inhibitor) while drugs in the short chain fatty acid class target only class I and IIa HDAC. 
Benzamide class drugs bind mainly to class I HDAC while the cyclic tetrapeptide 
romidepsin, inhibits only HDAC1 and HDAC4. Drugs which target class III or SIRTUINs 
include nicotinamide (all SIRTs), sirtinol (SIRT1 and 2) and cambinol (SIRT1 and 2). The 
classification by target sites, however, was varied depending on the definition of 
inhibition and availability of information (Bolden et al., 2006; Thomas et al., 2011; 








Class Drug name HDAC target Clinical status 
Hydroxamic acids Trichostatin A Pan Phase I clinical trial 
Vorinostat Pan Approved for cutaneous T-cell 
lymphoma 
Belinostat Pan Approved for peripheral T-cell 
lymphoma 
Panabiostat Pan Approved for multiple 
myeloma 
Givinostat Pan Phase III clinical trial 
Resminostat Pan Phase II clinical trial 
Abexinostat Pan Phase III clinical trial 
Quisinostat Pan Phase II clinical trial 
Rocilinostat Class II Phase II clinical trial 
Practinostat Class I, II and IV Phase III clinical trial 
Short chain fatty 
acids 
Valproic acid Class I and IIa Phase III clinical trial for 
cancer treatment 
Butyric acid Class I and IIa Phase II clinical trial 
Benzamides Entinostat Class I Phase III clinical trial 
Tacedinaline Class I Phase III clinical trial 
Mocetinostat Class I and IV Phase II clinical trial 
Cyclic 
tetrapeptides 




Nicotinamide Class III Phase III clinical trial 
Sirtinol SIRT1 and 2 Preclinical 
Cambinol SIRT1 and 2 Preclinical 
 
Table 4.2. Classification of histone deacetylase inhibitors and their clinical status. 







4.1.4 Pharmacodynamic biomarkers for histone deacetylase inhibitors 
 Recently, a number of HDAC inhibitors have been approved for clinical use and 
many more agents are being developed (Manal et al., 2016). Consequently, a number 
of robust biomarkers have been developed in order to evaluate the effect of these 
developed agents, with pharmacodynamic biomarkers required to prove the 
mechanism of action of the drug during development. Based on the histone 
acetylation pathway being targeted, either HDAC enzyme expression or histone 
acetylation have the potential to provide appropriate surrogate biomarkers. 
 As HDAC inhibitors inhibit the deacetylase activity of these target proteins, 
measurement of enzyme activity is the most direct approach for the assessment of 
HDAC inhibitor efficacy. In order to determine the enzyme activity, measurement of 
histone acetylation as downstream proteins of HDAC activity is selected. Histone 
acetylation of histones H3 and H4 represent the most extensively used biomarkers in 
preclinical and clinical trials involving HDAC inhibitors (Shi and Xu, 2013). These two 
proteins, especially histone H4, have become potential biomarkers since the loss of 
acetylation at Lys16 of histone H4 was found to be a common hallmark of human 
cancer (Fraga et al., 2005). Furthermore, a previously published study indicated that 
HDAC inhibitors globally enhance H3/H4 tail acetylation (Drogaris et al., 2012). 
Measurement of histone acetylation provides two key advantages compared to HDAC 
measurement. Firstly, histone acetylation is a modification catalysed by HDACs and 
HATs, so the level of acetylation reflects the enzyme activity of HDACs and HATs. 
Secondly, histone acetylation can be measured in white blood cells from peripheral 
blood which allows non-invasive procedures to be utilised in cancer patients (Plumb et 
al., 2003). 
 The utility of histone acetylation as a pharmacodynamic biomarker became 
well-known following publication of results from the SAHA study. Histone 
hyperacetylation in peripheral blood mononuclear cells was reported to be rapidly 
induced by 2-3 fold in patients receiving vorinostat, regardless of the drug level or 
tumour response (Garcia-Manero et al., 2008). However, using histone acetylation as a 
predictive or prognostic biomarker has been questioned due to its unpredictable 
response. For example, a study showed that the level of histone H4 acetylation in 
patients receiving belinostat returned to normal within 2 hours following drug 
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administration; this decrease was faster than the elimination rate of the drug (Steele et 
al., 2008). Moreover, an increase in acH4 was only observed within a certain dose 
range in the same study. These issues limit the applicability of histone acetylation as a 
predictive biomarker and need to be resolved in order to utilise these proteins in a 
clinical setting.  
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4.2 Chapter specific aims 
 The main objective of this study was to develop and validate an assay for 
detection of acH4 using an imaging flow cytometer. In particular, this study aimed to: 
• Optimise the concentration of acH4 antibody used in the developed assay by 
evaluation of acH4 expression in cells, and by measurement of mean acH4 
intensity and percentage of acH4 positive white blood cells. 
• Assess the precision of the flow cytometer used and determine inter-assay 
variability of the developed assay. 
• Test the applicability of the developed assay in HL-60 cell lines by 
measurement of mean and median intensity of acH4 expression as well as 
percentage of acH4 positive cells following concentration- and time-
dependent valproic acid treatment. 
• Test the applicability of the developed assay in WBCs treated with valproic acid 
outside the body (ex vivo) by measurement of mean and median intensity of 
acH4 expression as well as percentage of acH4 positive WBCs. 
• Investigate the characteristics of acH4 expression in myeloid and lymphoid cell 





4.3.1 Antibody validation 
 The antibody against histone H4 acetylation was tested to determine the 
optimal conditions for the assay. Whole blood samples from healthy volunteers were 
divided into two tubes; one was treated with 4 mM of valproic acid for 6 hours and the 
other was stored at room temperature for 6 hours. The condition of treatment was 
based on the concentration of valproic acid (>2 mM) that is known to inhibit HDACs 
and increase acH4 expression, and the treatment duration (≤6 hours) that does not 
change the phenotypic proteins in WBC. The processes of red blood cell lysis, antibody 
staining and imaging flow cytometry are described in Chapter 2. 
 Intensity histograms of acH4 expression at different concentrations of acH4 
antibody are illustrated in Figure 4.2, together with representatives of cell at the peaks 
of the histograms. The results suggest an increase in acH4 signal with increasing acH4 
antibody volumes (Figure 4.3); the mean acH4 intensity in untreated cells increased 
from 8,400 to 32,100 and in treated cells increased from 16,300 to 59,500 for 1 µL and 
4 µL of acH4 antibody used, respectively.  
 Focusing on cells with highly expressed acH4 intensity, namely acH4 positive 
cells, the percentage of acH4 positive cells increased with increasing volumes of acH4 
antibody (Figure 4.4). An increase in acH4 antibody volume from 1 µL to 4 µL resulted 
in an increase of acH4 positive cells from 3.75% to 74% for untreated cells and from 
19.7% to 91.6% for valproic treated cells, respectively. 
 Although these results suggest that 4 µL of the antibody did not result in 
saturation of acH4 intensity, nor the percentages of acH4 positive cells, the greatest 
ratio of acH4 signal over background noise was observed in 1 µL of antibody. Looking 
at fold change in acH4 positive cells between treated and untreated cells, an antibody 
volume of 1 µL generated a 5.25-fold increase while 2, 3 and 4 µL antibody volumes 
provided 1.69-, 1.43- and 1.24-fold increases, respectively. Therefore, 1 µL of antibody 






















Figure 4.2. Histograms of acH4 intensity and examples of cells at the peaks of 
histograms. 
WBCs shown were separated from whole blood either treated with 4 mM 
valproic acid for 6 hours or stored in EDTA tubes for 6 hours at room 
temperature. Cells were incubated with different volumes of acH4 antibody 
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Figure 4.3. Mean intensity of acH4 expression in WBCs incubated with different 
volumes of acH4 antibody (1-4 µL) overnight. 
WBCs were separated from whole blood samples treated with 4 mM valproic 
acid for 6 hours and untreated blood at the same condition. The results shown 
are from a single experiment. Mean intensity refers to average expression of 
protein in all cells collected from one sample. 
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Figure 4.4. Percentages of nuclear acH4 positive WBCs following incubation with 
different volumes of acH4 antibody (1-4 µL) overnight. 
WBCs were separated from whole blood samples treated with 4 mM valproic 
acid for 6 hours and untreated blood under the same conditions. The results 




4.3.2 Intra- and Inter-assay variation 
 The precision of the developed assay was tested prior to the analysis of clinical 
samples. Whole blood from a healthy donor was treated with 4 mM valproic acid for 6 
hours and then processed following the protocol described in chapter 2. White blood 
cells were divided into three tubes and each tube was incubated with 1 µL of acH4 
antibody overnight on three different days. The acH4 intensity was determined three 
times on day 1 to investigate the accuracy and precision of the imaging flow cytometer 
and the other two were measured once each on different days in order to investigate 
inter-assay variability. 
 The precision of imaging flow cytometer and variation of the assay for 
measuring acH4 positive cells are summarised in Table 4.3 and Table 4.4. For the first 
sample which was measured three times, the coefficient of variation (%CV) was 17.1% 
for myeloid cells, 18.2% for lymphoid cells and 17.8% for total WBCs. For inter-staining 
variation, %CVs in myeloid, lymphoid and total white blood cells were 14.2%, 13.3% 
and 12.8%, respectively. These findings suggested high precision (<20 %CV) of the 








1/1 14 21.3 19.4 
1/2 11.8 16.7 15.4 
1/3 9.92 15.1 13.8 
Flow cytometer 
precision 
Mean 11.91 17.70 16.20 
%CV 17.15 18.18 17.81 
 
Table 4.3. Precision of imaging flow cytometer by measurement of acH4 positive cells 
in the same sample three times. 












Average of sample 1 11.91 17.70 16.20 
2 10.50 17.50 15.60 
3 10.70 19.30 16.70 
Inter-staining variation Mean 11.04 18.17 16.17 
%CV 6.90 5.43 3.41 
Table 4.4. Inter-staining variation in acH4 positive cells in 7 samples from the same 
donor. 
 All three samples were stained using the same assay at three different days. 
4.3.3 Valproic acid concentration dependent in vitro experiments 
 HL-60 cell lines were incubated with different concentrations of valproic acid 
(0.5, 1, 2, 4 and 8 mM) for 6 hours. Culture media without the drug was used as a 
control. Cells were fixed and incubated with acH4 antibody following the protocol 
described previously (section 2.6.1) and the intensity of acH4 expression was 
measured by an imaging flow cytometer. 
 Examples of acH4 intensity histograms, scatter plots between similarity of acH4 
and DAPI and acH4 intensity, and representative cells showing acH4 and DAPI 
expression are illustrated in Figure 4.5. These results indicate a stronger intensity of 
acH4 expression and higher percentage of acH4 positive cells following an increase in 
valproic acid concentration. Average values together with SD of three repeats including 
mean intensity, median intensity and percentages of acH4 positive cells are shown in 
Figure 4.6. 
 Mean and median intensity of acH4 expression in HL-60 cell lines were found to 
be increased with increasing valproic acid concentrations (Figure 4.6A and Figure 4.6B). 
Both parameters provided comparable trends of increase with an average intensity of 
5,000 at control and 13,000 at a valproic acid concentration of 8 mM. Statistical 
analysis (One-way ANOVA) revealed significant increases for both mean and median 
acH4 expression (p-value <0.0001). Also, a multiple comparison approach indicated 
that there was no significant difference between valproic acid concentrations of 4 mM 
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and 8 mM (Mean difference -600, 95%CI -3066 to 1848) which suggested that 4 mM 
could generate a maximum signal for this assay. 
 Focusing on number of highly expressed acH4 cells (acH4 positive cells), the 
average percentage of acH4 positive cells was found to be increased with increasing 
concentrations of valproic acid (Figure 4.6C). The results showed that percentage of 
acH4 positive cells increased from 0.51±0.65% in control cells to 30.6±4.16% at a 
valproic acid concentration of 8 mM (One-way ANOVA, p-value <0.0001). No 
significant difference between 4 mM and 8 mM was observed (mean difference -5%, 
95%CI -16.44% to 6.37%). 
 All in vitro experiments investigating acH4 intensity and percentage of acH4 
positive cell suggested that 4 mM should be the highest concentration used for the 
developed assay, as higher concentrations did not generate higher signals. This 




















Figure 4.5. Intensity histograms of acH4 expression, scatter plots between similarity 
of acH4 and DAPI and intensity of acH4, and examples of HL-60 cell lines showing 
acH4 expression at the peaks of histograms. 
Samples were separated from HL-60 cells treated with valproic acid at 
concentrations of 0.5-8 mM for 6 hours. The control is untreated (0 mM 
valproic acid) HL-60 cells under the same conditions.  
Valproic acid 
concentration 
Intensity of acH4 Percentage of nuclear 
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Figure 4.6. Expression of acH4 in HL-60 cells treated with increasing concentrations of 
valproic acid (0-8 mM) for 6 hours. 
Figure 4.6A and Figure 4.6B indicate mean and median fluorescence intensity of 
acH4, respectively, and Figure 4.6C indicates average percentage of acH4 






4.3.4 Valproic acid time dependent in vitro experiments 
 In order to investigate the effect of duration of valproic acid treatment, HL-60 
cell lines were incubated with 4 mM valproic acid for up to 24 hours. The processes of 
cell fixation, antibody incubation and imaging flow cytometry were the same as 
previously described. The histograms of acH4 intensity, scatter plots between similarity 
of acH4 and DAPI and intensity of acH4, and examples of cells at the peaks of 
histogram showing the expression of acH4 are shown in Figure 4.7. 
 Data relating to average mean intensity of acH4, median intensity of acH4 and 
percentage of acH4 positive cells are summarised in Figure 4.8, with all three 
parameters exhibiting the same trend of change. For mean and median intensity 
(Figure 4.8A and Figure 4.8B), the expressions of acH4 were stable at 0.5 and 1 hour of 
drug incubation as compared to baseline; mean intensities of 3,500 at baseline and 
4,600 at 1 hour (one-way ANOVA, 95%CI of difference -3887 to 1565). Significant 
increases in acH4 expression were observed when duration of treatment was longer 
than 1 hour and peaked at 6 hours, with an intensity of 9,800 observed (one-way 
ANOVA, p-value <0.0001). However, the acH4 expression then decreased to 7,500 at 
24 hours of treatment. 
 The mean percentage of acH4 positive cells followed the same trend as 
intensity with no significant changes observed compared to baseline following 
incubation times of <3 hours (Figure 4.8C). Statistical analysis (one-way ANOVA and 
multiple comparison analysis) revealed that the mean difference between 0 hour and 3 
hours was -5% (95%CI -11.82% to 1.743%) and between 0 hour and 6 hours was -9.5% 
(95%CI -16.29% to -2.724%). A reduction in percentage of acH4 positive cells at 24 
hours was also observed but this was not statistically significant (Mean difference 
6.8%, 95%CI -0.75% to 14.41%). However, the overall increase determined by one-way 
ANOVA was significant (p-value 0.0032). 
 These results suggested that a 6-hour duration of treatment was suitable for 
further experiments due to a decrease in acH4 signal observed following an incubation 




















Figure 4.7. Intensity histograms of acH4 expression, scatter plots between similarity 
of acH4 and DAPI and intensity of acH4, and examples of HL-60 cell lines showing 
acH4 expression at the peaks of histograms. 
Samples were separated from HL-60 cells treated with 4 mM valproic acid for 
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Figure 4.8. Expression of acH4 in HL-60 cells treated with 4 mM of valproic acid for up 
to 24 hours. 
Figure 4.8A, B and C indicate mean fluorescence intensity, median fluorescence 
intensity and average percentage of acH4 positive cells, respectively. Mean and 







4.3.5 Valproic acid whole blood ex vivo experiments 
 The applicability of the developed assay to ex vivo incubations of human white 
blood cells was investigated by conducting concentration-dependent experiments in 
whole blood from three independent healthy donors. Whole blood samples were 
treated with increasing concentrations of valproic acid (0, 0.5, 1, 2, 4 and 8 mM) for 6 
hours. Protocols for red blood cell lysis, acH4 antibody incubation and imaging flow 
cytometry were described in Chapter 2. 
 Examples of white blood cells with and without acH4 expression are shown in 
Figure 4.9; Figure 4.9A and Figure 4.9B represent myeloid cells while Figure 4.9C and 
Figure 4.9D represent lymphoid cells with nuclear acH4 positivity and negativity, 
respectively. Moreover, Figure 4.9E shows clear cytoplasmic expression of acH4. 
Examples of acH4 intensity histograms and scatter graphs between similarity of acH4 
and DAPI and intensity of acH4 are illustrated in Figure 4.10 and Figure 4.11, 
respectively. 
 Based on the results shown, a difference in pattern of change between acH4 
expression in myeloid and lymphoid cells was observed. At baseline, both cell types 
expressed a single peak of acH4 intensity (Figure 4.10). After treatment with 8 mM 
valproic acid for 6 hours, the acH4 expression curve in myeloid cells became bimodal 
while in lymphoid cells it remained unimodal. These results conformed to the scatter 
graphs showing cells with high and low similarity between acH4 and DAPI which 
indicated nuclear and cytoplasmic expression of the protein. 
 As illustrated in Figure 4.11, the number of myeloid cells with cytoplasmic acH4 
expression increased when treated with 8 mM valproic acid compared to no 
treatment. Further analysis suggested that the second peak in the myeloid histogram 
was the population of cells with cytoplasmic acH4 expression (data not shown on the 
graph). This phenomenon, however, was less obvious in lymphoid cells and did not 









Figure 4.9. Representative images of myeloid cells with nuclear acH4 positivity (A) and negativity (B), lymphoid cells with nuclear acH4 
positivity (C) and negativity (D), and myeloid cells with cytoplasmic acH4 positivity (E). 
Samples were separated following incubation of WBCs with 8 mM sodium valproate for 6 hours. 
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Figure 4.10. Examples of acH4 intensity histograms of myeloid and lymphoid cells 
either untreated or treated with 8 mM valproic acid for 6 hours. 
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Figure 4.11. Examples of scatter plots of myeloid and lymphoid cells showing nuclear 
and cytoplasmic acH4 positive cells. 
WBCs were separated from whole blood either untreated or treated with 8 mM 











 A summary of data showing average mean intensity and median intensity of 
acH4 expression and average percentage of acH4 positive cells together with SD from 3 
independent healthy donors are presented in Figure 4.12. These three parameters 
showed significant increases following incubation with increasing concentrations of 
valproic acid. However, the difference between myeloid and lymphoid cells was not 
significant when looking at mean or median intensity. 
 When the concentration of valproic acid increased from 0 to 8 mM, the mean 
intensity of acH4 increased from 1,500 to 6,700 (4.5-fold) for myeloid cells and from 
1,600 to 6,100 (3.8-fold) for lymphoid cells, and median intensity of acH4 increased 
from 1,500 to 5,500 (3.7-fold) and from 1,600 to 5,600 (3.5-fold) for myeloid and 
lymphoid cells, respectively. A one-way ANOVA indicated significant increases for both 
mean and median intensity in both myeloid and lymphoid cells with p-values <0.01 
(Figure 4.12A and Figure 4.12B). However, when the increases observed in myeloid 
cells were compared with the increases in lymphoid cells, a two-way ANOVA analysis 
revealed that there was no significant difference between cell types for either mean or 
median intensity (p-values of 0.62 and 0.34). 
 In contrast, comparison of the change in percentage of acH4 positive cells 
showed significant differences between myeloid and lymphoid cells with a greater 
fold-increase than observed with intensity. An increase in valproic acid concentration 
from 0 to 8 mM resulted in increases in percentage of acH4 positive cells from 0.6% to 
55% (92-fold) for myeloid cells and from 2.1% to 70% (33-fold) for lymphoid cells; both 
increases were statistically significant with one-way ANOVA p-values <0.0001 (Figure 
4.12C). Moreover, two-way ANOVA indicated a significant difference between the two 
type of cells in terms of increases in myeloid and lymphoid cells (p-value <0.0001). 
 These ex vivo findings highlighted two important issues. Firstly, fold-increases 
observed in percentage of acH4 positive cells were higher than mean and median 
intensity of acH4 expression, so the percentage of acH4 positive cells is a better 
representative of the magnitude of change than acH4 intensity. Secondly, considering 
the increases in acH4 positive cells, the myeloid population provided a 3 times greater 
fold-change than lymphoid cells (92-fold vs. 33-fold). Together these results suggest 
117 
 
that the myeloid population may be more suitable than lymphoid cells for the 
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Figure 4.12. Expression of acH4 in myeloid, lymphoid and total white blood cells from 
whole blood samples treated with increasing concentrations of valproic acid 
(0-8 mM) for 6 hours. 
Expression is shown as mean intensity (A), median intensity (B) and percentage 






 An assay for detection of acH4 expression as a pharmacodynamic biomarker for 
valproic acid was developed and validated in cell lines (in vitro) and white blood cells 
(ex vivo). The assay was developed using an imaging flow cytometry based technique 
and the assessment of drug efficacy using percentage of acH4 overexpressed myeloid 
white blood cells. Results obtained in both cell lines and white blood cells showed 
similar responses of acH4 to the drug. The results generated have been published in 
the European Journal of Clinical Investigation (Uitrakul et al., 2019). 
 Since an interest in using acetylation of histone H3 and H4 as a potential 
biomarker has increased over recent years, various assays have been developed to 
measure these proteins including Western blot, immunohistochemistry, 
immunofluorescence and conventional flow cytometry (Chung et al., 2005; Ronzoni et 
al., 2005; Rigby et al., 2012). Although the current study was based on the principles of 
flow cytometry, it was imaging flow cytometry which provided additional information 
and facilitated a more detailed analysis. For instance, localisation of nucleus and acH4 
identification using the imaging flow cytometry software (Ideas 6.2) indicated which 
cells had nuclear or cytoplasmic acH4 expression without the need for additional 
antibodies. 
 It should be noted that the assays mentioned above only measured histone 
acetylation in PBMCs based on the results of a pioneering study which showed an 
increase in acH4 protein in mouse PBMCs treated with the HDAC inhibitor PXD101, 
measured by Western blot analysis (Plumb et al., 2003). PBMCs therefore have 
become the primary type of WBCs for measurement of histone acetylation. However 
the findings of this chapter indicate that myeloid cells, i.e. granulocytes and 
monocytes, provided a higher dynamic range than lymphocytes. This was related to 
the fact that myeloid cells had lower acH4 expression at baseline than lymphocytes, so 
any changes in myeloid cells could be more clearly observed than in lymphoid cells. 
Therefore these findings suggest a potential new surrogate cell type for the 
measurement of histone acetylation. 
 Another novel parameter which has not previously been investigated was the 
percentage of acH4 positive cells. All recent assays have measured the overall 
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expression of acetylated histones but none has focused on the overexpressed cells. 
Qualitative techniques such as Western blot are unable to quantify these cells, but 
with flow cytometry this is feasible. A study by Ronzoni, et al quantified mean 
fluorescence intensity of histone acetylation using conventional flow cytometry and 
reported the results as fold changes compared to control (Ronzoni et al., 2005). In 
addition, Rigby et al also reported mean and median fluorescence intensity of acH3 
and acH4 measured by conventional flow cytometry (Rigby et al., 2012). However, the 
findings of the current chapter suggest that counting the number of overexpressed 
cells provides a greater dynamic magnitude of change than fluorescence intensity 
approaches. This finding is supported by the fact that histone H4 and acH4 are proteins 
found in normal cells, so histone H4 acetylation can be observed even in untreated 
normal cells (Allfrey et al., 1964). Consequently, increases in acH4 levels were less 
pronounced when treated with HDAC inhibitors. Similarly, the concept of rare cells 
states that not every cell has the same response to a particular drug, so specifically 
considering the responsive cells might be more appropriate than considering the 
whole cell population (De Biasi et al., 2017). This conformed to the results in this 
chapter, which showed some cells with overexpression and some cells with normal 
expression of acH4, despite treatment with the same drug under the same conditions. 
Hyperacetylated cells, namely acH4 positive cells, were therefore measured in the 
developed assay instead of average fluorescence intensity. 
 A number of in vitro experiments included in published studies have 
investigated the hyperacetylation of histone H4 by valproic acid treatment measured 
by Western blot analysis. Results by Gottlicher et al showed a clear expression of acH4 
when cells were treated with ≥0.5 mM concentrations of valproic acid for a minimum 
of 4 hours (Gottlicher et al., 2001). Eyal et al showed acH4 accumulation at 0.5 and 
1 mM of valproic acid following a 1 hour incubation (Eyal et al., 2004) and Pheil et al 
reported a significant increase in acH4 expression when cells were treated with 2 and 
5 mM of valproic acid for 24 hours (Phiel et al., 2001). Also, Gurvich et al indicated 
increases in acH4 expression when cells were treated with 2 mM of valproic acid for 24 
hours (Gurvich et al., 2004). These previous findings are in agreement with results 
generated in HL-60 cell lines in the current study, which showed an increase in acH4 
expression at 0.5 mM of valproic acid and a more marked increase at 1 mM. Also, the 
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results in this chapter suggest that mean and median intensity of acH4 were increased 
over the concentration of valproic acid until 4 mM and become stable at higher 
concentrations.  
 Furthermore, a significant increase in percentage of acH4 positive cells was 
observed in this study when valproic acid incubation time was ≥3 hours. This increase 
was most marked at 6 hours, and then declined although cells were still incubated with 
the drug. This trend was also noticed in a study by Eyal et al, who noted a decline in 
accumulated acH4 in HeLa cell lines after 16 hours of valproic acid incubation (Eyal et 
al., 2004). This study also reported the same trend towards a decrease in signal when 
cells were treated with topiramate and 2-pyrrolidinone-n-butyric acid. There were 2 
possible suggestions to explain this phenomenon. 
 Firstly, this was possibly caused by an apoptotic effect of valproic acid when 
cells were treated for a long enough duration. Cells with overexpression of acH4 are 
more affected by the drug, resulting in greater instances of cell death than non-
responsive cells. As mentioned previously, however, almost all studies focused on 
overall expression, so apoptotic response of H4 hyperacetylated cells needs to be 
investigated further. For instance, apoptotic markers such as BID, BAX and cleaved 
Caspase-3 could be measured in acH4 positive cells as well as culture media. Another 
explanation relates to the potential for intracellular compensation to decrease the 
levels of acH4 in drug stimulating conditions; longer incubation times may trigger the 
reverse reaction, such as histone acetylation by HAT enzymes to maintain a normal 
acH4 level. However, this hypothesis also needs to be further studied. 
 The ex vivo results generated in the current chapter were comparable with cell 
line results. Increases in mean and median intensity of acH4 as well as percentage of 
acH4 positive cells were observed following an increase in valproic acid concentration. 
The magnitude of change was also in parallel with the in vitro results, with greater 
increases in percentage of acH4 positive cells from baseline than the increase in 
fluorescence intensity of acH4. Moreover, not only a change in the magnitude of acH4 
was observed, but a different pattern of increase in acH4 was also noted in this study, 
with greater cytoplasmic acH4 expression observed in myeloid than in lymphoid cells. 
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This phenomenon was detected only when cells were treated with high concentrations 
of valproic acid of 4-8 mM. 
  Histones are known to be present in both the nucleus and cytoplasm of cells 
but have to be transported into the nucleus to be acetylated (Apta-Smith et al., 2018). 
Therefore acH4 theoretically should not be detected in the cytoplasm. Results from 
Uchida et al, however, reported cytoplasmic acH4 expression when NIH3T3 cell lines 
were treated with 50 ng/mL trichostatin A for 12 hours (Uchida et al., 2007). This study 
suggested that cytoplasmic acH4 expression could be observed although, unlike 
nuclear expression, cytoplasmic acH4 did not respond to drug treatment. In the work 
presented in this chapter, only nuclear acH4 was measured as the importance of 
cytoplasmic acH4 has not been well characterised and its relevance as a biomarker for 
HDAC inhibitors is unclear. Additionally, cytoplasmic expression was only detected at 
high concentrations of valproic acid (>4 mM, Figure 4.11), which is unlikely to have 
clinical relevance.  
 In conclusion, the in vitro and ex vivo results summarised in this chapter show 
that the novel assay developed can be used to detect histone H4 acetylation in human 
white blood cells. These results suggested a novel parameter for acH4 assessment, i.e. 
percentage of acH4 positive cells, rather than acH4 fluorescence intensity. In addition, 
myeloid cells were shown to express a greater magnitude of change in acH4 than 
lymphoid cells. This assay has been applied to clinical blood samples from patients 






Chapter 5. Clinical application of a developed assay for detection of 
histone H4 acetylation as a pharmacodynamic biomarker for valproic 
acid 
5.1 Introduction 
 Since the HDAC inhibitory effects of valproic acid were first discovered, use of 
the drug has been investigated in many areas including cancer. Successful preclinical 
studies showing the potential efficacy of valproic acid in various cancer cell lines have 
been conducted, as previously described (Göttlicher et al., 2001; Phiel et al., 2001; 
Gurvich et al., 2004; Eyal et al., 2005). These studies contributed to a growing in clinical 
trials of valproic acid as a repositioned drug. Although a number of studies have shown 
clinical efficacy of valproic acid either alone, or in combination with other drugs in 
various types of cancer, relatively few studies have monitored the mechanistic effects 
of the drug on changing histone acetylation (Iwahashi et al., 2014; Issa et al., 2015; 
Krauze et al., 2015; Fushida et al., 2016; Nilubol et al., 2017). This was partly related to 
the publication of data from a clinical study that suggested no association between 
histone hyperacetylation and dose or concentration of belinostat as well as clinical 
response (Steele et al., 2008). 
 Furthermore, only a small number of studies have investigated the use of 
valproic acid in CNS tumours (Wolff et al., 2008; Su et al., 2011; Weller et al., 2011; 
Krauze et al., 2015). Most clinical studies of valproic acid have been carried out in solid 
tumours or leukaemia (Iwahashi et al., 2014; Issa et al., 2015; Fushida et al., 2016). 
Since this study focused on acH4 expression as a pharmacodynamic biomarker rather 
than predictive or prognostic biomarker, we are interested in published clinical studies 





5.1.1 Clinical studies of valproic acid as an HDAC inhibitor. 
5.1.1.1 Clinical cancer studies 
 Although associations between acetylated histone levels and dose and 
concentration of valproic acid have to date been somewhat unclear, approaches to 
measure histone acetylation have been incorporated into several clinical trials. 
Arguably the most relevant study was conducted by the Children's Oncology Group in 
the USA (Su et al., 2011). Childhood cancer patients with refractory solid or central 
nervous system tumours were treated with oral valproic acid twice daily, with a view 
to maintaining trough concentrations of 100 to 150 µg/mL (0.7-1 mM). Acetylation of 
histones H3 and H4 in PBMCs was measured pre- and post-treatment using 
commercial ELISA kits. The expressions of acH3 and acH4 were assessed and matched 
with total and free drug concentrations (Figure 5.1). The results indicated that 4 out of 
7 patients had lower acH3 and acH4 as compared to pre-treatment levels, despite the 
fact that only 2 of the 4 had achieved the target trough drug levels. Moreover, patients 
who had post/pre acH4 ratios higher than 1 still had progressive disease. Only one 
patient, who had an extremely high post/pre acH4 ratio (14.7-fold), exhibited a partial 
response. 
 Another phase I clinical trial in patients with refractory advanced cancers 
revealed similar results (Atmaca et al., 2007). Each patient received intravenous 
valproic acid starting at a dose level of 30 mg/kg, with a standard dose-escalating 
three-patient cohort design. Blood samples were taken at baseline, 6-hr, 24-hr and 
48-hr following administration of doses from 30-120 mg/kg. The results showed no 
relationship between acetylated histone levels measured in peripheral blood 
lymphocyte cell lysates and valproic acid dose, although an increase in histone 
hyperacetylation was observed in 12/16 (75%) patients. Four patients reported 
undetectable acH3 and acH4 by Western blot throughout the study, despite receiving a 
valproic acid dose of 120 mg/kg. Moreover, a patient who received 30 mg/kg exhibited 
a more marked acH4 expression than a second patient who received 60 mg/kg. 
Although the study mentioned an increase of the acetylation status of peripheral blood 
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Figure 5.1. Association between fold-change in acH3/acH4 expression and 
concentration of total valproic acid (A) and free valproic acid (B). 
Fold change was determined by dividing the histone expression observed at 
steady state by the expression determined pre-treatment. No target 
concentration for free valproic acid was set. Adapted from Su JM, et al. Clin 
Cancer Res. 2011;17(3):589-97. 
 
 These results conformed to the findings of three other clinical trials in prostate 
cancer, advanced solid tumours and leukaemia (Garcia-Manero et al., 2006; Sharma et 
al., 2008; Wheler et al., 2014), suggesting that valproic acid is unable to consistently 
cause histone acetylation in lymphocytes. In the same way, no association between 
histone acetylation and response was consistently observed across these studies. 
However, several clinical studies have provided conflicting observations (Munster et 





study in patients with advanced solid tumours who received valproic acid and 
epirubicin reported a significant correlation between histone H4 acetylation and 
valproic acid dose as well as valproic acid concentration (Munster et al., 2007). Unlike 
the studies mentioned above, this study indicated increases in acH4 expression in 
patients who received a valproic acid dose of 30 mg/kg/day and had plasma 
concentrations of >50 µg/mL (0.35 mM). These increases were observed between 
baseline and 3 days after treatment. Also, patients with acH4 increases achieved 
partial responses at the end of study. Similar results from the same cohort were 
presented by the same authors a year later (Munster et al., 2009). Additionally, this 
study indicated that there was a correlation between acH4 levels in PBMCs and 
valproic concentration, but not acH4 levels in tumour tissues. 
 A phase I-II clinical study of valproic acid plus chemo-immunotherapy in 
patients with advanced melanoma also showed positive results (Rocca et al., 2009). 
Patients were treated with 10 mg/kg/day valproic acid in three divided doses and the 
dose was increased weekly by 10 mg/kg/day, until 90 mg/kg/day or maximum 
tolerated dose for 6 weeks. Dacarbazine and interferon-α were then administered at 
week 7 in combination with valproic acid. Histone H4 acetylation in PBMCs was 
measured at the end of the second week of treatment, at the beginning of the 
combination phase and weekly thereafter using cytofluorimetric techniques developed 
by Ronzoni, et al (Ronzoni et al., 2005). The results showed that only 5 of 27 patients 
did not achieve acH4 increases (>1 Post/Pre ratio). Some patients with increases in 
acH4 had plasma valproic acid concentrations <100 µg/mL. The authors, however, 
highlighted that these values referred to the maximum values of plasma valproic acid 
concentrations and the maximum fold increase in histone acetylation reached during 
treatment at the maximal dose of valproic acid. They reported that patients who had 
more than a 4-fold acH4 increase did not maintain this increase at repeated 
measurements, notwithstanding maintenance of the valproic acid dose. 
 Another phase I/II clinical trial suggested similar results (Daud et al., 2009) 
following treatment of patients with valproic acid and karenitecin, a novel 
topoisomerase I inhibitor. Valproic acid dose was escalated until the occurrence of 
dose-limiting toxicities and acetylation of histone H3 and H4 in PBMCs was 
investigated by Western blot analysis. The fold changes between 3-day post-treatment 
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and baseline at doses of 60, 75 and 90 mg/kg/day were higher than 45 mg/kg/day. This 
increase, however, was not statistically significant and there was no difference 
between the three dose levels. 
 Western blot results from a phase I study in patients with cervical cancer also 
questioned the utility of acH4 expression in tumour cells as a biomarker (Chavez-
Blanco et al., 2005). Among tumour samples from 10 patients, 7 had clear hyper-
acetylation of histone H4 on day six after the five days of magnesium valproate 
treatment; the effects of the remaining patients were minor or non-existent. The 
magnitude of change, however, did not follow serum drug concentrations. The authors 
also mentioned heterogeneity in degree of baseline acH4, i.e. some patients had very 
strong pre-treatment acH4 while others had minimal levels.  
5.1.1.2 Clinical studies of non-cancer diseases 
 Discovery of the HDAC inhibitory effects of valproic acid is not only relevant to 
cancer research, but also other areas including epilepsy, migraine and bipolar mania, 
where valproic acid has been used for decades. Historically valproic acid has been used 
to treat these diseases without a full understanding of the potential role of histone 
acetylation, but recent discoveries suggest that histone acetylation may be relevant to 
many disease types. 
 A clinical study in patients with spinal muscular atrophy recently reported a 
significant increase in histone H4 acetylation with valproic acid treatment (Renusch et 
al., 2015). This study measured the expression of acH4 in patient PBMCs using a liquid 
chromatography/mass spectrometry technique. The AUC showed a significant increase 
in acH4 expression when treated with valproic acid for 6 months (from 0.599 to 0.683) 
and decrease when valproic acid treatment was stopped for 6 months (from 0.695 to 
0.616). Also, the authors indicated that approximately 71% of their subjects were 
‘responders’ to valproic acid, defined as those patients whose AUC increased by at 
least 15% after 6 months of treatment. However, this study did not conclude an 
association between acH4 and clinical outcome because of insufficient evidence to 
suggest a treatment effect. 
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 Another study reported measurement of acH3 and acH4 expression in 
lymphocytes from schizophrenic and bipolar patients using Western Blot analysis 
(Sharma et al., 2006). The results showed that acH3, but not acH4, significantly 
increased from baseline (p-value <0.03) when treated with valproic acid for 4 weeks. 
Moreover, acH4 expression was not found to be correlated with valproic acid levels or 
behavioural rating scores, while acH3 correlated with both valproic acid levels and the 
symptom severity of patients with schizophrenia. This contributed to a surge in using 
acH3 as a biomarker of HDAC inhibiting activity in the area of neurology, as opposed to 
acH4 (Gavin et al., 2009; Tremolizzo et al., 2012). 
 In addition, there were significant numbers of pre-clinical trials that 
investigated various effects of valproic acid as a HDAC inhibiting agent, in disease areas 
including autism, retinal ischemia injury, acute lung ischemia injury and acute central 
nervous system injury (Zhang et al., 2012b; Kataoka et al., 2013; Chen et al., 2014; Wu 
et al., 2015). Although the relationship between histone acetylation and clinical 
response is not clear, this emphasises the important role for robust biomarker 
development to allow the detection of histone acetylation as surrogate biomarkers for 




5.2 Chapter specific aims 
 This project primarily aimed to investigate the expression of histone H4 
acetylation (acH4) in patients receiving valproic acid as part of the SIOP Ependymoma 
clinical trial. The level of acH4 expression was measured using the assay developed and 
validated in the previous chapter. Specifically the objectives of this chapter were: 
• To measure mean acH4 intensity, median acH4 intensity and percentage of 
acH4 positive WBCs in patients receiving valproic acid in the SIOP Ependymoma 
trial. 
• To evaluate differences in acH4 expression between myeloid and lymphoid cell 
populations following administration of valproic acid. 
• To compare changes in percentage of acH4 positive myeloid cells between 
patients treated with valproic acid over several courses of treatment. 
• To investigate an association between changes in percentage of acH4 positive 
cells and valproic acid dose. 
• To investigate relationships between total and free valproic acid plasma 
concentrations and valproic acid dose. 
• To investigate associations between percentage of acH4 positive cells and both 






5.3.1 Patient characteristics 
 From October 2016 to December 2018, there were seven patients recruited 
onto the study. One patient had started valproic acid treatment before the first 
samples were collected for analysis of histone acetylation, therefore no pre-treatment 
sample was available for this patient. Table 5.1 describes the valproic acid dose that 
patient received at each visit. Doses were calculated by dividing the actual 
administered dose by the patient’s weight. One patient provided blood samples for 
analysis from one visit only (pre-treatment and 4-hour post-first dose). Baseline 
characteristics of all patients at the start of their treatment are described in Table 5.2. 
For the patient who started treatment before the first sample was collected for 
analysis, the data shown are from the first time that samples were sent to the 
laboratory. 
 The median age of the seven patients recruited was 11 years old. Numbers of 
male and female patients were similar (4:3). The highest creatinine value was 
25 µmol/L at the start of the clinical trial. Patient 5 presented the highest ALT enzyme 
(35 IU/L) and patient 6 presented the highest WBC count (17.62 ×109/L). Due to 
limitations in data availability, numbers of neutrophil shown were from only four 
patients. 
Patient Valproic acid dose (mg/kg/dose twice daily) 
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 
1 23* 28.9 35 40.5 42 45 29+ 
2 15 15 20 25 30 33 35 
3 15 15 19.5 20    
4 15 35.5 29.2     
5 15       
6 15 20      
7 15 19 28.5     
* Visit 1 of this patient was not the first dose of treatment 
+ Patient received this dose three times a day 
 
















1 11 Male 9.1 2.33 N/A 22 22 
2 36 Male 13.8 2.20 N/A 13 25 
3 7 Female 6.9 12.1 N/A 10 11 
4 5 Male 6.8 7.18 1.08 13 17 
5 11 Female 8.7 15.7 11.2 35 19 
6 19 Male 12.5 17.6 11.6 9 16 
7 19 Female 11.9 4.10 1.75 18 <18 
 
Table 5.2. Baseline characteristics of patients at the start of SIOP Ependymoma II trial 
until December 2018. 
 
 Figure 5.2 represents the WBC count of all patients at each visit. Most patients 
had values of WBC count within the normal range, except patient 1 who reached 
leukopaenic levels several times, including visits 2, 4 and 6. Also, clinical data indicated 
that patient 1 had neutropenia at visits 4 and 6. Figure 5.3 shows different patterns of 
results analysed in neutropaenic samples and non-neutropenic samples obtained from 
patient 1. The percentage of myeloid cell in neutropenic samples decreased to 22.5% 
as compared to 62.3% in non-neutropaenic samples. Since the developed assay mainly 
measures acH4 expression in myeloid cells, the proportion of neutrophils markedly 
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Figure 5.2. WBC counts measured at all visits of seven patients studied on the 
Ependymoma trial. 
WBC counts were determined in hospital before patients received valproic acid. 
Note that the interval between consecutive visits were not the same and could 
be several weeks or months. 
 
  
Figure 5.3. Representative samples from patient 1 with (A) and without (B) 
neutropaenia detected by imaging flow cytometry with gating between side scatter 
(SSC) and area of cell. 
The neutropaenic sample shown is from visit 4 and the normal sample shown is 






 All patients had received not only valproic acid, but also a number of 
concomitant medicines as listed in Table 5.3. The drugs patients received included 
antibiotics, analgesics, antihistamines and antiemetics as well as chemotherapeutic 
drugs. The chemotherapy most frequently administered to patients were platinum-
based (four patients) and vincristine-based regimens (three patients). Several classes 
of antibiotic were used in multiple patients including cephalosporins, 
fluoroquinolones, sulfonimides, aminoglycosides and carbapenems. Other drugs 




 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5* Patient 6 Patient 7 
Chemotherapy Cisplatin Vincristine Carboplatin Vincristine  Vincristine Cisplatin 
 Methotrexate Cisplatin Cyclophosphamide  Cyclophosphamide  
 Cisplatin      





Co-trimoxazole Meropenem   Flucloxacillin Co-trimoxazole 
Co-amoxiclav Tazocin Ceftriaxone   Ciprofloxacin Piperacillin / 
Tazobactam 
Meropenem Gentamicin Gentamicin   Co-amoxiclav  
Tobramycin  Teicoplanin     
Aciclovir  Co-trimoxazole     
  Anidulafungin     
Analgesics Oxycodone Morphine      
Antihistamines  Cetirizine      
Others Ranitidine Loperamide Domperidone Metoclopramide  Metoclopramide Ondansetron 
Metoclopramide Metoclopramide Ondansetron Ondansetron  Ondansetron  
Ondansetron Ondansetron    Glycopyrronium  
 Folic acid      
* Patient 5 received unknown chemotherapeutic drugs following the protocol. 
Table 5.3. List of medications that patients received alongside valproic acid not including topical medicines. 
Not all medicines were administered at the same visit and some medicines were administered at more than one visit.
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5.3.2 Phenotyping of WBCs and changes in acH4 expression 
 The developed assay was applied to measured acH4 positive cells in patients 
with ependymoma. In order to investigate the potential significance of the myeloid 
population observed in ex vivo results, WBCs from patient samples pre- and post-
treatment were incubated with acH4 antibodies and analysed using imaging flow 
cytometry. The intensity of acH4 expression and percentage of acH4 positive cells were 
then assessed for each type of WBC. 
 Figure 5.4 illustrates changes in mean and median intensity of acH4 expression, 
and percentage of acH4 positive WBCs between pre- and post-dose of valproic acid. 
Focusing on fluorescence intensity (Figure 5.4A and Figure 5.4B), average values for 
the mean intensity were higher than the median for all three populations (myeloid, 
lymphoid and total WBCs). Averages values for pre-treatment mean intensity of 
myeloid, lymphoid and total WBCs were 7600, 8600 and 7800 while median intensity 
values were 6100, 6400 and 6200, respectively. Similarly, averages in post-treatment 
mean intensity were 9400 for all three populations while median intensity values were 
7600, 7000 and 7400 in myeloid, lymphoid and total WBCs, respectively. The Wilcoxon 
matched-pairs signed rank test revealed significant differences between pre- and post-
treatment in myeloid cells for both mean and median acH4 expression, with p-values 
of 0.0059 and 0.0069, respectively. In lymphoid cells, however, neither parameter 
showed statistical significance between pre- and post-treatment samples (p-values of 
0.1482 for mean and 0.1111 for median intensity). 
 Mean percentages of nuclear acH4 positive cells post-treatment showed 
increases in myeloid, lymphoid and total WBCs as compared to pre-treatment: 0.70% 
to 1.44% in myeloid, 1.39% to 1.88% in lymphoid and 0.85% to 1.63% in total WBCs 
(Figure 5.4C). These increases were not significant in either myeloid or lymphoid cells 
with p-values of 0.0721 and 0.2660, respectively, measured by Wilcoxon matched-
pairs signed rank test. 
 Considering fold-changes in all parameters, mean intensity of acH4 provided 
lower average fold-changes with 1.2, 1.1 and 1.2-fold changes for myeloid, lymphoid 
and total WBCs, respectively. Similarly, average fold-changes in median intensity of 
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acH4 were 1.2, 1.1 and 1.2-fold for myeloid, lymphoid and total WBCs, respectively. 
The greatest average fold-increases were percentages of acH4 positive cells, with 2.7, 
2.5 and 2.3-fold increases observed in myeloid, lymphoid and total WBCs, respectively. 
 The results of fold-changes alongside significant values conformed to the 
previous ex vivo results in Chapter 4 and provide two conclusions. Firstly, percentage 
of acH4 positive cells was a more sensitive method for detection of acH4 changes than 
fluorescence intensity. Secondly, a higher dynamic change was observed in myeloid as 
compared to lymphoid cell populations. The percentage of acH4 positive myeloid cells 
was therefore used in further analyses. 
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Figure 5.4. Mean (A) and median (B) fluorescence intensity of acH4, and percentage 
of acH4 positive cells (C) in myeloid, lymphoid and total WBCs from patients pre- and 
post-administration of valproic acid. 
The marked lines indicate mean values. 
 
5.3.3 Individual percentages of acH4 positive myeloid cells pre- and post-valproic 
acid treatment in patients with ependymoma 
 For each study visit, blood samples were generally taken from the patient 
before and 4-hour after receiving valproic acid treatment. For patient 1 samples were 
taken before and 2-hour after receiving the drug. Processed blood plasma samples 
were delivered to the laboratory on dry ice to measure acH4 expression using the 
developed assay. Percentages of acH4 positive myeloid cells determined for each 
patient at each visit are shown in Figure 5.5A-G. 
 According to the figures shown, there was marked heterogeneity in degree of 
baseline acH4 as well as magnitude of change in acH4 expression following treatment 
with valproic acid. Most patients presented with less than 1% of acH4 positive myeloid 
cells at baseline (pre-treatment of the first visit) whilst patient 7 expressed 2.5% of 
acH4 positive cells. Changes in acH4 positive cells at 4-hr post-treatment were 
inconsistent but the majority showed relatively modest increases. The highest increase 
was from the third visit of patient 3, with a 7-fold increase from pre-treatment 
observed. Furthermore, decreases in acH4 post-treatment were observed in several 
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Figure 5.5. Percentages of acH4 positive myeloid cells collected from patients 1-7 
(A-G) with concentrations of valproic acid at each visit. 
Blood samples were taken pre- and 4-hr post valproic acid treatment, except 
patient 1 where a 2-hr post treatment was collected, at different dose levels. 
Visit 1 indicates the first time that each patient received valproic acid, except 
patient 1 who began treatment before samples were collected for acH4 
analysis. The concentrations of valproic acid shown on top of the bars are in 
mM. N/A indicates no data available. Note that the intervals between 
consecutive visits were not consistent between patients. 
 
 Focusing on each patient, most of the samples from patient 1 showed slight 
decreases following treatment with valproic acid (Figure 5.5A). There were two 
samples with extremely high increases in acH4 positivity. This patient, however, had a 
history of leukopenia and neutropenia (Figure 5.2) which could affect the 
measurement of acH4 positive myeloid cells. These increases were therefore 
questioned and will be discussed in the discussion part of this chapter. Patients 2, 3 
and 4 had similar profiles with increased acH4 positive myeloid cells observed post-
treatment on almost all study days, although the degree of increase was variable 
(Figure 5.5B-Figure 5.5D). Patients 5 and 6 had too few samples to draw any real 
conclusions from the results obtained, but there were no observed increases in acH4 
positivity in post-treatment samples (Figure 5.5E-Figure 5.5F). The response observed 
in patient 7 was variable, with a marked increase in acH4 following the first 






5.3.4 Associations between percentage acH4 positive myeloid cells and valproic acid 
dose 
 Patients recruited to the SIOP Ependymoma II trial were given oral valproic acid 
at a starting dose of 15 mg/kg/dose twice daily. Blood samples were taken to measure 
acH4 expression and valproic acid concentrations in plasma. The valproic acid dose was 
then adjusted based on the trough drug concentrations observed. Since there is no 
standard to measure change in acH4 positive cells, Figure 5.6 and Figure 5.7 
summarise the association between dose of valproic acid and change in acH4 positive 
myeloid cells calculated by two methods: absolute change (Difference) and fold 
change, respectively. 
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Figure 5.6. Association between valproic acid dose and difference in percentage of 
acH4 positive myeloid cells between post- and pre-valproate dose. 











          
























P a tie n t 1
P a tie n t 2
P a tie n t 3
P a tie n t 4
P a tie n t 5
P a tie n t 6
P a tie n t 7
 
Figure 5.7. Association between valproic acid dose and fold change in percentage of 
acH4 positive myeloid cells as compared to pre-valproate dose. 
Fold change was determined by dividing post-treatment value by pre-
treatment value. 
 
 Analysis of the results by Spearman correlation analysis showed no significant 
correlation between valproic acid dose and fold change (p-value 0.1538), or difference 
(p-value 0.3012) in acH4 positive myeloid cells. However, the different patterns of 
change between the two graphs were highlighted. The fold change observed at the 
highest dose of valproic acid for patient 7 was exceptionally high, whilst the actual 
change of acH4 at the same dose was close to zero. In contrast, the fold change at the 
highest dose of patient 1 was much lower than the difference at the same dose. As 
there are clear differences in the interpretation of the data depending on the method 
of analysis used, both approaches were used for further analyses. 
5.3.5 Associations between percentage acH4 positive myeloid cells and total valproic 
acid concentrations 
 Total valproic acid concentrations were measured using the homogeneous 
enzyme immunoassay technique performed by the Royal Victoria Infirmary. Details of 
the machine and protocol used for drug measurement are described in section 2.4. 
The results were reported to the lab and used to investigate potential relationships 
between drug concentration and percentage of acH4 positive myeloid cells. 
 There are several ways to investigate potential associations between valproic 
acid concentration and acH4 expression; the most commonly used method is an 
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assessment of fold change in acH4 expression and trough valproic acid concentration 
at steady-state as compared to pre-treatment. In the current study samples from each 
patient were not taken at the same time points, e.g. every 2 weeks or every month, so 
the comparison between samples at particular time point of all patients was not 
possible. Instead, the drug concentrations and acH4 positive cell results at all valproate 
administrations were used to investigate associations between these variables. 
 Figure 5.8 shows the relationship between total valproic acid concentration and 
percentage of acH4 positive myeloid cells in all patients regardless of pre- and post-
treatment. The overall results suggested no significant correlation between these two 
parameters (Spearman, p-value 0.171). Although subgroup analysis for each patient 
revealed a significant correlation for patient 4 with a p-value 0.033, this correlation 
was heavily biased by two data points and might not be of biological significance. 
 












           
















P a tie n t 3
P a tie n t 4
P a tie n t 5
P a tie n t 6
P a tie n t 2
P a tie n t 1
P a tie n t 7
 
Figure 5.8. Relationship between total valproic acid concentration and percentage of 
acH4 positive myeloid cells for all patients. 
Note that these values represent both pre- and post-treatment values. 
 
 A comparison of difference in valproic acid concentration and percentage of 
acH4 positive cells was analysed by two aspects; the fold change in acH4 positive cells 
is shown in Figure 5.9 and the actual difference in acH4 positive cells is shown in Figure 
5.10. Unlike the dose results, the patterns of fold change and difference in acH4 
positivity were similar. For instance, patient 3 showed the highest values for both 
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difference and fold change in acH4 positive cells when the concentration increased by 
0.235 mM. Patient 1 had the highest acH4 change at the valproic acid concentration of 
0.52 mM. Interestingly, for patient 4 who presented a correlation between acH4 
positive cells and valproic acid concentration, neither fold change nor difference in 
acH4 positive cells significantly correlated with increase in valproic acid concentration 
(Spearman, p-value 0.999 and 0.667, respectively). The results of all patients also 
indicated no statistical significance in either fold change or difference (Spearman, 
p-value 0.594 and 0.935, respectively). 
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Figure 5.9. Association between difference in total valproic acid concentration and 
fold change in percentage of acH4 positive myeloid cells. 
Difference was determined by post-treatment values minus pre-treatment 
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Figure 5.10. Association between difference in total valproic acid concentration and 
difference in percentage of acH4 positive myeloid cells. 
Difference was determined by post-treatment values minus pre-treatment 
values. 
5.3.6 Association between increase in acH4 positive myeloid cells and free valproic 
acid concentrations 
 Patient plasma samples were filtered through Centrifree ultrafiltration devices 
to obtain the ultrafiltrate with free valproic acid. The samples were then sent to the 
Royal Victoria Infirmary to measure the concentration of free valproic acid using the 
homogeneous enzyme immunoassay technique as described in Chapter 2. The results 
were compared with percentages of acH4 positive myeloid cells to investigate 
potential relationships. 
 Figure 5.11A shows a significant correlation between total and free valproic 
acid concentrations in clinical samples analysed (Spearman, p-value <0.0001). 
Regression analysis indicated a y-intercept of 0.144 mM, thus the concentration of 
total valproic acid needs to be higher than 0.144 mM to be able to detect free valproic 
acid. However, this number increased to 0.251 mM when analysed without the four 
free concentration values of 0 mM (data not shown). The slope of the graph was 0.299 
and the r2 value was 0.7923. 
 For the fraction of free valproic acid, Figure 5.11B illustrates the relationship 
between this parameter and total valproic acid, with a significant correlation between 
the two variables (Spearman, p-value <0.0001). The linear regression analysis indicated 
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a y-intercept of 0.062 mM, slope of 0.267 and r2 value of 0.712. Based on the graph 
shown, the free valproic acid fraction was found to be greater at higher concentrations 
of total valproic acid. For example, a sample with 0.257 mM of total valproic acid had 
8.1% free valproic acid detected, while another sample with 0.811 mM of total valproic 
acid had 39.3% free valproic acid detected. 
 










        



















































Figure 5.11. Correlation between total valproic acid and free valproic acid 
concentrations (A) and fraction of free valproic acid (B) in patients received different 
doses of valproic acid. 
Free valproic acid was analysed from the ultrafiltrates of patient 1, 2, 4 and 6. 






 The relationship between percentage acH4 positive myeloid cells and free 
valproic acid concentration was determined in the same way as total valproic acid, and 
the results were comparable to total valproic acid results in all dimensions (Figure 
5.12-Figure 5.14). Only patient 4 showed a significant correlation between free 
valproic acid concentration and percentage of acH4 positive cells (Spearman, p-value 
0.0056, Figure 5.12). This significance, however, disappeared when absolute change 
and fold change were determined instead of actual acH4 values. Patient 2 presented a 
trend towards an increase in fold change in acH4 positive cells with increasing free 
drug concentrations, although this increase was not significant (Spearman, p-value 
0.0773, Figure 5.13). 
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Figure 5.12. Association between free valproic acid concentration and percentage of 
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Figure 5.13. Association between difference in free valproic acid concentration and 
fold change in percentage of acH4 positive myeloid cells. 
Free valproic acid was analysed from the ultrafiltrates of patient 1, 2, 4 and 6. 
Difference was determined by post-treatment values minus pre-treatment 
values and fold change was determined by dividing post-treatment values by 
pre-treatment values. 
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Figure 5.14. Association between difference in total valproic acid concentration and 
difference in percentage of acH4 positive myeloid cells. 
Free valproic acid was analysed from the ultrafiltrates of patient 1, 2, 4 and 6. 






 The developed imaging flow cytometry assay for detection of acH4 expression 
in myeloid cells was used to analyse clinical samples collected from patients studied on 
the SIOP Ependymoma II trial. Seven patients were recruited onto the trial and blood 
samples were collected pre- and 4-hour post-administration of valproic acid on 
multiple visits to measure acH4 expression. Plasma concentrations of the drug were 
also measured and used to adjust subsequent doses. Expression levels of acH4 
analysed by this assay were compared to dose and concentration of drug in order to 
investigate potential relationships between these parameters. In addition, the 
association between total and free valproic acid concentrations was investigated as 
well as associations between free valproic acid concentrations, dose and acH4 cell 
positivity. Preliminary results from this study were published in the European Journal 
of Clinical Investigation in 2019 (Uitrakul et al., 2019). 
5.4.1 Histone H4 acetylation in human white blood cells 
 The acH4 analysis results showed modest differences in acH4 expression, i.e. 
mean intensity, median intensity and percentage acH4 positive cells, between pre- and 
post-treatment as shown in Figure 5.4. In particular, as compared to pre-treatment, 
the average percentage of acH4 positive cells increased more than mean and median 
fluorescence intensity of acH4. Regarding cell type, increases observed in all values 
were greater in myeloid as opposed to lymphoid cells. These findings therefore 
supported the use of percentage of acH4 positive myeloid cell as a surrogate tissue for 
acH4 measurement. 
 According to patient data obtained from the SIOP Ependymoma trial, some 
patients had very low WBC counts to the point of leukopenia and some also had 
neutropenia, which theoretically could result in changes in the number of acH4 
positive myeloid cells. Basically, identification of myeloid and lymphoid cells in the 
developed assay is based on gating by size of cell and intensity of side scatter which 
reflects cell granularity. This method sometimes provides overlap between the two 
populations. If there are fewer myeloid cells, it is possible to have more lymphocytes in 
the myeloid population, resulting in a higher number of acH4 positive cells because 
acH4 expression is stronger in lymphocytes. 
150 
 
 The results shown in this chapter, however, suggested that not all samples with 
neutropenia presented high numbers of acH4 positive myeloid cells. In fact, only the 
sixth visit of patient 1 provided extremely high acH4 positive myeloid cells (>10%) 
together with neutropenia. Other samples with neutropenia, such as the fourth visit of 
patient 1 and the second visit of patient 6, did not show such high acH4 positive 
myeloid cells. The overall results therefore were not changed, although the 
neutropenic samples were removed from the analysis. Since neutrophils or myeloid 
cells are rarely cells of specific interest in this type of clinical trial, the correlation 
between acH4 positive myeloid cell and neutropenia condition has not previously been 
shown and needs more investigation. 
 The heterogeneity of acH4 expression in human cells was observed in the 
current study. Differences in baseline acH4 expression were found in recruited 
patients; patient 7 presented higher than 2% of acH4 positive myeloid cells while 
others had lower numbers at the beginning of the study. This variation was mentioned 
in two phase I clinical trials which showed obvious differences in baseline acH4 
expression between their cohorts measured by Western blot (Chavez-Blanco et al., 
2005; Atmaca et al., 2007). These findings caused difficulty for interpersonal 
comparison of acH4 since the same magnitude of change in one patient could not be 
compared with others. 
 A possible covariate which might cause these markedly different acH4 baselines 
in patients was co-medication. The inclusion criteria of the trial mention that patients 
must have no previous chemotherapy and no co-existent unrelated disease. It does not 
state that patients must not have received any other medication prior to the trial. Thus 
it is likely that patients received drugs before and during the valproic acid treatment 
which may influence baseline acH4 levels. While it is impractical to investigate all 
medication that patients received before valproate treatment, this possibility should 
be taken into account. 
 Percentages of acH4 positive myeloid cells suggested a large variation – both 
intra-patient and inter-patient variation – in histone acetylation when treated with 
valproic acid. Marked increases in numbers of acH4 positive cells were found in small 
numbers of samples, while the majority of samples exhibited more moderate changes. 
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Focusing on intra-patient variation, the results suggested that an increase in 
percentage of acH4 positive myeloid cells did not correlate with duration of valproic 
acid treatment; the percentages of acH4 positive cells of a patient measured at later 
visits could be fewer than the first visit, regardless of the drug exposure in the 
individual patient. To the best of our knowledge, this is the first study reporting acH4 
expression in patients at multiple time points. Other studies have presented results at 
baseline and steady state, so the intra-patient variation during chronic treatment could 
not be assessed. 
 Inter-patient variation in acH4 positive cells following treatment with valproic 
acid was also observed in this study. Intuitively patients who continuously received 
valproic acid for longer durations would have higher acH4 expression than those 
treated with the drug for shorter periods. However, it was found that patients who had 
received valproic acid for longer time periods and at higher doses could have fewer 
acH4 positive cells than those who had received the drug for first time. This 
demonstrated differences in drug response between patients which could reflect the 
utility of histone acetylation as a predictive biomarker. On the other hand, it could be 
argued that these results may limit the applicability of acH4 as a pharmacodynamic 
biomarker, due to high variation of acH4 changes between patients. 
5.4.2 Associations between acH4 expression and valproic acid dose 
 Associations between dose of valproic acid and increases in acH4 expression 
have been widely studied and the results remain controversial, as previously 
mentioned (Chavez-Blanco et al., 2005; Atmaca et al., 2007; Munster et al., 2007). 
However, correlations between increases in acH4 positive myeloid cells, analysed as 
actual change and fold change, and administered dose of valproic acid were not 
observed in this study. Two possible explanations should be discussed. 
 First, the pharmacodynamic behaviour in children may be different from adults. 
Although several studies have suggested correlations between acH4 expression and 
valproic acid dose, all of them have studied adult patients. The published valproate 
study in children did not mention associations between dose and acH4 expression but 
reported no correlation between valproic acid dose and concentration (Su et al., 2011). 
Based on no correlation between fold-change in acH4 and drug concentration shown 
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in Figure 5.1, it could be assumed that valproic acid dose did not relate to acH4 
change. This finding suggested that changes in acH4 in children might not be 
comparable to the results in adults. 
 Secondly, patients studied in the SIOP Ependymoma study might have received 
too low doses of valproic acid, which insufficiently impacted on histone acetylation 
levels in the blood. According to the study in adults that found a correlation, patients 
were given valproic acid up to a dose of 80 mg/kg, while patients in the SIOP 
Ependymoma trial mostly received doses of 15-30 mg/kg and a maximum of 45 mg/kg 
(Munster et al., 2007). On the other hand, another phase I study administered doses 
up to 120 mg/kg of valproic acid to adult patients, but found no dose-dependent acH4 
expression (Atmaca et al., 2007). According to the US FDA recommendation, valproic 
acid at doses above 60 mg/kg/day is not recommended in children due to safety 
concerns (US FDA, 2011). It is known that the pharmacokinetics of children are 
different from adults and pharmacokinetic studies of valproic acid in paediatrics are 
limited as well as pharmacodynamic studies. A pharmacokinetic study, for example, 
indicated a lower volume of distribution and lower clearance of valproic acid in 
children as compared to adults (Cook et al., 2016). This therefore makes the estimation 
of effective valproic acid dose in children more difficult than adults. 
5.4.3 Associations between acH4 expression and valproic acid concentration 
 Associations between valproic acid concentration (both total and free 
concentrations) and acH4 expression were not found in this study, despite being 
reported previously (Munster et al., 2007; Munster et al., 2009; Rocca et al., 2009). 
Concentration of valproic acid was investigated in different aspects including original 
values, fold changes and absolute changes between post- and pre-treatment, but none 
of them showed significant correlations with percentage of acH4 positive myeloid cells. 
These results were comparable with a previous clinical trial in children which reported 
that only half of the patients had increased acH4 at the steady-state valproic acid 
concentrations (Su et al., 2011). Furthermore, a phase I study in adults indicated no 
correlation between acH4 expression and serum concentrations of valproic acid 
(Chavez-Blanco et al., 2005). This highlights current controversies in potential 
associations between histone acetylation and concentration of valproic acid, although 
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this association was noted in the previous ex vivo results. Focusing on this difference, 
there are some factors to be discussed. 
 First, the concentration of valproic acid which significantly increased acH4 
positive cells in ex vivo studies was 1 mM or higher. This effective concentration was 
similar to most pre-clinical and clinical studies mentioned above. The lowest 
concentration associated with significant acH4 increases in vitro was 0.5 mM, similar to 
a study in children with solid tumours that suggested at least 70 µg/mL (∼0.5 mM) was 
required to inhibit HDAC activity in PBMCs (Göttlicher et al., 2001; Eyal et al., 2004; 
Coulter et al., 2013). As this level was higher than the differences in concentration 
observed in SIOP Ependymoma patients (Figure 5.9 and Figure 5.10), increases in acH4 
level should not necessarily be expected in this study. 
 Secondly, the concentrations measured in published clinical studies were 
concentrations at baseline and trough steady-state, not a 4-hour post-treatment as in 
the SIOP Ependymoma study (Munster et al., 2009; Su et al., 2011). The effective 
concentrations of valproic acid reported (∼0.5 mM) therefore were the trough levels. 
However, the levels of acH4 expression in the Ependymoma samples at 4-hour post-
treatment were expected to be peak concentrations. If peak concentrations in 
Ependymoma samples were similar to trough concentrations in the above-mentioned 
studies, it could be assumed that their peak concentrations in published studies were 
much higher than in the Ependymoma patients. This therefore could be one of the 
reasons for differences in the results in this chapter and previously published results. 
 Thirdly, focusing on the ex vivo experiments, WBCs have been continuously 
treated with the same concentrations of valproic acid for 6 hours. This condition is 
totally different from the real pharmacokinetics in the human body, where drug 
concentrations are always changing. The time-dependent in vitro results in Chapter 4 
suggested that acH4 levels significantly changed when treated with 4 mM valproic acid 
for longer than 1 hours, in agreement with other pre-clinical studies (Eyal et al., 2004). 
However, there is no clinical pharmacodynamic publication stating an effective time of 
valproic acid treatment in humans, especially at low concentrations (<1 mM), so 
comparison between pre- and 4-hour post-treatment possibly was not enough to 
observe changes in acH4 expression. 
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 Fourthly, as explained earlier, almost all patients in this clinical trial had 
received co-medication such as antibiotics, chemotherapeutics and opioids. Although 
there is no strong information available for histone-relating effect of these drugs, drug 
repositioning studies hypothesise this possibility. For instance, sodium phenylbutyrate 
was registered for treatment of urea cycle disorders before the discovery of its class I 
and class IIa HDAC inhibiting effects. Nicotinamide was first used to treat acne vulgaris 
or other inflammatory skin disorders, but was recently found to exhibit a class III HDAC 
inhibitory effect (Elvir et al., 2017). Moreover, associations between morphine and 
histone acetylation have been studied for over a decade and results have shown 
morphine-induced histone acetylation in murine models (Koo et al., 2015). These 
studies suggest that there might be many available drugs with unknown histone-
related mechanisms of action. Furthermore, drug interactions with valproic acid may 
impact on acH4 expression. For example, a clinical study reported significant increases 
in histone acetylation after treatment with both valproic acid and temsirolimus, but 
not valproic acid alone (Coulter et al., 2013). In case that some patients received 
valproic-interacting drugs, the levels of acH4 would change regardless of valproic acid 
concentration. This could then result in a lack of a correlation between acH4 
expression and valproic acid concentrations whether or not it exists. 
 With respect to free valproic acid levels, a significant correlation between free 
and total valproic acid concentrations was observed in this study. The linear regression 
analysis revealed that no free valproic acid was detected if the concentration of total 
valproic acid was less than 30 µg/mL (Figure 5.11). Moreover, the results suggested an 
increase in fraction of free valproic acid following an increase in total valproic acid 
concentration. This trend was similar to a study in children with cancer which reported 
a positive relationship between free valproic acid fraction and total valproic acid 
concentration (Su et al., 2011). With total valproic acid concentrations less than 
50 µg/mL, the fraction of free valproic acid was 12.9%. When the concentration of 
total valproic acid was 50-100 µg/mL, free valproic acid fraction increased to 16.8% 
and when total drug concentrations were 100-125 µg/mL, the free drug fraction 
increased to 21.3%. These findings are similar to other published valproic acid studies 
(Otten et al., 1984; Herngren et al., 1991). The results of free valproic acid analysis 
suggest that samples need to have high enough concentrations of total valproic acid to 
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be able to detect free drug content. Moreover, similar to total valproic acid 
concentrations, no correlations between free drug concentrations, dose and 
percentage of acH4 positive cells were observed. 
 Regarding the use of valproic acid in epileptic patients in clinical settings, US 
FDA recommends the therapeutic range of valproic acid for adults and children >10 
years old of 50-100 µg/mL (0.35-0.69 mM) (US FDA, 2011). However, there is no 
information of valproic acid therapeutic range in neonate patients published. Focusing 
on the target concentrations in adults, valproic acid concentrations recommended for 
seizures are lower than the concentrations used in cancer studies and are too low to 
detect acH4 changes using the developed assay (Atmaca et al., 2007; Munster et al., 
2007; Su et al., 2011). Therefore use of the developed assay in patients receiving 
valproic acid for non-cancer treatments may not be appropriate until the sensitivity of 
the assay is improved. 
 In summary, the developed assay was applied to measure histone H4 
acetylation in patients in the SIOP Ependymoma II clinical trial and the results showed 
both high intra-patient and inter-patient variability in acH4 expression. There were 
also inconsistent changes in percentages of acH4 positive myeloid cells when treated 
with valproic acid as compared to before treatment. These changes did not correlate 
with dose, total concentration or free concentration of the drug, nor the duration of 
treatment. However, there were only seven patients recruited and none of them had 
achieved target trough concentrations, which is seen as the minimum effective 
concentration for histone acetylation. More patients with higher drug concentrations 
therefore may be expected to experience greater changes in acH4 and to confirm the 







Chapter 6. Clinical application of an assay for detection of ki-67 
expression in lymphoid cells as a potential prognostic biomarker 
6.1 Introduction 
6.1.1 Characteristics of ki-67 
 Ki-67 function in human cells and its potential use as a biomarker for cancer 
have been described in Chapter 3, section 3.1.5. High expression of ki-67 protein has 
been found in S, G2 and M phase cells, but not G0 (Gerdes et al., 1984). In G1 stage, ki-
67 concentrations are controlled by two mechanisms and its protein levels can vary 
(Sun and Kaufman, 2018). Although its function in human cells has not been fully 
elucidated, ki-67 is widely used as a marker of cell proliferation (Scholzen and Gerdes, 
2000). In cancer research, ki-67 has been studied both as a potential 
prognostic/predictive biomarker and as a therapeutic target. 
 Focusing on the prognostic utility of ki-67, associations between high levels of 
ki-67 positive cancer cells and poor prognosis have been reported in various types of 
cancer such as breast cancer (Agboola et al., 2013; Inwald et al., 2013; Mrklić et al., 
2013; Nishimura et al., 2014), nasopharyngeal carcinoma (Zhao et al., 2018), gastric 
cancer (Ko et al., 2017) and prostate cancer (Wilkins et al., 2018). The level of ki-67 
expression reported in these papers has been measured using IHC, which is a 
qualitative technique, and the assessment of percentage of ki-67 positive cells can be 
subjective. High variability of ki-67 expression measured by IHC techniques in different 
laboratories has been shown in several studies, resulting in no consensus being 
reached in terms of a cut-off value for ki-67 positivity (Mengel et al., 2002; Focke et al., 
2017). 
6.1.2 Cancer immune response 
 Associations between cancer and the immune system were first studied in 1863 
by Rudolf Virchow (Balkwill and Mantovani, 2001). He reported the prevalence of 
WBCs in tumour tissues and suggested linkage between cancer and chronic 
inflammation. Later, this association became one of the hallmark concepts for cancer 
prevention and treatment. 
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 The pathology of host immune response involves the presence of inflammatory 
cells and proinflammatory cytokines. When there are cancer cells in the body, 
macrophages are the major cell type that initiate response to the tumour cells in the 
form of tumour-associated macrophages (TAMs) (Mantovani et al., 1992a). These 
TAMs are led to cancer cells and activated by chemokines. The activated TAMs play a 
crucial role in killing cancer cells; however, they can also produce growth factors, 
angiogenic factors and protease enzymes which may help stimulate tumour cell 
proliferation (Mantovani et al., 1992b). Dendritic cells, also called tumour-associated 
dendritic cells (TADCs), have important roles in the activation of antigen-specific 
immunity and the maintenance of adaptive immunity. It was found that TADCs could 
stimulate T-cell activation in breast cancer (Allavena et al., 2000). When lymphocytes 
such as T-cells and B-cells are activated by inflammatory cytokines, they secrete 
additional cytokines that further support the activation of immunity (Finn, 2012). 
 The other major immune response to the presence of cancer cells is the release 
of proinflammatory cytokines such as tumour necrosis factor (TNF), interleukins (IL) 1 
and 6, and chemokines by both activated leukocytes and tumour cells (Hendry et al., 
2017). For instance, CD8+ cytotoxic T-cells and T-helper 1 (Th1) cells can produce 
interferon-γ. Similarly, Th2 cells, myeloid derived suppressor cells and FOXP3+ 
regulatory T-cells (Treg) can produce IL-10 and TGFβ. 
6.1.3 Prognostic utility of white blood cells in cancer 
 The prognostic impacts of WBCs in a cancer setting have been widely studied, 
mainly focusing on the total number of WBCs and the presence of tumour-relating 
WBCs. For WBC count, it was found to be associated with patient prognosis in several 
cancer studies. Hao et al reported poor prognosis in patients with non-small cell lung 
cancer who had WBC counts >7,000 cell/mL (Hao et al., 2018). This was in agreement 
with the results of Tibaldi et al who suggested an association between elevated WBC 
and poor prognosis (Tibaldi et al., 2008). Feng et al also reported that in patients with 
advanced pancreatic cancer, WBC counts >5,800 cell/mL were associated with a 
poorer overall survival (Feng et al., 2018). Moreover, in cases where patients 
presented with tumour-related leucocytosis, they had poorer prognosis than ones who 
showed leucocytosis by a known cause (Kasuga et al., 2001). 
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 Regarding tumour-infiltrating lymphocytes, these WBCs detected in tumour 
tissues were not only a focus for the development of cancer therapeutics, but were 
also found to be associated with prognosis in many cancer types (Gooden et al., 2011). 
A meta-analysis study in colorectal cancer reported that CD8+ and FOXP3+ infiltrating 
cells, but not CD3+ T-cells, were prognostic markers for overall survival (Zhao et al., 
2019). A meta-analysis in hepatocellular carcinoma showed significant associations of 
overall survival and lymphocytes with CD8+, FOXP3+, CD3+ and Granzyme B+ (Ding et 
al., 2018). In patients with oesophageal cancer, T-cells with CD8+, FOXP3+ and CD57+ 
were associated with overall survival while CD3+, CD4+ and CD45RO+ T-cells were not 
(Zheng et al., 2018). 
 These findings highlighted the potential for using protein expression in WBCs as 
a prognostic biomarker. The prognostic efficacy was observed when looking at the 
WBC count and the expression of some specific proteins in WBCs. This project 
therefore focused on the assessment of ki-67 expression in peripheral WBCs in order 
to investigate its potential to act as a prognostic biomarker in cancer patients. The 
project focused on patients in PROSPECT-NE study because these patients had end-
stage cancer diseases and received no anti-cancer therapy. Therefore the possibility of 




6.2 Chapter specific aims 
 This study aimed to investigate ki-67 expression in peripheral WBCs in cancer 
patients recruited to the PROSPECT-NE clinical study. The primary objective was to 
investigate the potential for using ki-67 expression in WBCs as a prognostic biomarker. 
Secondary objectives included the following: 
• To determine potential associations between ki-67 expression and patient 
clinical data and markers of frailty (including grip strength, gender, BMI and 
routine blood test). 
• To observe changes in ki-67 expression in patients with time (between hospital 
visits).  
• To compare ki-67 expression in WBCs measured by imaging flow cytometry and 
ki-67 expression in plasma measured by ELISA. Associations between ki-67 
expression in plasma and patient data were also investigated alongside ki-67 






6.3.1 Patient characteristics 
 The PROSPECT-NE clinical trial is an observational study in patients with end 
stage cancer diseases. Patients recruited in the trial will be collected blood samples 
and other clinical data for further molecular analysis without receiving any anti-cancer 
therapy. This trial started in September 2017, with the ki-67 analysis project beginning 
in February 2018. From February to December 2018, a total of 43 patients were 
recruited onto the ki-67 analysis project and were studied until the project finished. 
Among them, 15 patients entered the PROSPECT-NE trial before the ki-67 analysis 
project started, leaving 28 patients whose blood samples were collected at the first 
visit. At the end of the ki-67 project, 22 out of 43 patients had died, with 14 of these 22 
deceased patients having had blood samples collected at the first visit. 
 Baseline characteristics of patients at recruitment are shown in Table 6.1. Of 43 
patients recruited, 25 patients were male (58%). The median age and SD of all patients 
was 61 ± 11.4 years. The average BMI of all patients was 27 kg/m2 and all patients had 
performance status of 0-1 at the first visit. No patients with leukopenia or neutropenia 
were observed in this study. The mean right hand and left hand grip strengths at the 
first visit were 29.5 and 27.2 kg, respectively. A Z-score assessment of grip strength 
was calculated via the online calculator 
(https://stuartbman.github.io/grip_strength/index.html), which was developed within 
Newcastle University. This online tool adjusts the Z-score of a patient using age and 
gender as compared to the normative values from a meta-analysis of 12 British grip 
strength studies (Dodds et al., 2014). The mean ± SD of patients’ grip strength 
was -0.83±1.01 for right hand and -1.15±0.80 for left hand. The majority of cancer type 
in this study was colorectal (27.9%) and breast (16.3%) cancer. Examples of other 
cancer types in this study included mesothelioma, prostate cancer, lung cancer, gastric 







Age (year) (Median±SD) 61±11.4 
Male (n) (%) 25 (58%) 
Weight (kg) (Mean±SD) 77.5±14.9 
BMI (kg/m2) (Mean±SD) 27.2±4.4 
Performance status 1 (%) 24 (56%) 
LDH (U/L) (Mean±SD) 295±157 
Albumin (g/L) (Mean±SD) 42.3±4.3 
WBC count (×109/L) (Mean±SD) 6.8±3.0 
Neutrophil count (×109/L) (Mean±SD) 4.6±2.7 
Grip strength right hand (kg) (Mean±SD) 29.5±9.5 
Grip strength right hand (Z-score,  Mean±SD) -0.83±1.01 
Grip strength left hand (kg) (Mean±SD) 27.2±8.3 
Grip strength left hand (Z-score,  Mean±SD) -1.15±0.80 
* Z-score is calculated using the online system via 
https://stuartbman.github.io/grip_strength/index.html 
Table 6.1. Baseline characteristics of patients recruited in PROSPECT-NE trial (n=43). 
 
6.3.2 ki-67 expression in patient WBCs 
 Percentages of ki-67 positive white blood cells were measured in all patient 
samples sent to the lab using the developed assay as described in Chapter 2. The 
gating and analysis used in this project were the same as used to measure ki-67 
expression in Chapter 3. Representative images of myeloid and lymphoid cells with and 
without ki-67 positivity are illustrated in Figure 6.1. The percentages of ki-67 positive 
cells in myeloid, lymphoid and total WBCs from all patient samples are shown in Figure 
6.2. The median percentage of ki-67 positive myeloid cells was 0.45% while lymphoid 
cells was 1.93% (Mann-Whitney U-test, p-value <0.0001). Lymphoid cells were selected 










Figure 6.1. Examples of myeloid cells with ki-67 positivity (A) and ki-67 negativity (B), 
and lymphoid cells with ki-67 positivity (C) and ki-67 negativity (D). 
Samples were obtained from patients studied on the PROSPECT-NE clinical trial. 
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Figure 6.2. Percentages of ki-67 positive myeloid, lymphoid and total white blood 
cells in all cancer patients in PROSPECT-NE clinical trial. 
Y-axis data shown on a logarithmic scale; red lines indicate median values. 
 
 











 In order to confirm that the gating used in this study designated a lymphoid cell 
population without monocyte contamination, 9 patient samples were incubated with 
antibodies against ki-67 and CD14. WBCs were first gated to myeloid and lymphoid 
populations using side scatter and area, and then CD14 positive cells (which indicate 
monocytes) were removed from the lymphoid population. The percentages of 
lymphoid cells gated by only side scatter and by side scatter plus removing CD14 
positive cells were seen to be comparable (Figure 6.3A). The percentages of ki-67 
positive cells measured in these two populations were also comparable (Figure 6.3B). 
Additionally, the percentage of ki-67 and CD14 positive cells ranged between 0.1% to 
14.3%. Therefore, lymphoid gating by side scatter was suitable and could be used for 
this ki-67 analysis.  
 
     




































































































Figure 6.3. Percentages of lymphoid cells gated by only side scatter and by side 
scatter plus removal of CD14 positive cells (A), and percentages of ki-67 positive cells 
in lymphoid cell population gated by both methods (B). 
 
 The comparison of ki-67 positivity between cancer patients recruited to the 
PROSPECT-NE trial and healthy donors was investigated. Figure 6.4 shows the 
difference in ki-67 positive lymphoid cells between people with cancer and people not 
known to have cancer (Mann-Whitney U-test, p-value <0.0001). The median 
percentage of ki-67 positive lymphoid cells was 1.16% for healthy volunteers, with a 
maximum of 3%, and 1.93% for cancer patients, with the maximum of 32%. These data 
indicate that cancer patients have higher percentages of ki-67 positive lymphoid cells 
compared to a control population not known to have cancer. It should be noted that 




of association between ki-67, age and gender. Moreover, further results in this study 
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Figure 6.4. Comparison of percentages of ki-67 positive lymphoid cells in healthy 
donors and cancer patients recruited to the PROSPECT-NE trial. 
Healthy samples were collected from 8 independent donors and PROSPECT 
samples were from all study patients. Y-axis data shown on a logarithmic scale; 
red lines indicate median values. 
 
 Regarding subgroup analysis of cancer type, there was no significant difference 
in percentages of first-visit ki-67 positive lymphoid cells between cancer types (Figure 
6.5). The median percentage of ki-67 positive cells in all cancer types ranged between 
0.54 – 5.7%. The two samples with the highest proportion of ki-67 positive cells (8.5% 
and 6.1% positive cells) were from breast cancer and colorectal cancer patients. The 
median percentage of ki-67 positive cells in breast cancer was 1.79%, comparable to 
other cancer types. Patients with sarcoma had the highest percentages of ki-67 
positive lymphoid cells, with 5.7% positive cells. The number of patients in this 










































































Figure 6.5. Percentages of ki-67 positive lymphoid cells in PROSPECT-NE patients 
according to cancer type. 
Ki-67 values were from the first visit of the patients. Red lines indicate median 
values. 
6.3.3 Variation of ki-67 levels in patients throughout the study 
 Variations in percentages of ki-67 positive lymphoid cells were observed 
throughout the trial. Figure 6.6A suggests fluctuation in ki-67 expression in all patients 
and Figure 6.6B shows the same data in deceased patients only. Four patients had %CV 
over 100%, with the highest value of 150%. The greatest absolute change was 18.5%, 










           
























   

















Figure 6.6. Changes in percentage of ki-67 positive lymphoid cells in all patients 
studied (A) and in deceased patients (B) throughout the study. 
Only patients who had more than 1 visit were included in the graphs. 
 
 Focusing on the deceased patients, there was also a marked fluctuation in ki-67 
positive lymphoid cells observed throughout the study (Figure 6.6B). Two patients 
expressed clear decreases in ki-67 at their last visits whilst four patients had marked 
increases. The other patients showed minimal changes in ki-67 positive cells until their 
last visits. These results suggest no association between ki-67 expression and terminal 
stage of cancer patients. 
6.3.4 Association between ki-67 positive lymphoid cells and patient data 
 The association between percentages of ki-67 positive lymphoid cells and 





this study depending on variable type. A Spearman correlation analysis was used for 
continuous variables including percentage of ki-67 positive lymphoid cells, age, weight, 
BMI, LDH, albumin, WBC count, and Z-score of grip strength (right hand and left hand). 
The Mann-Whitney U-test was used for non-parametric categorical variables including 
gender and performance status. 
 The correlation analysis graphs showing percentage of ki-67 positive cells and 
each parameter alongside p-values, linear regression and 95% confidence intervals 
(95%CI) are illustrated in Figure 6.7. The correlation coefficients (r) of other continuous 
variables analysed by Spearman test are presented in Table 6.2 and p-values of other 
categorical variables analysed by Mann-Whitney U-test are presented in Table 6.3. 
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Figure 6.7. Association between percentage of ki-67 positive lymphoid cells and 
patient data including age (A), gender (B), weight (C), BMI (D), performance status 
(E), LDH (F), albumin (G), WBC count (H), Z-scores of grip strength right hand (I) and 
left hand (J). 
Data shown were collected at the first visit after patients were recruited to the 
clinical trial. Continuous parameters were analysed using the Spearman 
correlation test with linear regression and 95%CI shown; categorical 
parameters were analysed using the Mann-Whitney U-test with black lines 

















































































Z-score of grip strength 
right hand       1.000 
0.764 
(<0.001) 
Z-score of grip strength 
left hand        1.000 
 
Table 6.2. Correlation matrix of patient continuous data including age, weight, BMI, LDH, albumin, WBC count, and grip strength (of 
right and left hand) at the first patient visit. 
Correlation coefficients (r) are presented with p-values shown underneath. Data were analysed using the Spearman correlation 






Gender Performance status 
Age 0.001 0.291 
Weight 0.361 0.192 
BMI 0.733 0.472 
LDH 0.778 0.101 
Albumin 0.467 0.082 
WBC 0.388 0.019 
Z-score of grip strength right hand 0.320 0.216 
Z-score of grip strength left hand 0.325 0.575 
 
Table 6.3. P-values of difference in patient continuous data parameters including 
age, weight, BMI, LDH, albumin, WBC, grip strength (of right and left hand) at the 
first patient visit separated by patient gender and performance status. 
Data were analysed using the Mann-Whitney U-test and significance 
(p-value <0.05) is shown in bold. 
 
 For percentage of ki-67 positive cells (Figure 6.7), the results indicated no 
correlation with any variables. However, the analysis of covariates revealed some 
significance (Table 6.2 and Table 6.3). As expected, weight correlated with BMI and 
grip strength of right hand correlated with left hand. Patients with lower body weight 
had lower grip strength (left hand). This study found that older patients had lower 
albumin and higher WBCs. In addition, male patients in the study population were 
significantly older than the female patients and patients with higher performance 
status at recruitment had significantly higher WBC counts. 
 As presented above (section 6.3.3), variability in percentages of ki-67 positive 
lymphoid cells measured in multiple visits to the clinic was observed and associations 
between changes in ki-67 level and some parameters were investigated. A Spearman 
correlation analysis was performed to investigate associations between percentage of 
ki-67 positive cells and high-variability parameters including, LDH, albumin and WBC 
count from all patient visits. The results indicated no correlation between ki-67 
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Figure 6.8. Associations between percentage of ki-67 positive lymphoid cells and LDH 
level (A), albumin level (B), and WBC count (C). 
Data shown were collected from all patient visits and analysed using the 








6.3.5 Prognostic impact of ki-67 positive lymphoid cells on patient survival 
 Correlations between percentage of ki-67 positive lymphoid cells and patient 
survival status were determined using two analyses in this study: log rank test and 
Cox’s proportional hazards model (Cox regression). The first approach tests the 
difference between survival times of different groups of a variable while the second 
test is able to test the correlation of more than two variables (Bewick et al., 2004). 
Moreover, the Cox regression analysis allows testing of continuous variables whereas 
the log rank test uses only categorical variables. 
 Since the log rank test allows only categorical variables, the percentage of ki-67 
positive cells had to be categorised. Thus, the threshold of ki-67 level was developed to 
classify patients into high and low ki-67 expression groups. Figure 6.9 shows two 
receiver operating characteristic (ROC) curves analysed using percentage of ki-67 
positive cells from the first visit of each patient (A) and by the median percentage of all 
visits of each patient (B). The median value of all visits from one patient was also used 
as the representative of all ki-67 values for that patient in the ROC analysis because of 
no standard guideline suggesting which value of ki-67 should be used. Furthermore, 
using median values was expected to increase the sample size of the analysis because 
patients who were recruited into the study before the ki-67 project started could 







Figure 6.9. The ROC performed to calculate the optimal cut-off values of (A) 
percentage of ki-67 positive cells at the first visit and (B) the median percentage of 
ki-67 positive cells of all visits for overall survival. 
 
 Both ROC curves suggested neither significant difference between survival 
status and percentage of ki-67 positive cells at the first visit (AUC 0.658, p-value 0.165) 
nor median percentage of ki-67 of all visits (AUC 0.636, p-value 0.126). Using the 
Youden index method, a cut-off value for first-visit ki-67 positivity of 1.82%, with 
sensitivity of 0.818 and specificity of 0.647, was determined (Figure 6.9A). The cut-off 
value for the median of all visits was 1.61% with sensitivity of 0.727 and specificity of 
0.524 (Figure 6.9B). Based on the threshold of 1.82%, there were 13 patients classified 
as low ki-67 including 2 deceased patients and 15 patients classified as high ki-67 with 
9 deceased patients (Figure 6.10A). With the threshold of 1.61%, there were 17 
patients and 26 patients in low and high ki-67 groups, respectively. Only 6 patients in 
the low ki-67 group died while 16 patients died in the high ki-67 group (Figure 6.10B). 
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Figure 6.10. The numbers of alive and deceased patients at the end of study 
categorised into four groups. 
Figure 6.10A categorised using the percentage of ki-67 positive cells at first visit 
and Figure 6.10B using the median percentage of ki-67 positive cells of all visits. 
 
 Survival analysis was performed using the percentage of ki-67 positive cells at 
the first visit for two reasons. Firstly, ROC analysis suggested that the first-visit values 
provided higher sensitivity and specificity than the median values to predict mortality 
of patients. Secondly, using the first-visit values strengthened the predictive impact of 
ki-67 since there was no effect of intra-personal variability observed in other visits. 
This study therefore analysed the association between overall survival and percentage 
of ki-67 positive cells at the first visit. 
 The log rank test was first performed to determine differences in mortality 
between patients with high and low ki-67 positivity. A Kaplan-Meier curve of overall 
survival and percentage of ki-67 positive cells at first visit is shown in Figure 6.11. 





186 days (95%CI 121-250 days) while mean survival time of patients with low ki-67 
positivity was 271 days (95%CI 233-308 days); the p-value for the difference between 
the two groups was 0.011. Median survival time for the high ki-67 population was 136 
days (95%CI 99-174 days). However, there were too few deceased patients in the low 
ki-67 group to determine a meaningful median survival time. The longest survival time 
in this study was 151 days and the shortest survival time observed was 45 days after 
recruitment. Patients who were alive at the end of the project had a duration of 
observation ranging from 126 to 344 days. 
 
 
Figure 6.11. Kaplan-Meier curve of overall survival according to the percentage of 
ki-67 positive lymphoid cells at first visit. 
 
 Cox’s proportional hazard model was next performed to test for correlations of 
overall survival and other variables, as well as percentage of ki-67 positive lymphoid 
cells. All continuous variables were analysed as continuous parameters except for the 
percentage of ki-67 positive cells, which was analysed as both continuous and 
categorical variables using the cut-off value from the ROC analysis (1.82%). The 
categorical variables included gender and performance status. 
P-value = 0.011 
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 The Cox regression analysis results are shown in Table 6.4. Univariate analysis 
revealed significant correlations between overall survival and LDH level, Z-score of grip 
strength right hand and left hand with the hazard ratios of 1.006, 0.341 and 0.258, 
respectively. These variables were considered as covariates in the multivariate analysis 
of ki-67. Other variables, i.e. age, gender, weight, BMI, performance status, albumin 
level and WBC count, did not show correlations with overall survival and were not 
analysed further. 
 For ki-67 analysis, the results indicated a significant correlation between 
survival status and categorical ki-67 (p-value 0.025) but not continuous ki-67 values 
(p-value 0.363). The hazard ratio observed for categorical ki-67 was 5.86. However, 
when the three additional covariates were added to the multivariate equation, the 
association between categorical ki-67 and overall survival became non-significant, 
whilst LDH level remained as a significant variable. 
 
Variable Exp(B) SE Sig. 95.0% CI for Exp(B) 
Lower Upper 
Univariate analysis 
Continuous ki-67 alone 
Continuous ki-67 1.120 0.125 0.363 0.877 1.432 
Categorical ki-67 alone 
Categorical ki-67 5.860 0.786 0.025 1.255 27.357 
Age alone 
Age 1.012 0.027 0.660 0.960 1.066 
Gender alone 
Gender 1.190 0.607 0.774 0.362 3.913 
Weight alone 
Weight 0.991 0.018 0.592 0.957 1.026 
BMI alone 
BMI 1.000 0.058 0.995 0.893 1.121 
Performance status alone 
Performance status 0.222 0.786 0.056 0.048 1.037 
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Variable Exp(B) SE Sig. 95.0% CI for Exp(B) 
Lower Upper 
LDH alone 
LDH 1.006 0.002 0.007 1.002 1.010 
Albumin alone 
Albumin 0.918 0.073 0.243 0.796 1.060 
WBC count alone 
WBC count 1.028 0.101 0.786 0.843 1.253 
Grip strength right hand alone 
Grip strength right hand 0.341 0.427 0.012 0.147 0.787 
Grip strength left hand alone 
Grip strength left hand 0.258 0.476 0.004 0.101 0.656 
Multivariate analysis 
Ki-67, LDH and grip strength right hand 
Ki-67 4.931 0.905 0.078 0.836 29.08 
LDH 1.005 0.003 0.039 1.000 1.011 
Grip strength right hand 0.453 0.587 0.176 0.143 1.429 
Ki-67, LDH and grip strength left hand 
Ki-67 24.53 1.669 0.055 0.931 646.2 
LDH 1.009 0.004 0.042 1.000 1.018 
Grip strength left hand 0.155 1.201 0.121 0.015 1.634 
Note: categorical ki-67, gender and performance status were analysed as categorical variables; ki-67 was 
categorised by 1.82% cut-off value. Grip strength indicates Z-score of raw grip strength value which was 
calculated online via https://stuartbman.github.io/grip_strength/index.html 
Table 6.4. Regression analysis of ki-67 expression in lymphocytes 
The table shows coefficient value (Exp(B)), standard error (SE), p value (Sig) and 
95%CI of all variables. The univariate analysis was performed to find significant 
variables and then multivariate analysis of those variables was performed. 
Significant value (p-value <0.05) is shown in bold. 
6.3.6 Associations between ki-67 expression in patient’s lymphocytes and plasma 
 Associations between percentages of ki-67 positive lymphoid cells and 
circulating ki-67 plasma concentrations were investigated. Whole blood samples from 
patients in the PROSPECT-NE trial were centrifuged to obtain plasma using the 
protocol mentioned in Chapter 2. Ki-67 concentrations in plasma were measured by a 
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commercial ELISA kit. An example standard curve generated with the ELISA kit is 
shown in Appendix A. The results obtained were compared to percentages of ki-67 
positive lymphoid cells measured previously as well as overall patient survival data. 
Since the plasma ki-67 analysis project started after the ki-67 positive cells analysis, 
circulating ki-67 in plasma concentrations were only obtained for 26 out of 43 patients. 
In addition, of these 26 patients, only 16 provided samples at the first visit. The median 
circulating ki-67 concentration at the first visit determined from these 16 patients was 
82.2 ng/mL (range: 19 – 346 ng/mL), while the median of all visits was 57.5 ng/mL 
(range: 9 – 346 ng/mL). 
 Concentrations of circulating ki-67 values measured in samples collected from 
the 26 patients were compared with the percentage of ki-67 positive lymphoid cells. 
The correlation analysis results suggested a significant correlation between the 
percentage of ki-67 positive cells and mean circulating ki-67 in plasma (Spearman, 
p-value 0.0141, Figure 6.12). As was observed with the percentage of ki-67 positive 
cells, high intra-assay variability with CV values up to 104% were observed in plasma 
ki-67 concentrations. High variability in the plasma ki-67 of each patient was also 
observed throughout the study with no clear trend of increase or decrease over time 
(Figure 6.13). The largest absolute increase was 52.9 ng/mL and largest decrease was 
44.3 ng/mL. This very high intra-assay variability observed requires a better assay to be 
































Figure 6.12. Association between percentage of ki-67 positive lymphoid cells and 
circulating ki-67 expression in plasma. 
For samples where plasma ki-67 expression was measured three times, the 
mean of three values were used to correlate with ki-67 positive cells from the 
same blood sample. 
 
 





























Figure 6.13. Changes in mean circulating ki-67 expression in plasma for all patients 
measured throughout the study. 





 Survival analyses were also performed to determine potential correlations 
between circulating ki-67 in plasma and overall survival. To investigate prognostic 
effect, circulating ki-67 values at the first visit of each patient were used. A histogram 
showing data for all 16 patient is shown in Figure 6.14, and the cut-point of 250 ng/mL 
was selected to categorise patient samples into low and high ki-67 groups based on 
this graph. 
 After categorisation, 58% of patients who were alive had low circulating ki-67 
plasma concentrations as compared with 86% of deceased patients. The Kaplan-Meier 
curve indicated no significant difference between patients with high and low first-visit 
circulating ki-67 expression (log rank, p-value 0.229; Figure 6.15). The mean survival 
time for patients with high plasma ki-67 was 373 days (95%CI 314-434 days) while the 
comparable value for patients with low plasma ki-67 was 286 days (95%CI 211-361 
days). Median survival times could not be estimated in either group due to the limited 
numbers of deceased patients at the end of the study. 


















    















Figure 6.14. Histogram showing two distinct populations of circulating ki-67 in 
plasma from all patients. 






Figure 6.15. Kaplan-Meier curve of overall survival according to the circulating ki-67 
plasma concentrations measured on the first patient visits. 
 
 Cox’s proportional hazard model was also performed to confirm the log rank 
results. In contrast to the percentage of ki-67 positive cells, neither continuous nor 
categorical ki-67 expression in plasma correlated with overall survival (Table 6.5). 
Furthermore, univariate analysis revealed no significance between overall survival and 
variables including LDH and Z-score of grip strength. Therefore, multivariate analysis 









Variable Exp(B) SE Sig. 95.0% CI for Exp(B) 
Lower Upper 
Continuous ki-67 alone 
Continuous ki-67 0.999 0.002 0.408 0.995 1.002 
Categorical ki-67 alone 
Categorical ki-67 2.930 1.119 0.337 0.327 26.286 
Age alone 
Age 1.056 0.046 0.231 0.966 1.156 
Gender alone 
Gender 1.502 0.916 0.657 0.249 9.051 
Weight alone 
Weight 0.965 0.039 0.355 0.895 1.041 
BMI alone 
BMI 1.003 0.114 0.981 0.803 1.253 
Performance status alone 
Performance status 0.302 1.121 0.285 0.034 2.714 
LDH alone 
LDH 1.019 0.010 0.067 0.999 1.040 
Albumin alone 
Albumin 0.986 0.106 0.898 0.801 1.215 
WBC count alone 
WBC count 1.035 0.104 0.737 0.845 1.269 
Grip strength right hand alone 
Grip strength right hand 0.348 0.558 0.058 0.117 1.038 
Grip strength left hand alone 
Grip strength left hand 0.106 1.152 0.051 0.011 1.014 
 
Table 6.5. Univariate analysis of circulating ki-67 in plasma. 
The table shows coefficient value (Exp(B)), standard error (SE), p-value (Sig) and 95%CI of 
all variables. The variables included the first-visit circulating ki-67 expression in plasma 
(continuous and categorical variables), age, gender, weight, BMI, performance status, LDH, 
albumin, WBC count, and Z-score of grip strength right and left hand. ki-67 was analysed as 
both continuous and categorical variables; ki-67 was categorised by 250 ng/mL cut-off 
value. Grip strength indicates Z-score of raw grip strength value, which was calculated 
online via https://stuartbman.github.io/grip_strength/index.html. Significant value 




 The developed assay for the detection of ki-67 expression in lymphoid cells was 
applied to patient samples from the PROSPECT-NE clinical trial. The analysis of 
percentage of ki-67 positive WBCs, variability of ki-67 expression throughout the study, 
associations between ki-67 expression in lymphoid cells and patient clinical data 
including overall survival, and associations between circulating ki-67 in plasma and 
overall survival were investigated. 
6.4.1 Percentage of ki-67 positive WBCs and its variability  
 The first observation in this study was the difference in ki-67 positivity between 
myeloid and lymphoid WBCs. The results indicated significantly higher numbers of 
ki-67 positive lymphoid cells than myeloid cells. The appropriate gating of lymphoid 
cells was confirmed using an antibody against CD14 to ensure monocytes were not 
being captured in the lymphoid gate on a FSC/SSC plot. As higher ki-67 expression was 
observed in lymphoid WBCs, the lymphoid population was selected for further study. 
The percentages of ki-67 positive lymphoid cells in blood collected from cancer 
patients were significantly higher than observed in blood from healthy volunteers. 
Ki-67 expression in tumour tissues has been widely studied by IHC; in contrast, not 
many studies have assessed this parameter in WBCs (Todorov et al., 1998; Uchikawa et 
al., 2003; Bai et al., 2016; Sobecki et al., 2017; Ragab et al., 2018). A study in patients 
with multiple myeloma reported higher percentages of ki-67 positive cells in T and B 
lymphocytes than in healthy adult volunteers (Miguel-Garcia et al., 1995). A positive 
correlation between percentage of ki-67 positive cells and stage of multiple myeloma 
was also observed. Moreover, a pilot study revealed that the mean frequency of ki-67 
positive WBCs in patients with hepatocellular carcinoma was significantly higher than 
in healthy volunteers (Hutton et al., 2016). These differences therefore support the 
potential utility of ki-67 in peripheral white blood cells as a biomarker in cancer 
patients. 
Although differences in ki-67 expression between different types of WBC have 
been observed in some studies as noted above, no single study has compared 
differences between cancer types. Comparison of ki-67 expression across cancer types 
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may suggest the application of this protein in some specific cancers. However, the 
results of this study were not able to identify differences in percentages of ki-67 
positive lymphoid cells between cancer types, arguably due to the limited sample size 
for each cancer type. More patients in each cancer type should be recruited to future 
studies in order to further investigate the application of ki-67 positive cells as a 
prognostic biomarker more widely. 
 A challenging limitation of ki-67 as a prognostic/predictive biomarker may 
result from the high variability of ki-67 observed throughout the study. These results 
suggested marked differences in ki-67 expression between each visit for one particular 
patient, with up to a 15-fold change in ki-67 positive cells observed. These results 
demonstrate the highly dynamic modulation of ki-67 in peripheral WBCs, potentially 
relating to parameters which have not yet been elucidated. A plausible cause of ki-67 
change is the medication that patients receive during visits to an oncology clinic, such 
as corticosteroids, hormonal steroids and steroid-like drugs. The efficacy of steroid 
receptor agonists including sex steroids in terms of inhibition of ki-67 expression has 
been widely studied (Wagner et al., 2013; Urata et al., 2014; Zhao et al., 2017). For 
example, a study reported a significant decrease in ki-67 positive nasal epithelial cells 
when treated with oral methylprednisolone and nasal fluticasone for 3 weeks (Zhao et 
al., 2017). The negative correlation between ki-67 in cancer specimens and vitamin D3 
or calcitriol levels in cancer patients has been demonstrated in two studies (Wagner et 
al., 2013; Urata et al., 2014). Administration of the aromatase inhibitor exemestane, 
has been found to be associated with a significant reduction in ki-67 index in breast 
cancer patients, whereas tamoxifen treatment resulted in the opposite effect 
(Hachisuga et al., 1999; Toi et al., 2011). Moreover, ki-67 expression has been shown 
to be affected by menstrual cycle phase; the same patients could have different ki-67 
levels if the protein was measured at different phases of menstruation (Horimoto et 
al., 2015). 
 This information highlights a limitation of the current study as there were no 
patient medication profiles available and the above-mentioned drugs, especially 
corticosteroids, could conceivably have been given to these patients. High intra-
personal variation found in this study might result from a change in 
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medication/hormonal status at each visit. If patient medication profiles were available, 
this hypothesis could be investigated. 
6.4.2 Associations between percentage of ki-67 positive lymphoid cell and clinical 
data 
 The level of inter-patient variation in percentage of ki-67 positivity observed in 
these studies led to an interest in utilising this parameter as a prognostic biomarker. In 
order to investigate the prognostic impact, correlations between ki-67 expression and 
other variables including key clinical parameters should be tested. Associations 
between ki-67 positive lymphoid cells at first patient visit, overall survival and other 
variables including patient age, weight, BMI, performance status, LDH, albumin, WBC 
count, Z-score of grip strength (of right hand and left hand) were analysed using 
different tests depending on the variable type. 
 Firstly, correlations between ki-67 expression and the above-mentioned 
parameters were analysed by Spearman correlation analysis for continuous variables 
and the Mann-Whitney U-test for categorical variables (gender and performance 
status). No correlations between ki-67 positive cells and any variables studied were 
observed (Figure 6.7). This contrasted with results obtained from a previous 
preliminary study performed locally, which observed significant negative correlations 
between ki-67 positive lymphoid cells and grip strength and between ki-67 positive 
lymphoid cells and age (Talks et al., 2017). 
 Further analyses of all variables revealed a negative correlation between age 
and albumin level, and a positive correlation between age and WBC count. Based on 
previous studies, older patients were found to have lower albumin levels (Gom et al., 
2007; Weaving et al., 2016) and WBC counts (Kubota et al., 1991). An increase in WBC 
counts in older patients found in this study might suggest infectious conditions due to 
the frailty of old cancer patients. Similarly, the significant association between 
performance status and WBC count indicated that patients with higher performance 
status had higher WBC count and therefore higher chance to be infected patients. In 
addition, the analysis revealed that recruited male patients were significantly older 
than female, which conformed to studies showing a generally higher incidence of 
cancer in males across the older age ranges (White et al., 2010; Torre et al., 2016). 
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 Cox regression analysis was performed to investigate associations between 
overall survival and other variables. Two variables that showed significant correlations 
with overall survival were LDH level and Z-score of grip strength. The hazard ratio 
indicated that higher level of serum LDH significantly correlated with patient survival 
status. This conformed to previously published studies which suggested positive 
correlations between LDH level and mortality rate in cancer patients (Zhang et al., 
2016a; Zhang et al., 2016b; Deng et al., 2018). For example, Liu et al reported very 
short overall survival time (1.7 months) in patients who had non-specific cancer with 
LDH >1,000 U/L and a significant increase in overall survival when serum LDH was 
decreased (Liu et al., 2016). Moreover, several studies have reported a predictive 
effect of grip strength to all-cause mortality in old people; poorer grip strength being 
associated with a significantly increased risk of mortality including from cancer (Gale et 
al., 2007; Chaturvedi, 2015; Oksuzyan et al., 2017; Wu et al., 2017). Therefore, LDH 
level and grip strength should be considered as covariates for survival analysis of ki-67.  
 Regarding the percentage of ki-67 positive cells, an association between the 
percentage of ki-67 positive cells and overall survival was investigated using the log 
rank test and Cox regression analysis. To perform the log rank test, percentages of 
ki-67 positive lymphoid cells were categorised into high and low populations based on 
the ROC curve. It was found that percentage of ki-67 positive cells at the first visit for 
each patient provided higher sensitivity and specificity to overall survival, as compared 
to the median number of ki-67 positive cells across all visits, so only the first-visit 
values were used in survival analysis. 
 Significant differences in survival rates between high and low ki-67 groups were 
observed following the log rank test analysis. However, Cox regression analysis 
revealed a significant correlation of overall survival with only categorical ki-67 
(categorised into high and low levels) but not with continuous ki-67. Furthermore, 
categorical ki-67 became a non-significant parameter when adjusted for the two 
covariates above. These findings suggested that categorical ki-67 cell positivity might 
not be a strong prognostic indicator, especially when other variables are taken into 
account. Moreover, an optimal cut-off value is necessary to categorise ki-67 into 
positive and negative groups. Since there is no such gold standard cut-off value to 
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categorise ki-67, the utilisation of categorical ki-67 in clinical settings may be limited. 
This issue will be discussed later. 
With regards to the fluctuation of percentages of ki-67 positive cells 
throughout the study, a feasible hypothesis was that changes in ki-67 positive cells 
were related to some unknown parameters in the blood. Due to the limited availability 
of blood tests in the PROSPECT-NE trial, only WBC count, albumin levels and LDH levels 
obtained on each visit were tested for their associations with ki-67 expression. The 
results suggested no correlation between ki-67 expression and these three variables. 
Consequently, causes of the high variability in ki-67 positive cells needed further 
investigation. Potentially levels of ki-67 protein were variable as a result of 
spontaneous physiologic changes or a response to medication that patients received. 
The most pragmatic experiment is testing the association between ki-67 expression in 
WBC and commonly administered drugs such as corticosteroids. 
 Several flow cytometry assays for measurement of ki-67 in white blood cells 
have been developed over many years, but rarely have they been used in clinical 
practice (Vukmanovic-Stejic et al., 2008; Sanvito et al., 2011; Marcondes et al., 2018), 
thus the availability of data on prognostic impact of ki-67 expression in WBCs is very 
limited. All published studies have shown correlations between patient survival and 
ki-67 expression measured in tumour tissues by IHC. However, several studies have 
also shown the prognostic impacts of protein expression such as CTLA-4 and FOXP3 in 
WBCs, although their prognostic effects were first observed in tumour tissues (Shang 
et al., 2015; Hu et al., 2017). Furthermore, a study reported correlations between 
PD-L1 in tumour tissues and circulating WBCs which could be used to predict survival in 
patients with advanced-stage NSCLC (Ilié et al., 2017). These studies suggested a 
possibility of associations between protein expression in tumour tissues and WBCs, 
including ki-67 expression. 
 Focusing on ki-67 expression in tissues, its prognostic impact has been well 
documented as previously described. According to two large meta-analysis studies, 
ki-67 expression in breast tumour tissues appeared to be a promising marker for 
overall survival and disease free survival; high expression of ki-67 was found to be 
correlated with shorter overall survival and disease free survival (de Azambuja et al., 
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2007; Stuart-Harris et al., 2008). Prognostic values of ki-67 were also shown in gastric, 
bladder and prostate cancer (Tian et al., 2016; Berlin et al., 2017; Luo et al., 2017). 
There were two issues, however, that needed to be addressed before clinical 
application of these data. 
 Firstly, the thresholds of ki-67 positivity used in previous studies were variable. 
This reflected inconsistency of ki-67 expression between assays, and resulted in 
difficulty in compilation of all study data as well as difficulty in application of the 
results obtained from individual studies. The 2011 St.Gallen’s International Expert 
Consensus firstly recommended a ki-67 cut-off point of 14% measured by IHC, but this 
value has not been widely used (Goldhirsch et al., 2013). Another study, however, 
suggested that a cut-off value of 20% was the most effective prognostic factor 
(Tashima et al., 2015). While unresolved, the American Society of Clinical Oncology 
(ASCO) guidelines do not include ki-67 expression as a biomarker for cancers (Harris et 
al., 2007; Van Poznak et al., 2015).  Standardization of the most appropriate ki-67 
positive threshold is needed to support the routine clinical application of ki-67 as a 
prognostic biomarker. In order to standardise a positive threshold for ki-67, a larger 
sample size of well-controlled patients is required, as well as a more reproducible 
method for ki-67 measurement. 
 Secondly, the compiled studies in those meta-analyses contained high 
heterogeneity in the assays used. Although all of them have involved 
immunohistochemistry, there were dissimilarities in clones of antibody, patient 
treatments and types of result presented between the compiled studies. It was found 
that clones of antibody used in the assays affected the signal of ki-67 expression 
(Lindboe and Torp, 2002; Sun et al., 2016). The compiled studies in the above-
mentioned meta-analysis included anti-ki-67, anti-MIB-1, anti-ki-s5 and anti-ki-s11 
antibody clones which expectedly provided different values. Those values were then 
reported in diverse types such as mean, median, proportion, tertile distribution and 
arbitrary units. Furthermore, patients in some studies had been treated with hormonal 
therapy, some had been treated with only chemotherapy and some were untreated. 
As previously mentioned, some drugs could result in changes in ki-67 and the ki-67 
levels measured might not reflect the actual prognosis of patients. This inconsistency 
means the optimal cut-off value for ki-67 still remains controversial. 
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Although there is no published study showing a correlation between ki-67 
expression in WBC and cancer prognosis, the results of this study might suggest a 
feasibility of using ki-67 expression in WBC as a prognostic biomarker in solid cancers. 
More information between ki-67 expression and immune contexture in WBCs needs to 
be investigated. Moreover, higher number of patient samples in PROSPECT-NE trial as 
well as longer observational times should be considered for future work. Full patient 
profiles including all medication patients received should be collected to reduce any 
confounding factors to ki-67 expression. 
6.4.3 Association between percentage of ki-67 positive lymphoid cells and circulating 
ki-67 in plasma 
 The hypothesised association between percentage ki-67 positive WBCs and 
circulating ki-67 expression in plasma was based on the results of two studies by Bruey 
et al, which reported an association between elevated plasma ki-67 and shorter 
survival time in both ALL and CLL patients (Bruey et al., 2010a; Bruey et al., 2010b). 
This chapter therefore investigated concentrations of ki-67 in plasma using ELISA 
techniques, as compared to percentages of ki-67 positivity in lymphoid cells measured 
by imaging flow cytometry. 
 The results indicated a significant positive correlation between ki-67 expression 
in plasma and percentage of ki-67 positive lymphoid cells. However, high intra-assay 
variability in plasma ki-67 was observed. Moreover, high intra-patient variability in 
plasma ki-67 levels at different visits were observed throughout the study, although it 
was less marked than the variability in percentages of ki-67 positive lymphoid cells. In 
contrast to percentage of ki-67 positive cells, a log rank test analysis indicated that 
plasma ki-67 did not correlate with overall survival. Also, cox-regression analysis 
suggested that neither categorical nor continuous circulating ki-67 expression in 
plasma was significantly correlated with overall survival. Nonetheless, it was 
noticeable that patients with high ki-67 expression in plasma tended to have higher 
survival rates (Figure 6.15). 
 These findings contrast to the previously mentioned studies (Bruey et al., 
2010a; Bruey et al., 2010b). The difference observed in this study might result from 
two factors. Firstly, there were no patients with haematologic malignancies in the 
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PROSPECT-NE trial, so different types of cancer were studied between Bruey’s work 
and this study. As Bruey’s studies were performed in patients with leukaemia, with 
WBCs highly proliferated, they tended to have higher ki-67 expression levels in plasma 
than patients with solid tumours. The only study of serum ki-67 in solid tumour was 
from Ragab et al, but this study did not investigate the association between circulating 
ki-67 in serum and survival rate (Ragab et al., 2018). It was a study in breast cancer 
patients and reported significant differences in plasma ki-67 expression between 
patients with breast tumours and healthy people, but no difference between benign 
and malignant tumours. Another possible explanation was that too few patients were 
studied and the observational time was too short in this survival analysis of circulating 
ki-67.  
 As a result of the limited number of studies conducted and the inconsistent 
data generated, the potential relevance of circulating ki-67 expression in cancer 
patient plasma or serum needs further investigation. Similar to ki-67 expression in 
tumour tissues and WBCs, a precise assay, an optimal cut-off value and drug-
interaction data are necessary for further investigation of correlations of ki-67 
expression in plasma. Furthermore, larger sample size and controlled patients such as 
comparable medication received are needed for future studies. 
 In conclusion, the developed imaging flow cytometry assay was applied to 
measure ki-67 positive white blood cells in cancer patients in the PROSPECT-NE clinical 
trial. The percentage of ki-67 positive lymphoid cells was found to be higher than the 
percentage of ki-67 myeloid cells and was higher in cancer patients than in people not 
known to have cancer. A correlation between overall survival and percentage of ki-67 
positive lymphoid cells at first patient visit was observed when patients were 
categorised into high and low ki-67 groups. Furthermore, correlations between overall 
survival, LDH level and grip strength were observed in this study. However, only LDH 
level showed significance by multivariate analysis of three variables, so the prognostic 
effect of LDH should be studied in future works. Moreover, no significant correlations 
between ki-67 expression in plasma and overall survival were observed in this study. 
Larger sample sizes, longer observation times and more thorough patient profiles are 






Chapter 7. General discussion 
 The main objective of this PhD project was to investigate characteristics of 
protein expression in peripheral blood cells for the development of potential 
pharmacodynamic biomarkers for use in clinical trials in a cancer setting. The proteins 
of interest included CDC7, pMCM2, ki-67 and acH4. CDC7, pMCM2 and ki-67 were 
investigated as potential pharmacodynamic biomarkers for a phase I clinical trial 
(LY3143921), while acH4 was studied as a pharmacodynamic biomarker being utilised 
for a childhood cancer trial (SIOP Ependymoma II). An additional objective of the 
studies carried out was an investigation into the potential prognostic significance of 
the ki-67 protein within an early phase patient population as part of the PROSPECT-NE 
clinical study. 
 In order to investigate the pharmacodynamic properties of the proteins of 
interest, suitable assays were developed. The assay development processes for the 
clinical trials of interest included antibody optimisation, precision testing, and protein 
detection in cell lines and human WBCs. Lastly the applicability of the developed 
assays were assessed in patient samples participating in clinical trials. In the case of the 
LY3143921 trial, blood samples from mice treated in vivo were analysed ahead of 
future clinical sample analysis on an expansion phase of the trial which is yet to begin. 
 Patient samples from the PROSPECT-NE observational study were analysed for 
expression of the ki-67 protein using the previously developed assay. Correlations 
between protein expression and patient clinical data, including survival status, were 
investigated. Suitable statistical analyses, i.e. the Mann-Whitney U-test, Spearman 
correlation test and survival analysis, were performed as determined by the type of 
parameter being measured, the setting and the objectives of study. 
 
7.1 Development of an assay for detection of CDC7, pMCM2 and ki-67 
  An imaging flow cytometry assay for detection of CDC7, pMCM2 and ki-67 has 
been developed for use in an early phase clinical trial of LY3143921, a novel CDC7 
inhibitor. In addition to CDC7, pMCM2 was also chosen to be studied as it is a known 
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downstream protein of CDC7. Ki-67 protein, which is a well-known marker of cell 
proliferation, was included in this project since preliminary results showed cell 
proliferation inhibitory effects of the CDC7 inhibitor. 
 In order to develop an imaging flow cytometry assay, the volumes of antibody 
against CDC7, pMCM2 and ki-67 were first optimised. Precision of the assay including 
intra-assay and inter-assay precision, as well as precision of the imaging flow 
cytometry machine was tested. The results suggested less than 15% CV for all 
parameters investigated. This assay therefore offered the appropriate level of 
precision to measure protein expression in further samples. 
Expression of the three proteins was first investigated in HL-60 cell lines, using 
an imaging flow cytometry technique. When cells were treated with different 
concentrations of LY3143921, only pMCM2 expression decreased in parallel with 
increasing concentrations of the drug. Neither CDC7 nor ki-67 showed any change 
following treatment. Similar to the cell line results, only pMCM2 expression decreased 
when healthy whole blood was treated ex vivo with different concentrations of the 
drug. 
Although the CDC7 protein did not show any significant response to LY3143921 
and was excluded from the assay, the unique characteristics of this protein were of 
interest. While pMCM2 and ki-67 proteins showed slightly higher expressions in 
lymphoid as opposed to myeloid cell populations, CDC7 proteins showed very low 
expression in lymphoid cells as compared to very high expression in myeloid cells. 
Moreover, it was found that the majority of CDC7 expression observed in this study 
was cytoplasmic expression, which was in contrast to pMCM2 and ki-67. As the 
developed assay may not be effective for detecting nuclear CDC7, this protein was not 
further investigated using this assay. 
Another critical finding in this study was a new parameter for protein 
monitoring, i.e. percentage of protein positive cells based on the principal of rare cell 
populations. This study suggested that counting percentages of overexpressed cell 
showed greater dynamic changes than measuring intensity across all cells. As CDC7, 
pMCM2 and ki-67 are common proteins in normal cells, there will be basal expression 
levels of these proteins in all cells. These baseline expression levels could blind or 
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diminish a change in protein expression by drug treatment. Therefore, specifically 
looking at cells with overexpressed protein may provide better results, especially in 
comparison of changes. 
Focusing on the percentage of protein positive cells, both in vitro and ex vivo 
results in this study suggested a decrease in percentage of pMCM2 positive cells in 
WBCs following an increase in drug concentration. Although the decrease in 
percentage of pMCM2 positive cells was not significant in all WBCs, a significant 
decrease was observed when assessed as a proportion of ki-67 positive cells. In the 
same way, in vivo results showed a significant decrease in pMCM2 positive cells at a 
lower dose of LY3143921 (15 mg/kg) when specifically considering the ki-67 positive 
population. These findings highlight the importance of utilising ki-67 and pMCM2 as a 
dual pharmacodynamic biomarker for CDC7 inhibition. Moreover, the results suggest a 
potential mechanism of the drug involving cell cycle arrest, which resulted in steady 
levels of ki-67 in ex vivo experiments. 
With regard to the storage of samples, clinical blood samples need to be 
processed and transported from clinical sites to the laboratory, which can take up to 3 
days. Although four commercial preservative-containing tubes including EDTA, 
CellSave, TransFix and Streck tubes were examined, none of them were shown to 
be suitable, in terms of maintaining the percentage of pMCM2 positive in ki-67 positive 
cells for 3 days. However, it was found in this study that freezing WBCs in diluted 
Lyse/Fix buffer at -80°C was effective in terms of preserving the cell population for up 
to 5 days. This approach will therefore be adopted at allow delivery of clinical samples 
to the analysing laboratory, without impacting on the validity of the data generated 
following analysis. 
In conclusion, this PhD project has developed and validated an assay for 
detection of pharmacodynamic biomarkers for a new CDC7 inhibitor, LY3143921, by 
measuring the number of cells with overexpression of pMCM2 in the population of 
ki-67 positive cells. Furthermore, the freezing method for preservation of proteins 
during delivery has been validated. The assay is therefore ready to be applied to 
clinical sample analysis when the expanded phase of the clinical trial starts. Also, the 




7.2 Development of an assay for detection of acH4 
 An imaging flow cytometry assay for detection of acetylated histone H4 has 
been developed and validated for the analysis of clinical samples collected from 
patients on the SIOP Ependymoma II clinical trial. Patients in this clinical trial receive 
valproic acid which acts as an HDAC inhibitor. Since acH4 was considered as a potential 
pharmacodynamic biomarker for HDAC inhibitors, it was selected as a protein of 
interest in this study. The acH4 assay validation included antibody volume 
optimisation, intra- and inter-assay precision, and application in cell lines (in vitro) and 
human WBCs (ex vivo) before applying the assay to actual clinical samples. 
 The acH4 assay was developed appropriately and exhibited intra- and inter-
assay precision of <20% CV for both parameters. The in vitro results revealed increases 
in acH4 expression following increases in both valproic acid concentration and 
duration of treatment. Based on the results obtained, the minimum effective valproic 
acid concentration in these studies was 1 mM and the maximum effective 
concentration was 4 mM. Moreover, the peak expression of acH4 was observed at 6 
hours of drug treatment (4mM) with longer durations of treatment than 6 hours 
reduced the expression of acH4 in cell lines. The reason for this decrease has not been 
investigated in this project but should be further studied in order to more clearly 
understand the PK/PD of the drug. 
 Focusing on the expression of acH4 protein, this study compared changes in 
acH4 by monitoring two different parameters, i.e. mean/median intensity of acH4 
expression and percentage of acH4 positive cells. A greater dynamic change (higher 
fold-increase) was noted in percentage of acH4 positive cells compared to mean 
intensity. In agreement with the CDC7, pMCM2 and ki-67 assays, percentage of cells 
with protein overexpression was considered to be a more informative parameter than 
overall protein intensity, especially when used for comparison of change. Moreover, 
higher expression of acH4 was observed in lymphoid than in myeloid WBCs. This 
supported the use of PBMCs as a surrogate cell for measurement of acH4 in previous 
studies. However, the results in chapter 4 revealed higher fold-increases in the myeloid 
population following an increase in valproic acid concentration, as compared to 
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lymphoid cells. Based on these findings, this study focused on changes of acH4 in 
myeloid cells rather than lymphoid cells. 
 Another characteristic of acH4 expression in myeloid cells noted in this study 
was an increase in cytoplasmic acH4 expression. Based on the similarity between acH4 
and DAPI (nuclear) expression, more cytoplasmic acH4 positive cells were observed in 
myeloid WBCs treated with 8 mM of valproic acid as compared to lymphoid population 
with the same condition. Furthermore, the majority of cytoplasmic acH4 positive 
myeloid cells showed higher acH4 expression than nuclear acH4 positive cells. To date, 
there is only limited information relating to expression of cytoplasmic acH4 protein, 
although it has been reported in a previous study (Uchida et al., 2007). The 
characteristics and importance of this cytoplasmic acH4 should be investigated in 
future studies. 
 To conclude, an imaging flow cytometry assay for detection of acH4 expression 
in WBCs was validated in both cell lines and WBCs. The results obtained resulted in the 
proposal of myeloid WBCs as a novel cell population for acH4 monitoring. Also, the 
results suggested that percentage of acH4 positive cells, rather than overall acH4 
intensity, should be utilised to measure acH4 changes induced by valproic acid. 
Altogether this assay was suitable to be applied to patient samples from the 
Ependymoma trial. 
 
7.3 Measurement of acH4 positivity in Ependymoma patients and its 
pharmacodynamic significance 
 Whole blood samples from seven patients recruited to the SIOP Ependymoma 
clinical trial were analysed in terms of measurement of acH4 expression using the 
developed assay described in 7.2. Patient samples were collected pre- and 4-hour post-
valproic acid treatment at different dose levels. The percentage of acH4 positive 
myeloid cells was analysed and compared both between and within patients. 
Moreover, associations between the percentage of acH4 positive cells and dose and 
concentration of valproic acid were examined. Lastly, the association between free and 
total valproic acid concentrations in patient samples was also studied. 
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 Both intra- and inter-patient results revealed high heterogeneity in terms of 
percentage of acH4 positive cells. Within a patient, not all post-treatment samples 
showed increases in percentages of acH4 positive cells compared to pre-treatment. 
Also, the increase in acH4 positive cells did not follow the duration of treatment; 
patients who had been treated for longer periods of time possibly had lower acH4 
positive cells than those who received valproic acid for the first time. However, when 
comparing the results of the seven patients, no clear trends were observed. When 
comparable doses of valproic acid, e.g. 15 mg/kg were administered to patients, the 
post-treatment acH4 responses were different between each patient. Furthermore, 
patients who had been treated with the same dose for the same duration showed 
different levels of change in acH4 positive cells. These findings conformed to the 
results from several published clinical studies as discussed in Chapter 5. 
 With regards to observed trends in acH4 positive cells, the results showed no 
associations between percentage of acH4 positive cells and valproic acid dose, nor 
total drug concentration. No associations were observed in terms of actual values, 
absolute change (difference) and fold change. These findings were supported by other 
clinical studies showing no correlation of acH4 protein with valproic acid dose, 
concentration or clinical outcome (Garcia-Manero et al., 2006; Atmaca et al., 2007; 
Sharma et al., 2008; Su et al., 2011; Wheler et al., 2014). However, it should be noted 
that the concentrations of valproic acid in all patients in this study were much lower 
than the effective concentrations found in the pre-clinical results as discussed in 
chapter 4. These low concentrations may be associated with only modest changes in 
acH4 positivity and result in no correlations being observed with any of the parameters 
investigated. 
 Correlations between total and free valproic acid concentrations were 
observed in this study as shown in previously published studies (Otten et al., 1984; 
Herngren et al., 1991; Su et al., 2011). Furthermore, the free valproic acid fraction was 
found to be increased following an increase in total valproic acid concentration and no 
associations were observed between free valproic acid concentrations and parameters 
including percentage of acH4 positive cells. 
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 Overall, the developed assay was applied to clinical samples from the SIOP 
Ependymoma II trial and percentages of acH4 positive myeloid cells in all 7 patients 
were presented and discussed. No trends or changes in acH4 positivity between pre- 
and post-treatment were observed, or between the first dose and later doses in each 
patient. Also, there were no associations between the percentage of acH4 positive 
cells and parameters including dose, total concentration or free concentration of 
valproic acid. The limitations of this study included too few patient samples and low 
drug concentrations in plasma samples obtained from patients on the study. 
 
7.4 Measurement of ki-67 positivity in PROSPECT-NE patients and its prognostic 
impact 
 The assay for detection of ki-67 expression in WBCs was adapted from the 
combined assay developed for CDC7, pMCM2 and ki-67. This assay was applied to 
measure ki-67 positive cells in patient samples from the PROSPECT-NE observational 
study. The ki-67 results were studied in association with patient data and survival 
status to investigate its potential prognostic significance. Moreover, the potential 
prognostic impact of circulating ki-67 in plasma was also investigated in this study. 
 The patient results obtained indicated higher percentages of ki-67 positive cells 
in lymphoid as compared to myeloid WBCs. Unlike the SIOP Ependymoma clinical trial, 
PROSPECT-NE is an observational study with no defined treatment protocol. Lymphoid 
cells were considered to be a suitable surrogate population due to their relatively high 
level of ki-67 expression. Focusing on ki-67 positive lymphoid cells, the results in 
cancer patients from the PROSPECT trial showed higher ki-67 positivity than in healthy 
volunteers. However, no significantly high ki-67 expression was observed in any 
specific type of cancer. 
 Marked variation in ki-67 expression levels in some patients was highlighted, 
and this contributed to limitations in terms of interpretation of the results. Some 
patients had fluctuations of ki-67 throughout the study without any treatment, so the 
cause of change was unclear. Regarding the deceased patients in this study, no clear 
trend in ki-67 levels was observed, thus ki-67 was unlikely to change following patient 
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illness such as performance status and tumour stage. Correlation analysis performed in 
this study also showed no correlation of ki-67 with patient data including age, weight, 
BMI, LDH, albumin, WBC count or Z-score of grip strength (right hand and left hand). 
Based on these results, it is currently unclear what caused the high variability of ki-67 
levels observed in this study. 
 Although fluctuations in percentage of ki-67 positive cells were observed 
throughout the study, the percentage of ki-67 positive cells at the first visit of each 
patient appeared to be correlated with patient survival status. The survival analysis 
suggested that patients with a high percentage of ki-67 positive cells had significantly 
lower mean survival times as compared to those with low percentages of ki-67 positive 
cells. However, there was no association with overall survival when actual numbers of 
ki-67 positive cells, not categorised into high and low groups, were analysed. 
Furthermore, when ki-67 positive cell numbers were adjusted based on LDH and 
Z-score of grip strength, it lost the significance in survival analysis. The actual 
relationship between percentage of ki-67 positive cells and prediction of patient 
prognosis therefore needs further investigation. 
 Moreover, based on the published results by Bruey et al (Bruey et al., 2010a; 
Bruey et al., 2010b), this study investigated associations between circulating ki-67 in 
patient plasma and overall survival. In contrast with the mentioned studies, no 
correlation between the two parameters was observed. Also, no association between 
plasma circulating ki-67 expression and percentage of ki-67 positive cell was observed 
in the PROSPECT-NE study. However, it was found that patients with high circulating 
ki-67 expression generally had longer mean survival times than patients with low ki-67 
expression. The prognostic impact of circulating ki-67 expression in plasma needs to be 
further studied. 
 The results obtained in this study suggest a potential prognostic impact of ki-67 
positive cells. However, due to the unavailability of complete patient datasets and low 
sample size, this effect should be analysed with more detailed patient information and 
a larger number of patients in the future. Also, a longer observation time is needed in 





 This PhD project mainly aimed to develop imaging flow cytometry assays for 
detection of proteins as potential pharmacodynamic biomarkers for three particular 
studies, i.e. the LY3143921 phase I clinical trial, the SIOP Ependymoma II clinical trial 
and the PROSPECT-NE observational study. The protein characteristics and associations 
of protein expression with relevant clinical parameters were studied. 
 The assay for LY3143921 clinical study has been developed and validated to 
measure the expressions of CDC7, pMCM2 and ki-67 in WBCs. The results showed high 
precision of the assay and capability to detect changes in pMCM2 with LY3143921 drug 
treatment, most noticeably within a ki-67 positive cell population. Moreover, a 
clinically relevant freezing method for storage of proteins during delivery was 
validated. The clinical trial is currently recruiting patients to the dose escalation phase 
of the study, with the developed pharmacodynamic assay proposed to be used for the 
analysis of samples in the planned expanded phase of the study. 
 A pharmacodynamic assay for the SIOP Ependymoma trial has been developed 
and validated to measure acH4 expression in myeloid WBCs. In vitro and ex vivo results 
indicated high precision of the assay as well as a potential to detect protein changes 
following drug treatment. However, clinical results from seven patients studied to date 
have shown marked intra- and inter-patient variability and no associations have been 
observed between percentage of acH4 positive cells and either dose or concentration 
of valproic acid. Low concentrations of valproic acid in patient plasma alongside small 
numbers of patient samples represent clear limitations to this study and future work 
should take these issues into account. 
 For the PROSPECT-NE study, an assay was applied to measure ki-67 expression 
in lymphoid WBCs. The results showed no correlations with the available patient data, 
nor the patient overall survival. Although when ki-67 positivity was categorised into 
high and low groups, it showed a potential prognostic impact, multivariate analysis 
revealed no significance for ki-67 expression when adjusted with LDH and Z-score of 
grip strength. The prognostic effect of percentage of ki-67 positive cells should be 
further investigated, with larger numbers of patient samples studied and more 
detailed patient information made available. 
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 In summary, three assays for detection of proteins of interest including CDC7, 
pMCM2, ki-67 and acH4 were developed and validated and their clinical utility shown. 
A number of important lessons have been learnt which have applicability to the 
development of similar assays in the future, and the practical aspects of developing 
assays for use in clinical trials involving the analysis of clinical samples in real-time. 
Future studies should include more patient samples, longer observational times and 
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Appendix A. Association between percentage of ki-67 positive 
lymphoid cells and patient data 
Since this study analysed both percentage of ki-67 positive lymphoid cells at the 
first visit and the median value of all visits, the difference in ki-67 categorisation by 
different values is promising. The table A1 compares classification of each patient 
using percentage of ki-67 positive cells at the first visit, the median percentage of ki-67 
positive cells of all visits. Difference in ki-67 values determined by different parameters 
is also presented. 
 




from 1st visit 
Classification 
(Cut-off 1.61%) 
0.48 Low 0.48 0.00 Low 
1.07 Low 1.07 0.00 Low 
1.21 Low 1.21 0.00 Low 
1.77 Low 1.24 -30.23 Low 
1.41 Low 1.41 0.00 Low 
0.56 Low 1.46 159.82 Low 
0.71 Low 1.46 105.63 Low 
2.16 High 1.62 -25.00 High 
1.92 High 1.52 -21.09 Low 
2.57 High 1.54 -40.08 Low 
1.16 Low 1.60 37.93 Low 
1.85 High 1.85 0.00 High 
5.68 High 0.88 -84.51 Low 
1.79 Low 2.11 17.88 High 
2.21 High 2.21 0.00 High 
0.60 Low 2.75 357.50 High 
2.71 High 2.71 0.00 High 
2.82 High 2.82 0.00 High 
2.97 High 2.97 0.00 High 
1.17 Low 1.81 54.70 High 
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from 1st visit 
Classification 
(Cut-off 1.61%) 
1.75 Low 1.26 -28.00 Low 
3.81 High 3.30 -13.52 High 
6.10 High 3.30 -45.90 High 
2.05 High 3.17 54.63 High 
1.01 Low 2.01 98.51 High 
6.95 High 4.48 -35.61 High 
4.49 High 4.49 0.00 High 
8.54 High 16.20 89.70 High 
 
Table A1. Difference in classification of patients using different values and different 
cut-points 
The table shows difference between percentage of ki-67 positive lymphoid cells 
at the first visit with cut-off value 1.82% and median percentage of ki-67 
positive lymphoid cells of all visits of a patient with cut-off value 1.61%. 
 
The standard curves used for the analysis of absorbance by ELISA tests are 
showed in figure A1 together with three equations from three repeats. Four parameter 
logistic regression was used as recommended by the manufacturer. The standard 
curves ranged from 6.25 – 400 ng/mL. The concentration of sample which was lower 
than 6.25 ng/mL was identified as less than the lower limit of quantification (<LLOQ) 
and the value was set to 0 ng/mL. The concentration of sample which was higher than 
400 ng/mL was identified as greater than the upper limit of quantification (>ULOQ) and 
the value was set to 400 ng/mL. Both <LLOQ and >ULOQ values were not compared 
with percentages of ki-67 positive cells but were still used in the survival analysis. 
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1 s t re p e a t
2 n d  re p e a t
3 rd  re p e a t
 
Equation 1st repeat: y = -1E-10x4 + 9E-08x3 - 3E-05x2 + 0.0115x  R² = 1 
Equation 2nd repeat: y = -1E-10x4 + 9E-08x3 - 4E-05x2 + 0.0125x  R² = 1 
Equation 3rd repeat: y = -1E-10x4 + 1E-07x3 - 5E-05x2 + 0.0148x  R² = 1 
 
Figure A1. Standard curves of the absorbance and concentration of ki-67 measured 
by a commercial ELISA kit along with the curve-fit equations calculated using the MS 
Excel software. 




Appendix B. Conference abstracts 
Postgraduate Cancer Conference 2017, Newcastle University, Newcastle upon Tyne, 
UK – Oral presentation 
Characterisation of rare cell phenotypes in peripheral blood and utilisation as a 
surrogate tissue in pharmacodynamic biomarker assays 
Suriyon Uitrakul 
Introduction: LY3143921 is novel small molecule CDC7 inhibitor being investigated in 
early phase trials. To demonstrate mechanism of action pharmacodynamic biomarker 
assays are required. MCM2 is phosphorylated by CDC7 to yield pMCM2 which is 
detectable by a phosphospecific antibody. Ki-67 is a marker of proliferation.  
Objective: To develop and validate an imaging flow cytometry assay to detect pMCM2 
and ki-67 in circulating haematopoietic cells as a surrogate tissue to demonstrate 
LY3143921 mechanism of action. 
Method: Eighteen mice were divided into 3 equal groups and received 15 or 50 mg/kg 
LY3143921 p.o. or vehicle. Blood was taken from 3 mice per group pre-administration 
and at 3, 6, and 24h post-administration. Red blood cells were lysed and white blood 
cells (WBCs) fixed in formaldehyde before storage in methanol at -20°C. WBCs were 
incubated with antibodies to pMCM2, ki-67 and DAPI for 1h. Expression was measured 
by imaging flow cytometry. 
Result: The percentage of pMCM2 positive cells in the ki-67 positive WBC population 
at 0, 3, 6 and 24 hours post-LY3143921 treatment were 70.0%, 57.5%, 41.6% and 
38.6% (15 mg/kg group); 56.6%, 50.8%, 42.6% and 13.9% (50 mg/kg group) and 62.0%, 
67.5%, 70.0% and 71.3% for control animals. Two-way ANOVA showed significance in 
both duration of treatment and dose (p-values 0.035 and 0.024, respectively). The 
frequency of ki-67 positive cells was not affected by LY3143921 treatment.  
Conclusion: The assay is appropriate for analysis of changes in frequency of pMCM2 
positivity as a percentage of ki-67 positive cells over time, following administration of 
LY3143921.
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American Association for Cancer Research (AACR) Annual Conference 2018, Chicago, 
Illinois, USA – Poster presentation 
Imaging flow cytometry assay development and validation for the detection of 
histone H4 acetylation in white blood cells 
Suriyon Uitrakul, Gareth James Veal, Claire Hutton, David Jamieson 
Introduction:  Histone deacetylases have been identified as oncogenes in several 
cancer types, providing an attractive target for anticancer treatment. In this respect, 
the histone deacetylase inhibitor valproic acid has been shown to inhibit the growth of 
multiple paediatric tumour types and is well tolerated in children with refractory solid 
or CNS tumours. 
Objective: The aim of the current study was to develop and validate a novel imaging 
flow cytometry method for the detection of histone H4 acetylation in lymphoid and 
myeloid cell populations, and to assess the applicability of the method to a clinical trial 
setting. 
Method: HL-60 cells and whole blood samples from healthy volunteers were incubated 
with valproic acid (0.5-8 mM) for 0.5-24 hours, followed by RBC lysis for the whole 
blood samples and fixed with cold methanol. Additional blood samples were collected 
from patients with ependymoma who were receiving valproic acid as part of the SIOP 
Ependymoma II clinical trial. An imaging flow cytometry method was developed using 
an ImageStreamχ flow cytometer, collecting WBCs with excitation of PE conjugated 
acH4 antibody and DAPI. Data were collected using Inspire™ software and further 
analysed by Ideas™ software 6.2. Both in vitro and ex vivo experiments were repeated 
on at least 3 occasions. 
Result: In the HL-60 cell line the mean percentage of acH4 positive cells was 1.98% in 
the vehicle control sample, increasing to 10.9-77.9% when treated with 0.5-8 mM 
valproic acid for 6 hours, with percentages of 8.7-49.0% observed following incubation 
with 4 mM valproic acid for 0.5-24 hours. Comparable data were generated in 
lymphoid and myeloid WBC populations following ex vivo incubation of whole blood 
samples with valproic acid. Increases in the percentage of acH4 positive cells were 
observed in samples collected at 4 hours post-administration in patients receiving 
valproic acid as compared to pre-treatment samples. Myeloid cells appeared to have a 
smaller proportion of acH4 positive cells than observed in the lymphoid population but 
a greater fold increase above basal levels. 
Conclusion: A new assay for detection of histone H4 acetylation in WBCs by imaging 
flow cytometry has been developed and optimised. The assay showed increases in 
acH4 positivity in both in vitro and ex vivo experiments following exposure to valproic 
acid. The method can be used for the measurement of acH4 as a pharmacodynamic 
biomarker for histone deacetylase inhibitors in drug development and monitoring of 
drug efficacy in clinical trials. 
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1 |  INTRODUCTION
Histone deacetylase inhibitors (HDACIs) represent a novel 
type of anticancer drug which have been studied over a num-
ber of years since the association between HDAC expression 
and cancer was first observed.1,2 This class of drugs includes 
valproic acid, a well‐known anticonvulsant, which has been 
shown to exhibit HDAC inhibitory activity in a cancer set-
ting.4 In the modern era of cancer therapy, pharmacodynamic 
biomarkers play increasingly important roles in furthering 
our understanding of drug efficacy, with the development of 
novel and informative biomarker assays representing a key 
area of research.
Many proteins can be used as biomarkers of drug activ-
ity and histone H4 acetylation (acH4) has become a com-
monly used biomarker for measurement of HDACI activity 
in preclinical and clinical studies.5,6 Modulation of acH4 
has been measured by many techniques including Western 
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Abstract
Background: The histone deacetylase inhibitor (HDACI) valproic acid has been 
shown to inhibit the growth of multiple paediatric tumour types and is well tolerated 
in a childhood cancer setting. The current study was designed to develop a novel 
imaging flow cytometry method for the detection of histone H4 acetylation in white 
blood cells obtained from childhood cancer patients treated with valproic acid.
Materials and methods: HL‐60 cells and whole blood samples from healthy volun-
teers were incubated with valproic acid (0‐8 mM) for 0‐24 hours, with additional 
blood samples collected from ependymoma patients receiving valproic acid on the 
SIOP Ependymoma II clinical trial. An imaging flow cytometry method was devel-
oped using an ImageStream®χ flow cytometer, collecting 100 000 images per sample 
following excitation of PE tagged acH4 antibody and DAPI.
Results: The mean percentage of acH4‐positive cells increased to a greater extent 
than increases in mean and median fluorescence intensity following incubation with 
valproic acid. Comparable results were observed for in vitro and ex vivo experi-
ments, and the assay was shown to be appropriate for clinical sample analysis. 
Myeloid cells exhibited a smaller proportion of acH4‐positive cells than the lym-
phoid population, but a greater fold increase above basal levels.
Conclusions: The percentage of acH4‐positive myeloid cells has the potential to be 
used as a robust pharmacodynamic biomarker for the measurement of acH4 for 
HDACIs. The developed assay is now being utilised in a clinical trial involving the 
treatment of childhood ependymoma patients with valproic acid.
K E Y W O R D S
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Blot, ELISA, immunofluorescence and flow cytometry, but 
no imaging flow cytometry methods have been published to 
date.7,8 Furthermore, published assays have focused on the 
populations of peripheral blood mononuclear cells (PBMCs) 
and polymorphonuclear leucocytes (PMNLs), but none have 
investigated differences in acH4 expression between these 
populations.
The current study therefore aimed to develop and validate 
a novel imaging flow cytometry protocol for the detection of 
histone H4 acetylation by quantitative image analysis of nu-
clear acH4 signal, including studies to investigate differences 
in acH4 expression between myeloid and lymphoid WBC 
populations.
2 |  MATERIALS AND METHODS
2.1 | Reagents
Valproic acid sodium salt and RPMI‐1640 medium were 
from Sigma® Life Science. The acH4 antibody conjugated 
to PE was from Merck Millipore. DAPI (4',6‐Diamidino‐2‐
Phenylindole, Dilactate) was from BioLegend® (California, 
United States). BD Phosflow™ Lysis/Fix Buffer was ob-
tained from BD Biosciences. Bovine serum antigen (BSA) 
MACS® buffer was provided by Miltenyi Biotec Ltd. PBS 
was supplied by Thermo Fisher Scientific.
2.2 | Cell lines
Authenticated HL‐60 (Human promyelocytic leukaemia) 
cells were cultured routinely in RPMI‐1640 medium sup-
plemented with 2 mM L‐glutamine and 10% foetal bovine 
serum (FBS). Cells were grown in 75 mm2 flasks, incubated 
at 37°C in a 5% CO2 incubator.
2.3 | Blood samples
Whole blood from healthy volunteers was obtained 
from staff members in the Northern Institute for Cancer 
Research (Newcastle University) following standard op-
erating procedures. All blood samples were drawn from 
volunteer donors by registered doctors and were trans-
ferred directly to blood tubes. Additional blood samples 
were collected from patients with ependymoma who were 
recruited as part of the SIOP Ependymoma II clinical 
trial (ClinicalTrials.gov identifier: NCT02265770). This 
trial is designed to investigate the efficacy of combined 
chemotherapy including valproic acid, for children and 
young adults with ependymoma. Valproic acid (15 mg/
kg) was administered orally to randomised patients two 
or three times daily, with doses adjusted in individual 
patients to achieve target trough plasma concentrations 
of 100‐150 µg/mL (690‐1040 µM). Appropriate ethical 
approval and written informed consent for study patients 
were obtained. Samples for analysis of acH4 were col-
lected immediately before the initiation of valproic acid 
treatment (pretreatment baseline), at 4 hours post‐admin-
istration and at trough levels during continuous therapy 
across a range of valproic acid dose levels. Whole blood 
samples were taken from patients and directly added to 
prepared Lyse/Fix Buffer. Samples were then frozen and 
transported on dry ice to the Northern Institute for Cancer 
Research, Newcastle University, within 2 days.
2.4 | In vitro valproic acid treatment
HL‐60 cells (1 × 106) were seeded in 2 mL RPMI‐1640 me-
dium supplemented with 10% FBS in 6‐well plates. Valproic 
acid was dissolved in RPMI medium to make a stock solution 
of 100 mM. The stock solution was diluted with RPMI me-
dium by serial dilution to obtain final valproic acid concen-
trations of 0.5, 1, 2, 4 and 8 mM, with RPMI alone included 
as a negative control, and the plate was incubated at 37°C, 
5% CO2 for 6 hours. Additional experiments investigated the 
effect of a fixed concentration of valproic acid (4 mM) at 0.5, 
1, 3, 6 and 24 hours. Collected samples were washed with 
PBS and fixed in −20°C methanol overnight. Experiments 
were repeated three times.
2.5 | Ex vivo valproic acid treatment
Whole blood samples from healthy volunteers were col-
lected in EDTA tubes, then divided into Falcon™ tubes 
(2 mL blood/tube). Valproic acid sodium salt was dissolved 
in RPMI‐1640 medium to obtain a final concentration of 
100 mM. The drug solution was added to each blood tube to 
generate final concentrations of 0.5, 1, 2, 4 and 8 mM with 
RPMI included as negative control. Tubes were incubated in 
a shaking incubator at 200 rpm, 37°C for 6 hours. All blood 
samples were lysed and fixed using the protocol described 
below. This experiment was repeated three times with three 
independent donors.
2.6 | Red blood cell lysis
Red cells in whole blood samples were lysed with Lyse/Fix 
Buffer, diluted in distilled water (1:5) and added directly to 
the whole blood tube (20 mL of diluted lysis buffer per 1 mL 
of blood). The solution was mixed by inversion, incubated 
at 37°C for 10 minutes and centrifuged at 500 g for 10 min-
utes. The supernatant was gently poured off and the cell pel-
let re‐suspended in 5% BSA in PBS for 30 minutes. The tube 
was centrifuged again at 500 g for 5 minutes and the cell 
pellet re‐suspended in methanol for permeabilisation. The 
white blood cell suspension was stored at −20°C for at least 
24 hours.
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2.7 | Flow cytometry
Cell pellets were re‐suspended in PBS at a density of 
1 × 106 cells and incubated in 1 mL of 5% BSA in PBS 
for 1 hour. Cells were then centrifuged at 500 g for 5 min-
utes and 90% of the supernatant aspirated. Approximately 
100 μL of each cell suspension was incubated with 1 μL of 
acH4 antibody at 2‐8°C overnight. Samples were washed 
with 1 mL of 5% BSA in PBS, re‐suspended in 100 μL of 
5% BSA in PBS with 5 μL of DAPI and incubated at room 
temperature for 1 hour. Cells were washed with 1 mL of 
5% BSA in PBS and the acH4 signal measured by imaging 
flow cytometry.
2.8 | Imaging flow cytometry analysis
Imaging flow cytometry was performed using an 
ImageStream®χ flow cytometer (Amnis), collecting 
100 000 images per sample. The instrument was set to 
excite the PE tagged acH4 antibody and DAPI by 488 nm 
(100 mW) and 405 nm (30 mW) lasers, respectively. Data 
were collected using Inspire software and further ana-
lysed by Ideas software 6.2. The process of data collec-
tion and gating used in this study is illustrated in Figure 
S1 (supplementary data).
2.9 | Statistical analysis
Mean and standard deviation (SD) values were calculated for 
all experiments. One‐way ANOVA was performed to com-
pare results obtained from in vitro and ex vivo experiments. 
A paired t test was used for the comparison of myeloid and 
lymphoid acH4 positivity. All statistical data were generated 
using Prism 6.0 software.
3 |  RESULTS
3.1 | Assay validation in cell lines
In order to investigate acH4 expression using the proposed 
method, HL‐60 cells were treated with valproic acid across a 
range of concentrations and time points and the percentage of 
acH4‐positive cells was determined. Figure 1 provides exam-
ples of acH4‐positive (1A) and acH4‐negative (1B) cells as vis-
ualised on the imaging flow cytometer. The expression of acH4 
was quantified using three parameters as shown in Figure 2.
The first and second parameters, mean and median in-
tensity of fluorescence, have previously been used to mea-
sure changes in acH4. An average mean intensity of acH4 
in control cells of 5051 increased to 13 044 when treated 
with 8 mM of valproic acid (Figure 2A). Increase in median 
F I G U R E  1  Representative images of 
HL‐60 cells with nuclear acH4 positivity 
(A) and negativity (B), myeloid cells with 
acH4 positivity (C) and negativity (D), and 
lymphoid cells with acH4 positivity (E) 
and negativity (F). Samples were separated 
following incubation of cells with 4 mM 
sodium valproate at 37°C for 6 h



















4 of 7 |   UITRAKUL eT AL.
intensity of acH4 was similar to the increase in mean inten-
sity (4730 and 12 311, respectively; Figure 2B). The third pa-
rameter reported was the percentage of nuclear acH4‐positive 
cells, developed based on the functionality of the imaging 
flow cytometer. Cells with ≥2 in similarity between DAPI 
and PE and ≥45 000 in intensity of PE were identified as 
nuclear acH4‐positive cells and expressed as a percentage of 
the total number of cells present. The average percentage of 
F I G U R E  2  Expression of acH4 in HL‐60 cells treated with valproic acid (0‐8mM) for up to 24 hours. Figure 2A and 2B indicate mean and 
median fluorescence intensity of acH4, respectively, and Figure 2C indicates average percentage of acH4‐positive cells following treatment for 
6 hours. Figure 2D, 2E and 2F indicate mean fluorescence intensity, median fluorescence intensity and average percentage of acH4‐positive cells, 
respectively, when treated with 4 mM valproic acid for up to 24 hours. Mean and SD shown from three separate experiments. Level of significance 
from one‐way ANOVA statistical analysis is shown
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acH4‐positive cells was 0.51% in the vehicle control sample 
and increased to 30.6% when treated with 8 mM valproic acid 
for 6 hours (Figure 2C).
Figure 2D‐F show the expression of acH4 following dif-
ferent incubation times with valproic acid at a concentra-
tion of 4 mM. The average mean and median fluorescence 
increased approximately twofold (Figure 2D‐E), while the 
percentage of acH4‐positive cells increased from 0.22% to 
9.7% (>10‐fold) following incubation of HL‐60 cells with 
4 mM valproic acid for 6 hours, respectively (Figure 2F). 
All increases shown in Figure 2 were statistically significant 
(P < 0.001).
3.2 | Assay validation in white blood cells
The method developed in HL‐60 cells was applied to the 
measurement of acH4 expression in WBCs following incuba-
tion of whole blood from healthy volunteers ex vivo with val-
proic acid. The process of red blood cell lysis and cell staining 
was the same as HL‐60 cells. Example images of four types of 
white blood cell are shown in Figure 1, namely acH4‐positive 
myeloid (1C), acH4‐negative myeloid (1D), acH4‐positive 
lymphoid (1E) and acH4‐negative lymphoid (1F).
Levels of acH4 detected in WBCs were increased fol-
lowing exposure to valproic acid, with the proportion of 
acH4‐positive cells in the untreated WBC population mark-
edly lower than in cells treated with valproic acid and a 
clear concentration‐dependent effect observed in all three 
parameters measured (Figure 3 and supplementary Figure 
S2). Fold changes in mean fluorescence, median fluores-
cence and nuclear acH4‐positive WBCs over a concen-
tration range of 0‐8 mM valproic acid were 3.9‐, 3.5‐ and 
57‐fold, respectively. Measurement of the percentage of 
acH4‐positive cells was therefore selected to measure dy-
namic change in acH4 in clinical samples.
Looking at the data generated in different types of WBC 
in Figure 3C, percentages of acH4‐positive myeloid cells in-
creased from 0.60% to 54.9% (92‐fold) with a valproic acid 
concentration of 8 mM, as compared to untreated cells. In 
comparison, percentages of acH4‐positive lymphoid cells 
increased from 2.2% to 70.5% (33‐fold) under the same 
conditions. Fold changes in mean and median acH4 signal 
exhibited the same trend. These increases between myeloid 
and lymphoid cells were significantly different (P = 0.03). 
Lymphoid cells therefore exhibited a higher percentage of 
acH4‐positive cells than myeloid cells but a lower magnitude 
of increase when treated with drug.
3.3 | Clinical sample analysis
Blood samples from four patients receiving valproic acid 
treatment on the SIOP Ependymoma II trial were analysed 
to examine applicability of the assay to a clinical setting. 
Whole blood samples collected pre‐administration and 
at 4 hours post‐administration of valproic acid were pro-
cessed as described.
F I G U R E  3  Expression of acH4 in myeloid, lymphoid and total 
white blood cells from whole blood samples treated with different 
concentrations of valproic acid (0‐8 mM) for 6 hours. Expression 
is shown as mean fluorescence (A), median fluorescence (B) and 
percentage of acH4‐positive cells (C); mean data shown from three 
independent donors. Significant differences between acH4 changes 
in myeloid and lymphoid cells were observed in Figure 3C (ANOVA, 
P = 0.0313). Significant changes in acH4 with increasing valproic acid 
concentrations were observed in all cell populations (ANOVA, P < 0.01)












































































6 of 7 |   UITRAKUL eT AL.
Figure 4 indicates the percentage of acH4‐positive cells 
in 38 samples collected from four ependymoma patients 
receiving valproic acid, suggesting a trend towards an in-
crease in acH4‐positivity post‐treatment. In agreement with 
the ex vivo results, myeloid cells appeared to have lower 
acH4 expression but a greater increase in percentage of 
acH4‐positive cells after valproic acid treatment than lym-
phoid cells. These data confirm that myeloid cells represent 
the preferred population of interest for the developed assay.
The association between percentage acH4‐positive myeloid 
cells and valproic acid concentrations measured in plasma from 
two patients where sequential blood samples were collected is 
shown in Figure 5. For each patient, samples were collected be-
fore the initiation of valproic acid (treatment naïve), at 4 hours 
following drug administration and at 12 hours following drug ad-
ministration (trough level before next dose) over a treatment pe-
riod of up to 3 months and across a range of doses of valproic acid 
(from 15‐35 mg/kg). Increases in valproic acid concentrations be-
tween pre‐ and post‐treatment ranging from 0.17‐0.35 mM and 
a maximum post‐treatment concentration of 0.81 mM observed.
4 |  DISCUSSION
A novel method for the detection of histone H4 acetyla-
tion by imaging flow cytometry has been developed and 
its applicability in cell lines (in vitro), white blood cells 
(ex vivo) and clinical samples obtained from patients 
receiving treatment with valproic acid investigated. The 
assay showed increases in acH4 positivity in both in vitro 
and ex vivo concentration‐dependent experiments follow-
ing exposure to valproic acid.
This is the first assay which describes the quantification 
of acH4‐positive cells using an imaging flow cytometry ap-
proach, although previous studies have described methods to 
detect histone acetylation levels by conventional flow cytom-
etry.11-13 Unlike these previous approaches, imaging flow cy-
tometry as utilised in our study can also provide valuable 
information on localisation of the antibody:antigen inter-
action in WBCs, allowing identification of nuclear expres-
sion of acH4. This function allows us to measure histone H4 
acetylation by quantifying the number of nuclear acH4‐pos-
itive cells, as compared to previously published techniques 
used to measure acH4, based on observing the expression 
of acH4 intensity.11-13 Our results suggest that nuclear acH4 
positivity is a markedly more sensitive approach to measur-
ing relative changes in acH4 expression as compared to mean 
and median intensity, although absolute numbers were lower.
In our assay, acH4 expression in lymphoid cells was sig-
nificantly higher than expression observed in myeloid cells, a 
finding that may support the use of PBMCs to measure acH4 
expression in previously published clinical trials.7,8 However, 
our results suggest that a larger dynamic range in response to 
valproic acid treatment, in terms of the magnitude of increase 
from baseline, was observed in myeloid as compared to lym-
phoid cells. To compare the expression of acH4 in WBC, 
therefore, the percentage of myeloid cells in whole blood 
should ideally be considered.
The clinical application of the current assay was tested 
using blood samples obtained pre‐ and post‐treatment from 
F I G U R E  4  Percentage of acH4‐positive cells in cell populations 
isolated from patient samples collected pretreatment and 4‐h post‐





















































F I G U R E  5  Association between valproic acid concentration and 
percentage acH4‐positive myeloid cells in two patients treated with 
increasing doses of valproic acid on the SIOP Ependymoma study. 
Samples were collected at 4 h following drug administration or 12 h 
following drug administration (trough level before next dose) over a 
range of doses of valproic acid (from 15‐35 mg/kg)
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children being treated on the SIOP Ependymoma II clinical 
trial. In contrast to in vitro and ex vivo experiments, changes in 
acH4 positivity observed were modest. In this respect, it should 
be noted that plasma drug concentrations achieved in the study 
patients were markedly lower than concentrations used in ex 
vivo experiments (Figure 5), thus resulting in smaller increases 
in percentages of acH4‐positive cells. In a previously pub-
lished clinical trial, an approximate threefold increase in H4 
acetylation was observed at a valproic acid plasma concentra-
tion of ≥1 mM,8 markedly in excess of plasma concentrations 
observed in the patients in the current study. Another clinical 
trial reported no clear changes in acH4 expression ratios be-
tween post‐ and pre‐valproic acid treatment at a mean valproic 
acid concentration of 0.65 mM.9 Similarly, results from a third 
study suggested that patients with significant increases in his-
tone acetylation (>4‐fold) had valproic acid plasma levels in 
excess of 0.8 mM.10 It is highly likely that the small increases 
in acH4 positivity observed in our limited number of patient 
samples analysed to date, reflect the low plasma concentra-
tions of valproic acid observed in these patients at the doses 
administered at early time points in the current study. Further 
clinical samples collected from patients receiving increased 
valproic acid doses will be analysed as the trial progresses.
In conclusion, a novel assay for the detection of histone 
H4 acetylation in myeloid white blood cells by imaging flow 
cytometry has been developed and optimised. The method 
can be used for the measurement of acH4 as a pharmacody-
namic biomarker for HDACIs in drug development and mon-
itoring of drug activity in a clinical setting.
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